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The Prostate
Pim J. van Leeuwen
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1.1 INTROdUCTION
The prostate is a gland in men which is located immediately below the bladder and just 
in front of the bowels (Figure 1)1. Its main function is to produce a fluid that usually con-
stitutes 25-30% of the volume of the semen. Additionally, the prostate contains some 
smooth muscles that help expel semen during ejaculation. In younger men the prostate 
is about the size of a walnut, however, the prostate usually enlarges with age. Growth 
of the prostate gland can eventually result in the most common prostate problem, i.e., 
benign prostatic hyperplasia (BPH). Other health problems of the prostate gland are 
prostatitis and prostate cancer (PC).
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figure 1. Anatomy of the male reproductive and urinary systems, showing the prostate, urethra, seminal 
vesicle, ejaculatory duct, testicles, bladder, and other organs.
1.2. bENIGN PROSTATIC HyPERPLASIA (bPH)
Benign Prostatic Hyperplasia (BPH) is a common problem in older aged men. BPH is pres-
ent in more than 50% of men aged over 60 years2. Between 15% and 30% of these men 
have lower urinary tract symptoms (LUTS), however, not all such symptoms are caused 
by the hyperplasia, and many are attributable to various types of dysfunction of smooth 
muscle (detrusor) of the bladder3. LUTS due to BPH occur if the enlargement is sufficient 
to squeeze the urethra which passes through the prostate. The main complaints consist 
of awaking frequently at night to urinate, sudden or urgent need to urinate, difficulty 
in starting to urinate and slow flow of urine and difficulty in stopping4. BPH is a benign 
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condition, however, which can be treated effectively. Treatment of BPH may require 
specific drugs, or, in more developed cases, an operation to widen the urethral passage. 
The most common procedure is a transurethral resection of the prostate (TURP). Under a 
general anaesthetic, an instrument is passed up the urethra through the penis and some 
of the prostate is removed to improve urine flow.
1.3. PROSTATITIS
Prostatitis is a benign condition which is caused by usually bacterial inflammation of 
the prostate. It can cause discomfort deep inside the pelvis continuously, when passing 
urine or during ejaculation. It can be painful and can spread to other areas of the pelvis. 
Other complaints could consist of a sudden or urgent need to urinate, discomfort during 
urinating, painful ejaculation, presence of blood in the urine or semen. If the prostatitis 
is caused by an infection it will be treated with antibiotics.
1.4. PROSTATE CANCER
Prostate cancer (PC) is the most commonly diagnosed malignancy (excluding non-
melanoma skin cancer) and the third leading cause of death from cancer in men in 
Western countries (after lung and colorectal cancer)5-6. The lifetime risk of a PC diagnosis 
is 15.8% for an individual man in the United States and approximately 9% for a man in 
Western Europe7-9. The lifetime risk of dying from PC is low relative to the lifetime risk of a 
PC diagnosis, i.e. 2.8% in the United States and 3.1% in Western Europe7-9. Overall, these 
incidence and mortality rates give PC an important public health relevance10.
The introduction and widespread use of prostate specific antigen (PSA) testing for the 
early detection of PC has led to major changes in PC incidence, the tumour grade and 
stage at diagnosis, treatment, and the mortality from PC over the past two decades. The 
effects of PSA testing and PC screening are described in chapter 2 and 3. An increase in 
PSA testing has increased the detection of PC during the last two decades, and have lead 
to the diagnosis of cancers that rather should not have been diagnosed, as their detec-
tion and subsequent treatment is unlikely to benefit patients, or even might harm them. 
Related to this, the term ‘overdiagnosis’ is used. The clinical definition of overdiagnosis 
is the diagnosis of a tumour that would otherwise remain clinically unrecognized until 
the individual died from other causes. Overdiagnosis occurs when screening detects 
small tumours that would otherwise remain clinically unrecognized until the individual 
dies from other causes. Overdiagnosis appears to be especially harmful when it results 
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in invasive treatment of the tumours that would unlikely to be harmful. This is called 
overtreatment.
1.4.1 Symptoms and signs
As the majority of PC originates in the peripheral zone of the prostate gland (Figure 
2), they tend not to cause local symptoms until they are large tumours11. Invasion of 
a PC into the urethra or bladder neck may cause lower urinary tract symptoms, which 
are usually voiding symptoms such as poor flow, straining or hesitancy although stor-
age symptoms such as frequency, nocturia or urgency can also occur12. In the pre-PSA 
era, more men presented with evidence of locally advanced or metastatic disease such 
as back or pelvic pain due to bony metastasis, lower limb oedema due to lymph node 
involvement or compression of the iliac veins, or with renal failure due to bilateral ure-
teric obstruction13. Rare presentations include spinal cord compression or disseminated 
intravascular coagulation14-15.
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Apa t from the signs and symptoms mentioned above, there are few other physical 
signs associated with localised PC. As many tumours arise in the peripheral zone, they 
may be palpated by digital rectal examination (DRE). In advanced disease, physical signs 
may be related to local invasion such as haematuria, impotence or lower urinary tract 
obstruction. Symptoms can also be related to metastatic spread such as pathological 
fracture or lower limb oedema. With the widespread use of PSA testing, the majority of 
men are asymptomatic at diagnosis after having been investigated due to an abnormal 
PSA result7, 16-17.
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1.4.2 diagnosis of prostate cancer
DRE, PSA and transrectal ultrasound (TRUS) are the three main modalities for the early 
detection of PC.
1.4.2.1 DRE
DRE is possible due to the prostate anatomic position in the pelvis, with easy access 
for palpation using a finger placed per rectum (Figure 3). Prior to the introduction of 
PSA testing, DRE was the primary modality for diagnosing prostate cancers. Jewett 
found that approximately 50% of palpable prostate nodules were diagnosed as prostate 
cancers on prostate biopsy18. However, DRE findings are only moderately reproducible, 
even amongst experienced urologists19-20. Further, DRE tended to diagnose PC when 
they are pathologically advanced and therefore less likely to be curable by radical pros-
tatectomy21-22. The value of DRE as an early detection modality will be discussed in more 
detail in chapter 2.
 
 
Figure 3. Digital Rectal Examination of the Prostate, obtained from24 
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figure 3. Digital Rectal Examination of the Prostate, obtained from24
1.4.2.2 Prostate Specific Antigen
PSA is a protease, almost exclusively produced by the prostatic ductal and acinar epi-
thelium, which may leak into the blood stream23. PSA is in widespread use in urological 
oncology as a marker for the risk assessment before diagnosis and for the oncologic 
evaluation after treatment. An increased serum PSA level indicates an increased pros-
tate cancer risk. However, an increase in the serum PSA may also have other causes: 1) 
an increase in normal prostate glands like BPH or 2) an increased leakage of PSA into 
the bloodstream due to infectious processes or obstruction24-26. The value of PSA for the 
early detection of PC will be discussed in more detail in chapter 2.
The prostate 19
1.4.2.3 TRUS and prostate needle biopsy
TRUS, with associated prostate needle biopsy, has shown increasing popularity since 
the mid-1980s and is considered a gold standard for investigation of PC. With the de-
velopment of improved high-frequency transducers, the prostate can be visualised with 
greater resolution to aid in the identification of prostate cancer. TRUS has the advantage 
of facilitating more accurate measurements of prostate size, which may help interpreta-
tion of PSA results27-28. Prior to TRUS, biopsies were digitally directed or ‘blind’. Hodge 
et al. introduced systematic sextant biopsies which proved to be superior to blind 
biopsies29.
1.4.3 Tumour Staging
The extent of the disease is classified according to the Tumour/Node/Metastasis (TNM) 
classification (Table 1). There are two main goals for an accurate staging of PC. Firstly, to 
predict overall prognosis and secondly, to select appropriate treatment based on the 
extent of the disease. The local stage of the tumour determined by DRE, TRUS and/or 
Magnetic Resonance Imaging (MRI), is known as the clinical tumour stage. The definive 
stage, or pathological tumour stage, can only be obtained after a radical prostatectomy.
1.4.4 Histopathology of prostate cancer
Over 95% of PC are adenocarcinomas30. The rare subtypes that occur tend to be more 
aggressive than adenocarcinomas. Mucinous adenocarcinoma and ductal adenocarci-
noma occur in less than 1% of the cases but both have a more aggressive behaviour31-32. 
Transitional cell carcinomas occur in 1 to 4% of all PC and tend to be locally advanced at 
the time of presentation33. Other subtypes include small cell carcinoma and squamous 
cell carcinoma, both of which have a very poor prognosis34-35.
1.4.4.1 Tumour grade
Tumour grade describes the degree of cellular differentiation as assessed by light 
microscopy. A number of grading methods has been described for PC although the 
majority of pathologists now use the Gleason grading system. This system gives a grade 
of differentiation ranging from 1 to 5, where grade 1 is very well differentiated whilst 
grade 5 is poorly differentiated or anaplastic (Figure 3)36. The Gleason score is the sum of 
the primary Gleason grade (the most common pattern) and the secondary grade, which 
is the next most common pattern (but which should comprise of greater than 5% of the 
total tumour tissue). In cases where only one pattern is identified, the primary grade is 
doubled i.e. 3+3 = 6. The Gleason score therefore ranges from 2 to 10.
Since the introduction of the Gleason grading system more than 40 years ago many 
aspects of PC. The system was updated at a 2005 consensus conference of interna-
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Table 1. Tumour, node, metastasis (TNM) classification of prostate cancer (2009 version)
T: Evaluation of the (primary) tumour (a)
TX: Primary tumour cannot be assessed
T0: no evidence of tumour
T1: tumour present, but not detectable clinically or 
with imaging
T1a: tumour was incidentally found in less than 
5% of prostate tissue resected (for other reasons)
T1b: tumour was incidentally found in greater 
than 5% of prostate tissue resected
T1c: tumour was found in a needle biopsy 
performed due to an elevated serum PSA
T2: the tumour can be felt (palpated) on examination, 
but has not spread outside the prostate
T2a: the tumour is in half or less than half of one 
of the prostate gland’s two lobes
T2b: the tumour is in more than half of one lobe, 
but not both
T2c: the tumour is in both lobes
T3: the tumour has spread through the prostatic 
capsule (if it is only part-way through, it is still T2)
T3a: the tumour has spread through the capsule 
on one or both sides including microscopic 
bladder neck involvement (b).
T3b: the tumour has invaded one or both 
seminal vesicles
T4: Tumour is fixed or invades adjacent structures 
other than seminal vesicles: external sphincter, 
rectum, levator muscles, and/or pelvic wall.
It should be stressed that the designation “T2c” implies a tumour which is palpable in both lobes of the 
prostate. Tumours which are found to be bilateral on biopsy only but which are not palpable bilaterally 
should not be staged as T2c.
N: Evaluation of the regional lymph nodes (c)
NX: cannot evaluate the regional lymph nodes
N0: there has been no spread to the regional lymph 
nodes
N1: there has been spread to the regional lymph 
nodes
M: Evaluation of distant metastasis (d)
MX: cannot evaluate distant metastasis
M0: there is no distant metastasis
M1: there is distant metastasis M1a: the cancer has spread to lymph nodes 
beyond the regional ones
M1b: the cancer has spread to bone
M1c: the cancer has spread to other sites 
(regardless of bone involvement)
(a) Tumour found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is 
classified as T1c.
(b) Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is not classified as pT3, 
but as pT2.
(c) Metastasis no larger than 0.2 cm can be designated pN1 mi.
(d) When more than one site of metastasis is present, the most advanced category should be used.
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tional experts in urological pathology, under the auspices of the International Society 
of Urological Pathology. Gleason score 2–4 should rarely if ever be diagnosed on needle 
biopsy, certain patterns (i.e., poorly formed glands) originally considered Gleason pat-
tern 3 are now considered Gleason pattern 4 and all cribriform cancer should be graded 
pattern 437. These changes have resulted in disease upgrading. Comparing the original 
and modified Gleason systems on needle biopsy material, Gleason score 6 cancers de-
creased from 48.4% to 22% of the total, whereas Gleason score 7 increased from 25.5% 
to 67.9%38. For the most part Gleason’s original pattern 5 has remained unchanged in 
modern practice. Consequently it is difficult to compare prostate cancer data sets over 
time because survival rates seem to improve due to changes in classification. In the 
older literature Gleason score 6 included admixed cases that today would be diagnosed 
as Gleason pattern 4, with a correspondingly worse prognosis. Today cases of Gleason 
score 6 are a homogenous group of tumors lacking cribriform and poorly formed glands 
with a better prognosis. This artificial change in prognosis has been referred to as the 
Will Rogers phenomenon39.
1.4.5 Treatment
Treatment for PC depends on patient’s tumour characteristics, age and co-morbidities. 
In the management of localised PC it is impossible to state that one therapy is clearly 
superior over another because of the lack of randomized controlled trials. Localised PC 
may be treated with radical surgery (open/ laparoscopic or robot-assisted laparoscopic 
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prostatectomy) or radiation therapy (external beam radiation therapy or brachytherapy). 
A third option for patients with localized PC is active surveillance. Several factors should 
be considered when selecting a treatment option. One would be of failure based on 
clinical stage, PSA level, and Gleason score. Specific initial therapies are recommended 
according to whether the risk category is low, intermediate or high, referring to the 
patient’s risk of recurrence after therapy. Low is defined by D’Amico et al. as men with 
stage T1-T2a PC, a Gleason score 2-6, and a PSA value ≤ 10 ng/ml. Intermediate is de-
fined as any T2b PC or any Gleason 7 score or PSA value between 10 and 20 ng/ml. High 
risk is defined as those with ≥T2c PC, a Gleason scor 8-10 or a PSA value > 20 ng/ml. 
Other factors to consider when recommending treatment options include patient’s life 
expectancy, underlying medical conditions, and patient preference.
To date, it is impossible to state that one therapy for localized PC is clearly superior 
over another because of the lack of randomised controlled trials in this field. However, 
based on the available literature, some recommendations can be made. Expectant man-
agement, which is also called active surveillance consists of initially withholding radical 
treatment such as surgery or radiation therapy, but monitoring the disease instead 
according to a fixed pattern of frequent investigations40. When the first indications arise 
that disease progression occurs, the switch to radical treatment with curative intent and 
within the window of curability is advised. Since approximately 50% of men with screen 
detected PC are overdiagnosed, meaning, their cancer would never have caused any 
symptoms, active surveillance is an attractive approach to the management of early PC. 
This may save men the side effects of treatment, without compromising survival. There 
are no data from randomized trials on the safety and efficacy of active surveillance; 
however, encouraging results have been reported from several centers41-42.
Radiation therapy is another option for the treatment of localized PC. Previously, the 
use of nonconformal radiation therapy necessitated lower doses of radiation to avoid 
an unacceptably high risk of side effects; this resulted in a higher likelihood of cancer 
recurrence43. Currently, radiation therapy is most commonly delivered by means of 
conformal, externally applied techniques. Either three-dimensional imaging is used to 
localize the prostate and the beams are shaped to match the contour of the prostate, or 
radioactive iodine-125 or palladium-103 seeds are implanted directly into the prostate. 
Prospective studies have shown that higher doses of radiation can be delivered safely 
with the use of conformal techniques, with better cancer control than is achieved with 
the use of nonconformal techniques44-45. The advantages of radiation therapy are that 
it is noninvasive or minimally invasive and it is less likely than radical prostatectomy to 
cause certain complications such as severe urinary incontinence46. In addition, radiation 
therapy can be used in the care of men with nonmetastatic prostate cancer of various 
degrees of severity, including men who are at higher risk for extraprostatic extension. 
There are no data from well-controlled, randomized trials comparing the treatment out-
The prostate 23
comes of radiation therapy and surgery. Nonetheless, observational data suggest that 
the long-term disease control achieved with contemporary radiation therapy is similar 
to that achieved with radical prostatectomy47-48.
Radical prostatectomy involves removal of the entire prostate and seminal vesicles 
along with sufficient surrounding tissue to obtain a negative surgical margin; this pro-
cedure is often accompanied by a bilateral pelvic lymph-node dissection. The perceived 
advantage of radical prostatectomy is that there is no better way to cure a cancer that 
is completely confined to the prostate than total surgical removal. Radical retropubic 
and perineal prostatectomies are performed through open incisions or laparoscopically, 
sometimes with robot-assisted methods. As compared with other approaches, laparo-
scopic approaches are associated with less blood loss during surgery, but this reduction 
in blood loss has not led to a reduction in the need for transfusion, nor has it led to a 
decrease in pain or the duration of hospitalization49. Observational data indicate that, 
as compared with earlier surgical approaches, the anatomical approach results in less 
blood loss, a 30-day mortality after surgery that is 10 times lower (0.2 to 0.4%), and, 
in the hands of an experienced surgeon using the nerve-sparing technique, reduc-
tions in the rates of the two most common surgical complications: clinically significant 
incontinence (3%) and impotence (30%)50-51. However, other estimates from studies in 
the United States have been less promising, with rates of incontinence as high as 74% 
and rates of impotence as high as 90%52-53. Thus, patients considering surgery should 
be referred to surgeons with considerable experience in order to optimize the likeli-
hood of effective cancer control and to minimize the likelihood of complications. One 
randomized controlled trial is known comparing radical prostatectomy with expectant 
management of localized PC. It has shown improved cancer-specific survival rates in 
favour of radical surgery54-55. This study concluded that it is effective to treat men with 
early stage PC who have a life expectancy of at least 10 years or more. However, most of 
the patients in this study did not harbour screen-detected PC, so these data cannot be 
automatically transferred into daily routine practice.
Metastasized PC cannot be cured and will in time always lead to death unless co-
morbidity causes interfere earlier. Temporary suppression of the disease is possible 
using different types of hormonal therapy; chemotherapy is an option in the terminal 
phase of the disease56-57.
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2.1 bACkGROUNd
Secondary prevention through screening would be an appealing option for PC. This 
chapter aims to present the evidence available on the efficacy of screening of asymp-
tomatic men for PC.
2.2 EVIdENCE ACqUISITION
A MEDLINE search was performed using the term “prostate cancer” and “screening” with 
other relevant keywords. Randomized controlled trials of screening versus no screening 
for PC were included. Studies with inadequate randomization were excluded. Studies 
that evaluated the complications, and the sensitivity and specificity of the screening 
test used, were eligible for this review. The searches were limited to English-language 
articles.
2.3 SCREENING fOR CANCER
The objective of screening is to identify a disease at a stage in its natural history where 
treatment can be applied to prevent death or suffering58. Screening aims to avoid deaths 
from cancer by preventing the development of advanced disease. Therefore, effective 
treatment of early staged disease is essential to attain the aims of screening. Although 
screening may lead to an earlier diagnosis, screening tests will not always benefit the 
person being screened; overdetection (detected cancers that would not have been diag-
nosed in the absence of screening) with potential resultant of overtreatment (treatment 
of cancers that would not have been diagnosed in the absence of screening), increased 
costs, side effects and complications are potential adverse effects of screening58-59.
The final endpoint of a cancer screening trial is cancer specific mortality. However, 
there are more criteria that have to be fulfilled before screening can be adopted in a 
public health program. A total of ten WHO-criteria for appraising the validity of a 
screening program were developed by Wilson and Jungner, Table 160. These criteria 
were listed in 1968 and still upheld today as “classic” and “the gold standard” of screen-
ing assessment61. Nevertheless, these criteria have been discussed to be too vague or 
theoretical, and an exchange of views regarding screening policies has occurred over 
the last decades62-63. This has resulted in several adoptions to the classic criteria, which 
are emerged in ten new criteria, Table 2. The majority of the more recent criteria overlap 
with the classic criteria, particularly with regard to screening for health conditions at an 
early stage, where there exist effective interventions to improve outcomes compared 
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to clinical care. Finally, many Western European countries have their own updated legal 
regulations on mass screening64-67.
2.4 SCREENING TESTS fOR PROSTATE CANCER
The main tool in screening for PC is the Prostate Specific Antigen (PSA) test. PSA is a 
human protein that is secreted by prostate epithelial cells23-24. The PSA test seems to be 
acceptable to the population as a screening procedure since the participation and ad-
herence to screening in subsequent screening rounds is overall high68. PSA is a specific 
organ marker, but not strictly a tumour marker, since prostatitis and benign prostate 
hyperplasia (BPH) can also increase the serum PSA69-70. In part due to this, no clear PSA 
threshold level exists for the detection of PC71.
Thompson et al. demonstrated this in a study in which men with a PSA ≤ 3.0 ng/ml 
and a normal Digital Rectal Examination (DRE) were randomized to an antiandrogen 
Table 1. Ten criteria by Wilson and Jungner, 196862
1. Condition sought should be an important health problem.
2. There should be an accepted treatment for patients with recognized disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to declared disease, should be 
adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically 
balanced in relation to possible expenditure on medical care as a whole. 
10. Case finding should be a continuing process and not a “once and for all” project 
Table 2. The ten updated criteria by Andermann et al.65
1. The screening programme should respond to a recognized need.
2. The objectives of screening should be defined at the outset. 
3. There should be a defined target population. 
4. There should be scientific evidence of screening programme effectiveness. 
5. The programme should integrate education, testing, clinical services and programme management. 
6. There should be quality assurance, with mechanisms to minimize potential risks of screening. 
7. The programme should ensure informed choice, confidentially and respect for autonomy. 
8. The programme should promote equity and access to screening for the entire target population. 
9. Programme evaluation should be planned from the outset. 
10. The overall benefits of screening should overweight the harm. 
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and placebo72. After 7 years, in all men with a PSA < 4.0 ng/ml and a normal DRE biopsies 
were performed and in 15% of these men PC was detected. In 15% of these PCs a tumour 
with a Gleason score ≥ 7 was detected72. According to these study results, a physician 
who would like an 80% confidence in not missing a PC, should apply a PSA cut-off value 
of 1.1 ng/ml as indication for biopsy, which would result in 60% unnecessary (negative) 
biopsies73. In Table 3, the continuum of PC risk for different PSA ranges is presented as 
a result of the Prostate Cancer Prevention Trial (PCPT) and the European Randomised 
Study of Screening for Prostate Cancer (ERSPC)72,  74. As shown, sensitivity decreases 
with the increasing PSA level, while specificity increases with the increasing PSA level. 
Consequently, lowering PSA cut-off levels leads to a higher detection rate of PC, but also 
leads to an increase of negative (unnecessary) biopsies and of the diagnosis of cancers 
which might otherwise never bother their carrier (potentially overdiagnosed cancers)75.
Currently, the suggested PSA cut-off to biopsy a man for screening differs between 
2.6 and 4.0 ng/ml68, 76-77. Future data that include the comparison of the different studies 
Table 3: The continuum of prostate cancer risk for different PSA ranges
Authors Methods Results Notes
Thompson 
et al., 
2005, 
PCPT73
Among 5587 men a 
PSA determination 
and a sextant 
prostate biopsy was 
performed to assess 
the sensitivity and 
specificity of PC 
detection for all PSA 
ranges in relation to 
Gleason grade.
PSA, 
ng/ml
PC, any grade PC, Gleason grade ≥ 8 N= 1225 
(21.9%) 
were 
diagnosed 
with 
prostate 
cancer
Sen (%) Spec (%) LR Sen (%) Spec (%) LR
1.1 83.4 38.9 1.4 94.7 35.9 1.5
2.1 52.6 72.5 1.9 86.0 65.9 2.5
2.6 40.5 81.1 2.1 78.9 75.1 3.2
3.1 32.2 86.7 2.4 68.4 81.0 3.6
4.1 20.5 93.8 3.3 50.9 89.1 4.7
6.1 4.6 98.5 3.1 26.3 97.5 10.5
10.1 0.9 99.7 3.0 5.3 99.5 10.6
Schröder 
et al., 
2008, 
ERSPC76
Among 9779 men 
the cancer detection 
rate for different PSA 
ranges in the ERSPC, 
section Rotterdam 
was assessed. 
Distribution of PSA 
and prostate cancers 
in men aged 55-74 
yr biopsied (2267 
men) for PSA ≥ 4.0, 
DRE, and TRUS are 
demonstrated.
PSA, 
ng/ml
Total 
biopsies (%)
Cancer 
(n)
Total 
cancer (%)
PPV Biopsy (n) 
per cancer
0.0-0.9 36.4 4 0.8 2.2 45.8
1.0-1.9 31.2 45 9.5 8.8 11.4
2.0-2.9 12.3 30 6.3 13.6 7.4
3.0-3.9 7.2 44 9.3 25.3 3.9
4.0-9.9 10.9 241 51.0 24.5 4.1
≥ 10.0 2.1 109 23.0 56.5 1.8
PCPT: Prostate Cancer Prevention Trial, ERSPC: European Randomised Study of Screening for Prostate 
Cancer, PC: prostate cancer, PSA: prostate specific antigen, DRE: digital rectal examination, TRUS: 
transrectal ultrasound, Sen: sensitivity, Spec: specificity, LR: likelihood ratio, PPV: positive predictive value
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with long follow up might show the difference in mortality and morbidity outcomes 
using these different PSA thresholds.
Although DRE is widely used for the diagnosis of PC, the value of DRE remains con-
troversial in screening and early detection programs for PC78. The acceptability of the 
DRE test as a screening procedure seems to be less than PSA since the participation in 
Table 4: Positive predictive of DRE for prostate cancer detection in low PSA ranges
Authors Methods Results
Crawford., 199681 Methods of prostate cancer early detection, 
to assess the positive predictive of DRE for 
different PSA values. N = 31 953
The positive predictive value of DRE in 
the lower PSA areas:
PSA PPV
0.0-4.0 15%
4.1-9.9 34%
Schröder et al.,1998, 
ERSPC82
To assess the usefulness of DRE as a stand-
alone screening test in low PSA ranges, ERSPC-
Rotterdam.  N= 10 523
The positive predictive value of DRE in 
the lower PSA areas:
PSA PPV
0.0-0.9 4%
1.0-1.9 10%
2.0-2.9 11%
3.0-3.9 33%
4.0-9.9 45%
Yamamoto et al., 
200183
Investigate the usefulness of DRE for prostate 
cancer diagnosis in subjects with PSA levels of 
4.0 ng/ml or less. N = 90
The positive predictive value of DRE in 
the lower PSA areas:
PSA PPV
0.0-0.9 4%
1.0-1.9 0%
2.0-2.9 19%
3.0-4.0 44%
Bozeman et al., 
200584
Men with abnormal DRE findings and a PSA 
level less than 4.0 ng/ml who underwent 
prostate biopsy to assess the positive 
predictive value of DRE for men PSA <4.0 ng/
ml. N= 986
The positive predictive value of DRE 
for PSA < 4.0 ng/ml:
PSA PPV
0.0-0.9 2%
1.0-1.9 6%
2.0-2.9 13%
3.0-3.9 21%
Andriole et al., 2005, 
PLCO85
Diagnostic evaluation of DRE as initial 
screening test in lower PSA ranges.
N = 34 115
The positive predictive value of DRE in 
the lower PSA areas:
PSA PPV
0.0-4.0 17%
4.1-7.0 47%
ERSPC: European Randomised Study of Screening for Prostate Cancer, PLCO: Prostate, Lung, Colorectal, 
and Ovarian Cancer Screening Trial, PC: prostate cancer, PSA: prostate specific antigen, DRE: digital rectal 
examination, Gr: group, PPV: positive predictive value, CDR: cancer detection rate
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a screening program with combined DRE and PSA was twice as low as with PSA alone68. 
Table 4 provides an overview of the positive predictive value for DRE in the lower PSA 
ranges. According to Table 4, DRE has a low sensitivity and predictive value in men with 
low PSA levels79-83. The positive predictive value of DRE is limited to 4–19% at serum PSA 
levels below 3.0 ng/ml. This proportion equals to the percentage of 15% cancers that 
were diagnosed in the study of Thompson et al. in which they performed biopsies in 
all men with a PSA < 4.0 ng/ml without using DRE72. Therefore, the studies presented in 
Table 4 might have found a similar PC detection rate without the use of DRE in the PSA 
levels 3.0 ng/ml and lower. Accordingly, it might be concluded that men with low PSA 
values have a 15% PC detection rate with or without the use of DRE, and that conse-
quently the additional value of the DRE is restricted in lower PSA ranges.
In contrast, several researchers still suggest that with the use of DRE men will be 
screened more selectively. It is shown that men with a positive DRE are more likely to 
have high grade PC than men with non-palpable tumours84-85. For this reason, the risk 
of omitting DRE, and therefore the omission of biopsies at PSA <2.6, <3.0 or <4.0 ng/ml, 
might be that potentially aggressive tumours at these low PSA levels remain undetected 
at screening. Catalona et al. have confirmed this risk by showing that a substantial 
proportion of PC detected by DRE at PSA levels lower than 4.0 ng/ml have features as-
sociated with clinically aggressive tumours and that the omission of DRE from screening 
protocols might comprise treatment outcomes as omitting DRE at PSA levels less than 
3.0 ng/ml would have detected 14% fewer PC overall and 7% fewer PC with a Gleason 
score of 7 or higher86. In contrast, it is shown that screening without DRE at low PSA 
levels (PSA<3.0 ng/ml) did not lead to the detection of significantly more (poorly dif-
ferentiated) PCs 4 years later compared to screening with the use of DRE in the ERSPC87.
2.5 COMPLICATIONS Of SCREENING TESTS
The complications of the PSA and DRE are limited, but prostate biopsies are related to 
clinical complications88-89. These complications vary between studies since they depend 
on the antibiotic prophylaxis used, study population and the number of prostate biop-
sies performed88-89. Djavan et al89 reported in their literature review, that included eleven 
prospective PC detection studies, haematuria and haematospermia in 12.5-58.4% and 
5.1-50.5% of the procedures, respectively. In these same studies, rectal bleeding was 
reported in 2.8-37.1% of men, 1.4-4.2% of men reported fever after prostate biopsies, 
0-0.5% of men needed hospitalization due to symptoms of sepsis or prostatitis89. Overall, 
0-1.2% of men reported urinary retention after prostate biopsies89.
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2.6 RANdOMIzEd CONTROL TRIALS fOR PROSTATE CANCER SCREENING
Two leading randomized control studies are designed to evaluate the effectives of 
screening (Table 5). The European Randomised Study of Screening for Prostate Cancer 
(ERSPC) and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO 
trial) were designed to evaluate whether population-based screening reduces the 
mortality from PC, with an acceptable level of quality-of-life aspects and the associated 
costs68, 77.
The ERSPC is conducted in eight European countries (Belgium, Finland, France, Italy, the 
Netherlands, Spain, Sweden, Switzerland) and enrolled 267,994 men 55-74 years of age. 
All men with a prior diagnosis of PC were excluded. In the ERSPC men were screened in 
most countries with an interval of four years, however, in Sweden men were screened 
with an interval of two years. The screening algorithm differed among the study centres 
(Table 5)90-96.
The PLCO is a trial in the United States that enrolled 155,000 women and men, 55-74 
years of age, in ten screening centres. All men with a prior diagnosis of PC were excluded. 
Table 5. Characteristics of the randomized control trials for prostate cancer screening
Study: European Randomised Study of Screening for Prostate Cancer70
Methods: Initiated in 1993, randomized 267,994 men.
Participants: Male inhabitants of Belgium, Finland, France, Italy, the Netherlands, Spain, Sweden, 
Switzerland, aged 55–74 years.
Men with a previous diagnosis of prostate cancer were excluded.
Intervention: Screening with an interval of 4-years (except in Sweden, i.e. 2-years) versus control (not 
invited for screening).
Screening included a PSA test or a DRE/TRUS. TRUS biopsy was performed in screen 
positives. Men were screen positive in France, Sweden, Switzerland, Spain by a PSA ≥3.0 
ng/ml; in Finland by PSA ≥4.0 ng/ml (men PSA 3.0-3.9 had an ancillary test, i.e. DRE until 
1998, free/total PSA ratio with a cut-off ≤ 0.16 from 1999 onwards); in Italy by PSA ≥ 4.0 ng/
ml (men PSA 2.5-3.9 ng/ml had an ancillary test, i.e. DRE and TRUS); in the Netherlands and 
Belgium by positive DRE and/or TRUS and/or PSA ≥ 4.0ng/ml, but after 1997 by PSA ≥3.0 
ng/ml only.
Study: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial79
Methods: Initiated in 1993, randomized 76,693 men.
Participants: Male inhabitants of United States, aged 55–74 years.
Men with a previous diagnosis of prostate cancer were excluded.
Intervention: Annual screening versus control (not invited for screening).
1st screening round included a PSA test and a DRE. TRUS biopsy was recommended in 
cases with PSA 4.0 ng/ml and/or abnormal DRE. Follow up screening included a PSA test 
and a DRE during the first three screenings.
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In the PLCO men in the intervention arm received annual screening by DRE and serum 
PSA determination (Table 5)77.
2.6.1 RESULTS
2.6.1.1 Interim results prostate cancer screening
In the ERSPC and the PLCO trial more men were diagnosed with PC in the intervention 
arm than in the control arm of the study97-98. In the ERSPC the cumulative incidence of PC 
was 8.2% and 4.8% for the intervention and control group respectively after 9 years98. In 
the PLCO trial, PC was diagnosed in more subjects in the intervention group (7.3%) than 
in the control group (6.0%) at 7 years97.
In the ERSPC and PLCO screening trial a stage distribution was observed among men 
that were screened for PC. In the Rotterdam section of the ERSPC, after comparing the 
intervention arm with the control arm, a statistically significant migration to more favour-
able stages was observed in the intervention arm (Table 6)99. In the screening population 
of the PLCO the large majority of PC were stage II at diagnosis, regardless of the mode 
of detection in the screening group. However, overall the numbers of subjects with ad-
vanced (stage III or IV) tumours were statistically similar in the screening and the control 
group, with 122 men in the screening group and 135 men in the control group (Table 6)100.
Table 6. Tumour characteristics prostate cancer detected in the intervention and the control arm of the 
ERSPC and the PLCO101-102
ERSPC study, section Rotterdam
Tumour stage Intervention arm
No. men, (%)
Control arm
No. men, (%)
1st screening round
No. men, (%)
2nd screening round
No. men, (%)
I 685 (40.6) 114 (33.9) 252 (30.8) 203 (60.4)
II 553 (43.6) 84 (25.0) 391 (47.8) 120 (35.7)
III 184 (14.5) 64 (19.0) 164 (20.0) 13 (3.9)
IV 13 (1.0) 13 (4.0) 11 (1.4) -
Unknown 4 (0.3) 61 (18.1) - -
PLCO study
Tumour stage Intervention arm
No. men, (%)
Control arm
No. men, (%)
1st screening round
No. men, (%)
2nd screening round
No. men, (%)
I 18 (0.5) 15 (0.5) 2 (0.4) 2 (0.1)
II 3297 (95.5) 2790 (93.8) 516 (94.0) 1458 (97.2)
III 49 (1.4) 56 (1.9) 12 (2.2) 22 (1.5)
IV 73 (2.2) 79 (2.7) 19 (3.4) 15 (1.0)
Unknown 15 (0.4) 34 (1.1) 0 (0.0) 3 (0.2)
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The reported interval cancers (those clinically diagnosed within a screening interval) in 
the ERSPC and PLCO trial were infrequent and in general had favourable characteristics. 
The ERSPC-Rotterdam reported in the first four years after initial screening 25 interval 
cancers. Seven of the 25 cancers were diagnosed in men who had refused a recom-
mended biopsy at their initial screen. Of the remaining 18 cancers, all were classified as 
stage T1A-C or T2A, none were poorly differentiated or in a metastatic stage101. In the 
PLCO, 204 interval cancers were diagnosed. Of these cancers 96.1% were classified as 
stage T1A-C or T2A and 2.0% were classified as stage IV disease100.
2.6.1.2 final results prostate cancer screening
Mortality data have been presented by the ERSPC and PLCO trial (Table 7). The ERSPC 
trial reported that PSA screening without digital rectal examination was associated with 
a 20% relative reduction in the death rate from PC at a median follow-up of 9 years102. 
The absolute reduction in the screening population was 7 PC deaths per 10,000 men 
that were screened. The results were associated with a number of 1410 men that needed 
to be screened and 48 men that needed treatment to save one death from PC death. 
The treatment distributions were slightly different between the two groups, however 
unlikely to play a major role in interpretation of the final results103. Data analysis of the 
ERSPC with adjustment for the diluting effect of nonattendance and contamination 
showed that the mortality effect among men was increased to 30%104-105. In the ERSPC, 
82.2% of the men in the screening group were screened at least once and the average 
Table 7.  Final outcomes prostate cancer screening trials and limitations
ERSPC study100
Reduction PC mortality NNS NNT Limitations
Rate Ratio: 0.80
(95%CI:0.60-0.99)
1410 48 Different study protocols: The different centres of participants used 
(marginally) different study protocols.
Contamination: In 20-30% of men in the control group a PSA test 
was performed.
PLCO study99
Reduction PC mortality NNS NNT Limitations
Rate Ratio: 1.13
(95%CI:0.75-1.70)
- - Contamination: In 40-52% of men in the control group a PSA test 
was performed and in 41-46% of men a DRE test. 9.3% of men 
reported having had two or more PSA tests before start of the study.
44% of the men in each study group had undergone one or more 
PSA tests before randomization.
Low compliance prostate biopsies: in 40% of men with a positive 
screening test a biopsy was actually performed in the intervention 
arm.
ERSPC: The European Randomised Study of Screening for Prostate Cancer; PLCO: The Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial; NNS: number needed to screen to save one death from 
prostate cancer. NNT: number needed to treat to save one death from prostate cancer
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rate of compliance with biopsy recommendations was 85.8% (range, 65.4 to 90.3)98. The 
level of contamination by PSA testing in the control group was estimated in the order 
of 20-31%104, 106-107.
The Gothenburg screening trial, which is part of the ERSPC, has published their own 
mortality outcomes. The Gothenburg trial was initiated as an independent study in 1994 
as an effectiveness trial (without upfront informed) but joined the ERSPC trial shortly 
thereafter. Data up to 2008, after a median follow up of 14 years, showed a RR for PC 
death of 0.56 (95%CI 0.39-0.82, p = 0.002). This resulted in a NNS of 234 and NNT of 15. 
The main differences with the ERSPC as a whole are the type of randomization, younger 
age, a shorter screen interval, and, most importantly, a longer follow-up due to the 
simultaneous randomization of all participants in 1994.
The PLCO trial found no mortality benefit from combined screening with PSA testing 
and DRE during a median follow-up of 7-10 years comparing those screened to those 
that were not97. The incidence of PC death per 10,000 person-years was 2.0 (50 deaths) 
in the screening group and 1.7 (44 deaths) in the control group (rate ratio, 1.13; 95% CI, 
0.75 to 1.70) after a median of 7 years follow-up. The data at 10 years were 67% complete 
and consistent with these overall findings. The treatment distributions were similar in 
the two groups within each tumour stage97. In the PLCO trial the compliance with the 
screening protocol overall was 85% for PSA testing and 86% for DRE97. The average rate 
of compliance with biopsy recommendations was 40%. The level of contamination is 
well established, i.e. the rate of PSA testing was 40-52% and the rate of screening by DRE 
ranged from 41 to 46% in the control group97. Approximately 44% of the men in each 
study group had undergone one or more PSA tests before randomization, which would 
have eliminated some cancers detectable on screening from the randomized popula-
tion, especially in health-conscious men (who tend to be screened more often, a form of 
selection bias). No results are available for the effect of screening after the adjustment 
for the contamination, however the PC specific mortality was 25% lower among the men 
who were screened prior to randomization in the PLCO97.
Whereas the ERSPC found a statistically significant reduction in PC mortality with screen-
ing, the PLCO trial did not. In the PLCO trial the contamination in the control group and 
compliance with the screening protocol in the intervention group is of major influence. 
This is highlighted in the stage distribution among the men in the control arm of the 
PLCO study. In comparison to the 96% of men diagnosed with a stage ≤ II tumour in the 
intervention arm, were 94.3% of men with a stage ≤ II tumour diagnosed in the control 
arm of the PLCO. Consequently, the PLCO trial is more a trial comparing two screen-
ing strategies of a different intensity and is inadequate in establishing if PC screening 
has the potential to reduce the PC specific mortality. Therefore, we can conclude that 
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systematic PC screening is not effective in terms of reducing the PC specific mortality in 
comparison to widespread opportunistic screening and early detection.
The ERSPC is a randomized controlled trial with an adequate methodological design, a 
high level of compliance in the intervention group and a relative low level of contamina-
tion in the control group of the study. Furthermore, an intention-to-screen analysis, and 
an analyses with adjustment for non-attendance and contamination are available. In 
essential, the ERSPC provides clear evidence that screening for PC has the potential to 
reduce the PC specific mortality.
2.7 POTENTIAL HARMS Of PROSTATE CANCER SCREENING
It is proven that screening increases the PC incidence97-98. The excess incidence and over-
treatment are associated with a distinct pattern of change in quality of life108-109. Quality 
of life (QoL) parameters that are affected, are a change pattern in the urinary, bowel, and 
erectile functions, as well as the emotional distress and anxiety108-109. Currently, no QoL 
analysis is presented by the ERSPC study group, nore by the PLCO study group.
2.8 COST EffECTIVENESS Of PROSTATE CANCER SCREENING
No results from randomized controlled trials are reported on cost effectiveness, cost 
utility or cost benefit of screening for PC.
2.10 OTHER CANCER SCREENING PROGRAMS
Randomized controlled trials demonstrated contradictory results that mammographic 
screening reduces mortality from breast cancer or not. Two trials with adequate ran-
domisation did not show a significant reduction in breast cancer mortality: rate ratio (RR) 
0.93 (95CI: 0.80 - 1.09) at 13 years110. In contrast, four trials with adequate randomisation 
showed a significant reduction in breast cancer mortality, RR: 0.75 (95%CI: 0.67 - 0.83)110. 
The RR for all six trials combined was 0.80 (95%CI: 0.73 - 0.88)110. Data from prospective 
studies have found that the NNS to save one breast cancer specific death to be 1500 and 
the NNT to save one cancer specific death 10110-112. It has been established that breast 
screening is cost effective (Table 8)113.
Screening for colorectal cancer is implemented in many European countries114. For 
colorectal cancer screening data is available from four eligible randomised control trials 
showing that participants allocated to screening with faecal occult blood test had a 16% 
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reduction in the relative risk of colorectal cancer mortality, RR: 0.84 (95%CI: 0.78-0.90)115. 
When adjusted for screening attendance in the individual studies, there was a 25% rela-
tive risk reduction (RR 0.75, 95%CI: 0.66 - 0.84) for those attending at least one round of 
screening using the faecal occult blood test115-116. The NNS to save one cancer specific 
death would be in the order of 600 cases and the NNT in the order of 2 cases115-117. Sev-
eral studies indicated that colorectal screening is cost effective (Table 8)118-119.
Lung cancer screening using regular chest radiography and sputum examination pro-
grams were not effective in reducing mortality from lung cancer. Studies showed that 
early detection of lung cancer was possible with such programs, but mortality was not 
improved120. Currently, randomized control studies using computed tomography (CT) 
scan are ongoing for lung cancer in high risk patients, however results are not expected 
before 2010 (Table 8)121-122.
Table 8.  Screening for breast, colorectal, lung and cervix cancer
Breast Cancer60-63
Mortality NNS NNT Cost effectiveness Comments
RR: 0.80 (95%CI: 0.73-0.88) 1500 10 Yes - Results from RCT
- Contradictory results 6 trials
Colorectal Cancer65-68
Mortality NNS NNT Cost effectiveness Comments
RR: 0.84 (95%CI: 0.78-0.90) 600 2 Yes - Reduction mortality increased 
to 25% after adjustment for 
nonattendance.
Lung Cancer69,70
Mortality NNS NNT Cost effectiveness Comments
No reduction - - No - RCT with chest radiography and 
sputum cytology  showed no 
reduction in mortality.
- RCT with computed tomography 
are ongoing
Cervix Cancer71-73
Mortality NNS NNT Cost effectiveness Comments
Reduction between 5-80% - - Yes - No results RCT
- Mortality declined between 5 
and 80% in 5 countries after start 
screening.
NNS: number needed to screen to save one death from cancer. NNT: number needed to treat to save one 
death from cancer. RCT: Randomized Controlled Trial
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For cervical cancer, Cytological Papanicolaou (Pap) smear screening remains the 
best method readily available in reducing the incidence and mortality. No randomized 
controlled trials are performed indicating that screening for cervical cancer reduces the 
mortality. However, various studies (mainly time series and case-control) revealed that 
widespread use of cervical screening in developed countries has been associated with 
the substantial reduction in rate of mortality from cervical cancer. A study conducted in 
five northern European countries investigated the time trends in mortality from cervical 
cancer in relation to the extent and intensity of organised screening programmes. In 
all five countries the cumulative mortality rates (0-74 years) fell with 80%-5% between 
1965 and 1982123. The NNS was in the order of 100-300 women124. Although there is 
no universal criterion that defines a threshold cost-effectiveness ratio, above which 
an intervention would not be considered cost-effective, the cost-effectiveness studies 
concluded that cervical screening falls within the acceptable limits of cost-effectiveness, 
i.e., less than $500 per year of life saved (Table 8)125.
PC screening has, relative to screening for breast and colorectal cancer, a comparable 
impact on the relative risk reduction in cancer specific mortality. Nevertheless, the 
absolute benefit of PC screening is modest compared to screening for colorectal cancer. 
For this reason, compared to other colorectal cancer screening, a relatively high number 
of men would need PC screening to prevent one man from cancer specific death. Finally, 
the additional number of men that are diagnosed with PC is large in comparison to 
breast and colorectal cancer screening. On this regard, the main limitation of PC screen-
ing is the difference in natural history of the disease and/or the lack of a screening test 
with a high sensitivity and specificity for aggressive cancer. Finally, in comparison to 
screening for breast, cervical and colorectal cancer, no evidence is available that PC 
screening is cost effective.
2.11 CONCLUSIONS
Based on the presented evidence so far we can conclude that in theory screening for 
PC is an appealing option since the disease has a number of characteristics that makes 
it suitable for screening. PC is an important public health problem with 20 men dying 
every day from PC in the Netherlands. With PSA and DRE, acceptable and moderately ac-
curate tests are available and the complications of prostate biopsies are limited. PC has 
a long latent stage which provides the possibility to produce a beneficial stage shift to 
more favourable stages by screening. Curative treatment of localized PC reduces the PC 
specific mortality relative to expected management in a selected population. Screening 
for PC reduces the disease-specific mortality significantly. However, PC screening causes 
Prostate cancer screening 39
a significant increase in the cumulative incidence of PC and no robust evidence is avail-
able regarding the economical quality of life implications of PC screening. Furthermore, 
there is limited understanding of the natural history of screen-detected PC, meaning 
that there is a lack of data indicating which specific PC will develop from indolent to 
significant disease and which PC will not surface clinically during lifetime if left undiag-
nosed and/or untreated. For these reasons, there is no agreed policy which men should 
be treated with aggressive curative treatment and which men might be treated by an 
expectant management in order to reduce the overdiagnosis.
In conclusion, currently the scientific basis for the introduction of a population-
based PC screening program is insufficient since a number of essential criteria are not 
met60, 63-67. Follow up of the ongoing randomized controlled trials is crucial before rec-
ommending population based prostate cancer screening. A more convenient balance 
between the screening harms and benefits seems to be needed in which a reduction 
of the overdiagnosis is crucial. Since the decision whether to introduce a population 
based screening program will also be based on an appropriate economic and quality 
of life analysis taking into account the quality of life aspects of the screening program, 
introduction of a population based PC screening program depends on further progress 
in these areas of regards.
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3.1 INTROdUCTION
Trends in prostate cancer (PC) incidence, survival and mortality have been changing 
worldwide during the last three decades7, 126. The interpretations of these trends have 
shown to be confusing without proper knowledge of the natural history of PC and 
proper statistical data on outcomes. In this chapter we explored the outcome measures 
(i.e., cancer incidence, survival and mortality) in general, and studied the trends in PC 
incidence, survival and mortality during the last decades in the Netherlands.
3.2 INCIdENCE
Cancer incidence is defined as the number of new cancers occurring in a specified popu-
lation during a year, usually expressed as the number of cancers per 100,000 persons 
at risk7. Cancer incidence is an important measure since it reflects the processes that 
drive disease progression, the inheritance of predisposing genetic variants, and the 
consequences of carcinogenic exposures.
Cancer incidence trends could be misinterpreted due to potential technical diagnostic 
difficulties that have to be taken into account. First, incidence data have to be quantified 
and evaluated on incompleteness and inaccuracy127. Additionally, a consensus has to be 
made with respect to the definition of cancer. Usually cancers are defined by patholo-
gists in terms of the extent of tumour invasion, however, studies attest that there is not 
a complete concordance between pathologists in the diagnosis of cancers and some 
types of cancer are often not histologically proven128.
A more serious problem is that the cancer incidence is measured at a point in time at 
which the diagnosis takes place, somewhere in the continuum of the natural history of 
cancer. Histological specimens taken from individuals, in whom there were no symptoms 
or no clinical suspicions of cancer, can detect cancers that would not have surfaced clini-
cally during an individual’s lifetime129. This can occur during opportunistic or systematic 
screening for cancer. Screening aims to advance the diagnosis, and so when introduced 
it will give rise to a temporary rise in incidence58. Therefore, screening for cancer can be 
of major influence on the cancer incidence over time.
3.2.1 PROSTATE CANCER INCIdENCE
The incidence of PC has been rising during the last decades in the Western world8. Figure 
1 presents the age-standardized rates for PC incidence between 1988 and 2006 in the 
Netherlands. With the introduction of PSA testing in the late 1980s, the age-adjusted 
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incidence rates rose from 60.1 cases / 100,000 men in 1990 to more than 100 cases / 
100,000 men after 2003.
It is the effect of screening which has resulted in the dramatic increase in PC incidence 
during the last decades130. Since the intensity of screening differs between different 
population it affects incidences in different population to a different degree. Given the 
very large affect of screening on incidence it is unlikely that the inheritance of predis-
posing genetic variants and the consequences of the change in carcinogenic exposures 
will be quantified by the population based PC incidence trends of the latest years.
3.2.2 ExCESS INCIdENCE ANd OVERdIAGNOSIS
Screening and early detection should identify cancers that will become clinically rele-
vant. In this case, the number of individuals diagnosed with cancer would be unaffected 
by screening. However, early detection and screening can be associated increases in 
incidence, raising the question of over-diagnosis. The clinical definition of overdiagnosis 
is diagnosing tumors that would otherwise remain clinically unrecognized until the 
individual died from other causes. Overdiagnosis occurs when screening detects small 
tumors that would otherwise remain clinically unrecognized until the individual dies 
from other causes. Thus, cancers that are found by over-diagnosis never progress to 
cause symptoms or death. In PC, randomized screening trials show an excess incidence 
in the screened group compared to control subjects. Excess incidence is considered a 
proxy for over-diagnosis. Excess incidence is defined as the difference between the actu-
ally observed and the expected number of cancers at a moment of follow-up.
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3.3 SURVIVAL
Cancer survival is the study of the distribution of times, e.g., the time from a diagnosis to 
some terminal event (relapse or death)131. It refers to the fraction of a population which 
will survive past a certain time. Two methods for studying cancer survival are discussed 
hereunder, i.e., cause specific survival and relative survival. Cause specific survival 
represents the probability of surviving a given cancer at a particular point in time132. It 
allows excluding death due to unrelated causes in patients suffering from the cancer 
in question. As a result, the estimation of cause specific survival proportions require 
reliably coded information on cause of death. It is possible to reliably ascertain causes of 
death by the review of patients medical records with the use of predetermined clinical 
algorithms133. However, usually the causes of death are based on the primary cause of 
death that is recorded on the death certificate134. Consequently, this assessment of the 
cause of death may not be sufficiently reliable particularly when patients are older or 
have considerable co-morbidities133, 135-137.
The second method is the relative survival analysis. Relative survival is defined as the 
ratio of the proportion of observed survivors in a cohort of cancer patients to the pro-
portion of expected survivors in a comparable cohort of cancer free individuals138. In 
practise the expected survival is often calculated on the basis of a cohort of individuals 
from the general population matched by age, race, sex, and period139. There are three 
methods that differ regarding how long each individual is considered to be at risk for the 
purpose of estimating expected survival.
1. Ederer I method: the matched individuals are considered to be at risk indefinitely 
(even beyond the closing date of the study). The time at which a cancer patient dies 
or is censored has no effect on the expected survival.
2. Ederer II method: the matched individuals are considered to be at risk until the cor-
responding cancer patient dies or is censored.
3. Hakulinen method: if the survival time of a cancer patient is censored then so is 
the survival time of the matched individual. However, if a cancer patient dies the 
matched individual is assumed to be at risk until the closing date of the study.
For all three methods, each individual must have equal life expectancy as the patient 
should have in the absence of cancer. Eventually, the relative survival is calculated as the 
ratio of the survival probabilities for a patient and age and gender matched individu-
als. Advantage of relative survival analyses is that information on cause of death is not 
required. However, it requires accurate estimation of expected survival in a comparable 
population of cancer free individuals. For most types of cancer, patients diagnosed with 
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cancer are representative of the general population, so their expected mortality can 
be estimated using general population mortality rates. The most notable exceptions 
are smoking-related cancers where patients will have lower survival than the general 
population due to numerous other smoking-related conditions (e.g. cardiovascular dis-
ease)140. Furthermore, estimation of the expected survival may not be sufficiently reliable 
particularly for screening-related cancers since screening patients are often healthier 
and of higher social economic class (healthy screenee bias)141.
Both survival measures are typically expressed as the proportion of patients alive at 
some point subsequent to the diagnosis of their cancer131. Thus, survival represents the 
difference in time between two dates and is therefore sensitive to changes in either of 
the dates. As a result, survival analyses could be plagued by three potential biases, i.e., 
lead time, length time and overdiagnosis142. The potential magnitude of lead time on 
patient’s survival is graphically presented in Figure 2. In Figure 2a the diagnosis was 
made in a patient who presented with symptoms and the survival time is the time 
between this diagnosis and the date of death. However, if the cancer was detected by 
screening (Figure 2b) the survival time increased by an amount, called the lead time, 
even if the date of death remained unchanged. Now we would hope that the early 
diagnosis increases the potential for cure so that death is postponed and survival time 
further increased (Figure 2c). It is this improvement in survival resulting from postpon-
ing death that is of real interest. However, it is difficult to separate this component of 
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patient survival since it cannot be easily separated from other components such as 
lead time.
Length time may also occur in the seting of screening for a disease. Length time reflects 
the effect that screening predominantly detects slow growing tumours, as they remain 
longer in the preclinical detectable phase than fast growing tumours142. Hence, slow 
growing tumours are likely to be over-represented in screening populations and are 
ironically associated with improved survival (Figure 3). As shown, slowly growing tu-
mours remain for a relatively long period in the zone before the cancer is spread beyond 
the prostate while this period for fast growing tumours (patient D) stay relatively short 
in this zone. Consequently slowly growing tumours have a relatively increased chance in 
being diagnosed as screen detected cancer in a program with repeated screening and 
form a high percentage of all screen detected cancers. Relative overrepresentations of 
slowly growing and probably favourable prognostic cancers positively bias the survival 
rate; the survival will improve even if there is no effect of screening.
The third bias that influences the survival rate is overdiagnosis. Overdiagnosis is defined 
as the diagnosis of a disease that will never cause symptoms or death during a patient’s 
lifetime142. Screening detects a considerable part of insignificant cancers that would 
never have surfaced during the lifetime of a patient. Consequently, if overdiagnosis were 
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the only effect of screening the observed improvement in survival is caused by increas-
ing the number of patients (most of whom would not have died of the disease in the 
first place). Figure 4 demonstrates two possible conditions, i.e., a situation in which only 
clinical significant diseases are diagnosed (Figure 4a) and in which clinically significant 
and insignificant diseases are diagnosed (Figure 4b). Accordingly at every point in the 
follow-up, in Figure 4b relative to Figure 4a, the number of men at risk to die of the 
disease is increased by overdiagnosis but the number of men who actually die of the 
disease is unaffected. Therefore the probability of survival improves while the number 
of men that die from the disease remains the same.
3.3.1 PROSTATE CANCER SURVIVAL
The survival rates for PC have been improving during the last 30 years in several coun-
tries. Figure 5 presents the 5-years relative survival from PC diagnosed in a part of the 
Netherlands between 1988 and 2005. 5-year relative survival improved 8% between 
1988-1992 and 1993-1996, and more than 10% between 1993-1996 and 2001-2005. 
Although these improvements in survival patterns are encouraging, the survival rates 
are likely to have changed over time with earlier diagnoses following the advent of PSA 
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testing. The PSA test enables invasive PC to be indentified earlier than it might have 
been diagnosed clinically on the basis of symptoms (lead time). However PSA also 
enables the identification of latent tumours that have caused symptoms during the 
man’s lifetime (overdiagnosis). For PC screening the mean lead times and rates of over-
diagnosis depends on a man’s age at screening. For a screening program with a 4-year 
screening interval from age 55 to 67, the estimated mean lead time is approximately 11 
years (range = 10.8-12.1 years), and the overdetection rate is 48% (range = 44%-55%)129. 
Consequently, since the introduction of the PSA test, lead time and overdiagnosis have 
a significant influence on the changes observed in the PC survival rates. These effects are 
illustrated by the 16% difference in 10-years PC specific survival between men diagnosed 
with PC in the screening and control arm of the ERSPC section Rotterdam between 1993 
and 2006 (figure 6).
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In conclusion, patients live longer with the diagnosis of PC (more person years) due 
to a PC diagnosis at an earlier age and with on average a PC of a lower grade and stage 
during the last two decades. Since the effect in survival cannot be separated from other 
components such as lead time, length time and overdiagnosis which are extensively 
in present in these analyses, survival rates fail to demonstrate the improvement in PC 
survival resulting from postponing PC death. Consequently, survival in a clinical situa-
tion of increasing overdiagnosis, is not an appropriate endpoint.
3.4 MORTALITy
Three methods can be used for cancer mortality analyses, i.e., all cause mortality, a cause 
specific mortality and an excess mortality analysis. An all cause mortality analysis mea-
sures the total number of deaths in a population per unit time. Benefits of the all-cause 
mortality are that it does not require judgments about the cause of death, and that 
all-cause mortality can capture unexpected lethal side effects of medical care.
3.4.1 CAUSE SPECIfIC MORTALITy
A cause specific mortality analysis measures the number of deaths due to a specific 
cause in a population per unit time131. Similar to the cause specific survival, accurate 
information on the cause of death is required for this analysis136. Cause specific mortal-
ity analyses have both their advantages and disadvantages (Table 1). Cause specific 
mortality has the aim to measure if the mortality is directly attributable to the cancer in 
question. Deaths which are due to the cancer are counted as deaths (or its treatment), 
while all other deaths are treated as censored observations (i.e. observed until the time 
of death, considred alive at that moment within the context of the analysis). For this 
reason it is a suitable method e.g. the effect of screening on the mortality related to the 
cancer of interest. The concept disease specific mortality implies a dichotomy that not 
always reflects the clinical reality since it might be difficult to decide whether a person 
died either entirely due to the cancer in question or completely unrelated to the cancer 
Table 1. Cause Specific mortality versus Excess Mortality
Measure Advantage Possible bias
Cause Specific Mortality Measures mortality directly due to 
cancer
Accurate classification of cause of death
Excess Mortality Measures mortality due to cancer, 
capturing both direct and indirect 
mortality
Accurate estimation of expected 
mortality in a comparable population 
without the disease of interest
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in question. Especially for PC when there are several competing causes of death. E.g., 
in elderly PC patients there are often a considerable number of co-morbidities and the 
dichotomy could be an oversimplification of reality. Therefore, cause specific mortality 
has shown to be more valid in clinical studies where more effort is made to distinguish 
between the deaths due to cancer and deaths due to competing risks. Studies that have 
questioned the validity of death certificate-assigned causes of death in PC reported that 
between 4 and 46% of death certificates were inaccurately coded135, 137, 143-144.
3.4.2 ExCESS MORTALITy
Excess mortality is the difference between the total (all-cause) mortality of the patients 
and the mortality that would be expected in the absence of cancer145. Excess mortality 
is related to relative survival, i.e., the number of observed deaths in a cohort of can-
cer patients to the number of expected deaths in a comparable cohort of cancer free 
individuals138. Excess mortality provides a measure of the mortality associated with a 
diagnosis of cancer irrespective of whether the excess mortality is directly or indirectly 
attributable to the cancer. The excess mortality rate is defined as the actually recorded 
number of cancer patient deaths in excess of the number expected on the basis of a co-
hort of cancer free individuals per unit of time. Excess mortality can also be expressed as 
a count, i.e., the actually recorded number of cancer patient deaths in excess of the num-
ber expected on the basis of a cohort of cancer free individuals during a defined time of 
follow-up. If the excess mortality is defined as a count it will not be affected by the above 
mentioned biases (lead time bias, length time and overdiagnosis). The biases mentioned 
above only affect the time period that an individual is identified as having the disease or 
the number of people that are considered to have the disease, not the probability to die 
of it. Note that the time is not specified if the excess mortality is expressed as a count, 
thus e.g., lead time bias (which occurs in the relative survival analyses) does not affect 
the outcome. Excess mortality analyses have both their advantages and disadvantages 
(Table 1). Information on cause of death is not required for an excess mortality analysis, 
thereby circumventing problems with the inaccuracy of the assessment of the cause of 
death140. An excess mortality analysis measures the difference between the mortality in a 
group of patients and the mortality in that group that would be expected in the absence 
of cancer. It is a suitable measure to assess the burden from a specific cancer on the total 
mortality since it measures all the mortality that is associated with cancer. It measures 
not only whether cancer leads directly to death, but it also measures whether the death 
is indirectly attributable to cancer. The latter cosist of amongst others deaths from “in-
tercurrent causes”, for example pneumonia, which were not taken by pneumonia if they 
were in the absence of cancer, or deaths due to treatment complications or suicide are 
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examples of deaths which may be considered indirectly attributable to the cancer of in-
terest. For an excess mortality analysis an accurate estimation of the expected mortality 
is needed. For most types of cancer, patients diagnosed with cancer are representative 
of the general population, so their expected mortality can be estimated using general 
population mortality rates. The most notable exceptions are smoking-related cancers 
where patients have a lower survival than the general population due to numerous 
other smoking-related conditions (e.g. cardiovascular disease).
3.4.1 PROSTATE CANCER MORTALITy
The age-standardized rate for mortality from PC between 1988 and 2006 in the Nether-
lands is presented in Figure 1. Mortality from PC slowly increased through the 1980s, and 
levelled in the early 1990s. There has been a steady decrease in mortality between 1993 
and 2002 from 39.3 cases / 100,000 men to 26.6 cases respectively (23.9% decrease). 
Many studies have explored the connection between interventions and PC mortality 
declines in the US and Western Europe. The first decrease is likely to be due to better 
treatment of more advanced disease and the increasing use of treatment with curative 
intent for localized disease before the PSA era146-147. Furthermore, incorrect attribution 
of cause of death may have made a substantial contribution to the decline. This bias in 
attribution may have been reduced after physicians got used to the idea that many men 
with PC not die of their disease when they were labelled as having the disease as a result 
of screening. Although conflicting opinions exist8, 148-149, PSA screening likely accounts 
for a part of the most recent decline in PC mortality.
3.5 CONCLUSIONS
Trends in PC incidence are not reliable for measuring the increases in environmental 
risk factors since the practices in screening and early detection have changed too much 
during the last decades. Therefore, trends in PC incidence are likely to reflect the change 
in the intensity of screening and early detection activities over time.
Trends in PC survival are suspected to be unreliable because they are based on the 
same series of patients as incidence rates, and any inflation of incidence due to the inclu-
sion of less malignant or nonmalignant diseases increases survival rates. As a result, PC 
survival rates should be interpreted with caution and with the knowledge of the effects 
of lead time, length time and overdiagnosis on survival outcomes.
Trends in PC mortality are the principal measures through which the success of the 
different interventions on population basis can be determined. Two mortality analyses 
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can be used, i.e., cause-specific mortality and excess mortality, of which cause specific 
mortality is more accepted in clinical epidemiology. Although both measures might be 
similar in practice, differences can exist (Table 1). In chapters 8-10 of this thesis the value 
of these mortality measures for PC analyses will be discussed in further detail.
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4.1 SCOPE
It is widely accepted that PSA based screening has the potential to reduce the prostate 
cancer (PC) specific mortality. However, more evidence on the trade-off between the 
harms and benefits is needed before PC screening can be justified as a population based 
screening program. Concerns exist whether the reduction in PC specific mortality is 
underestimated by the widespread testing of asymptomatic men for PC who are partici-
pating in the control population of the ongoing randomized controlled trials. Given the 
modern tendency of testing asymptomatic men and the aggressive investigation in men 
with low PSA values, there will be little opportunity for new randomized control trials. 
Therefore populations with very low intensity of screening are useful for comparison. 
Northern Ireland represents a unique population for research on PC screening. It has 
excellent data on PC investigations and screening and early detection have not been 
routinely performed during the last decades. Comparing the intervention population of 
a large screening trial with the population in Northern Ireland provides an estimation 
of the benefits of prostate cancer screening after adjustment for contamination and a 
stratified analysis according to men’s baseline serum PSA to asses whether the mortality 
reduction of screening is limited to men with PSA in a particular range.
Now since the outcome of a randomized PC screening trial shows an unfavorable 
trade-off between the harms and benefits, it is unrealistic to think that population based 
PC screening programs will be implemented according to the algorithm used within the 
trial. Approaches that aim to improve the screening algorithm in order to reduce the 
harms and to increase the benefits of screening and early detection are needed. Part IV 
of this thesis contributes to the improvement of future screening strategies, indicating 
that screening algorithms have to be made more specific and should be based on the 
individual risk stratification in men.
Finally, although disease specific mortality is a generally used endpoint of cancer 
screening trials, alternatives to this approach have to be investigated. It comprises the 
estimate of the excess mortality rate in the cancer patients in both arms of the study. 
No differences in the disease specific mortality and excess mortality rates are expected 
to be found. This is conditional on PC being the only factor affecting differences in 
mortality, the accurate ascertainment of the disease specific mortality and an accurate 
estimate of the expected mortality. Whether the disease specific mortality rate differs 
from the excess mortality rate in men, who are systematically screened for PC, and in 
men who are not systematically screened is relevant information. The potential absence 
of a discrepancy supports the established effect of screening on prostate cancer mortal-
ity, the presence of a significant discrepancy warrants further research.
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4.2 OUTLINE
In Part II we describe the effectiveness of PC screening on the PC specific mortality com-
paring the intervention arm of the ERSPC section Rotterdam to the general population 
of Northern Ireland. Two studies are performed, both with a different aim. The first one 
to assess the effect of screening on the PC specific mortality after adjustment for the 
diluting effect of opportunistic PSA testing, in the control population of the randomized 
controlled trials. The second, to provide a stratified analysis according to men’s serum 
PSA on study entry to asses whether the mortality reduction of screening was limited to 
men with PSA in a particular range.
In Part III the excess mortality analysis for the ERSPC is assessed. It includes four 
subsequent analyses. First we performed a pilot excess mortality analysis based on 
data of the ERSPC section Rotterdam. Secondly, we described the theory of performing 
an excess mortality analysis in a randomized controlled trial of screening for PC. This 
includes a method for validating the expected mortality and coping with the effect of 
non-attendance in the intervention arm of the trial. Third, an excess mortality analysis 
is performed based on the data of the four largest centres of the ERSPC. Finally, we 
have tried to quantify the results found in the pilot excess mortality analysis, which in 
contrast to the disease specific mortality rates showed an increased difference in the 
excess mortality rates between the two arms, by studying the causes of death among 
the excess deaths.
In Part IV, in chapter 11 the effect of using a 2 year screening interval or a 4-years 
screening is assessed by studying the proportional incidence of advanced screen and in-
terval detected cancers in the ERSPC-Gothenburg, that uses a 2 year screening interval, 
and the ERSPC-Rotterdam, that uses a 4 year interval. Chapter 12 contains an evaluation 
of the use of sextant biopsies in men with larger prostate glands in men who participate 
in a screening program with a four year interval. Both studies aim to evaluate the effect 
of adjustment of the screening algorithm on the harms and benefits trade-off of PC 
screening. In chapter 13 of Part IV a competing risk stratification is made for men with 
localized PC who consider treatment with radical surgery for dying from PC or another 
cause of death.
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AbSTRACT
background: To estimate the benefits of prostate specific antigen (PSA) screening on 
prostate cancer (Pca) metastasis and Pca specific mortality, we compared two popula-
tions with a well-defined difference in intensity of screening.
Methods: Between 1997 and 1999, a total of 11,970 men, aged 55-74 years, were includ-
ed in the intervention arm of the European Randomized Study of Screening for Prostate 
Cancer (ERSPC) section Rotterdam. Control population consisted of 133,287 men, aged 
55-74 years, between 1998 and 1999 in Northern Ireland (NI). Men were followed for Pca 
incidence, Pca metastasis and cause of death until December 31, 2006.
Results: Median age in both groups was 63 years at study entry (p=0.184). 94.2% of 
men in Rotterdam and 6% of men in NI underwent PSA testing. In Rotterdam, 1,153 
men (9.6%) were diagnosed with Pca with median baseline PSA 5.1ng/ml. In NI, 3,962 
men (3.0%, p<0.001) were diagnosed with Pca with median baseline PSA of 18.0ng/ml 
(p<0.001). The relative risk of Pca metastasis during observation in the intervention com-
pared to control population was: 0.47 (95%CI, 0.35-0.63, p<0.001). The relative risk of Pca 
specific mortality was also lower in the intervention compared to the control population 
after a median follow-up of 8.5 years: 0.63 (95%CI, 0.45-0.88, p=0.008); absolute mortal-
ity reduction 1.8 deaths per 1000 men.
Conclusions: A relative reduction in Pca metastasis of 53% and Pca mortality of 37% was 
observed in the intervention population after 8.5 years of observation. The impact of 
overdiagnosis, quality of life benefits and cost-effectiveness need to be assessed before 
population-based PSA screening can be recommended.
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5.1 INTROdUCTION
Over the past decade, there has been a marked decline in prostate cancer (Pca) mortal-
ity, starting in Northern America and later also observed in many European countries 
where currently mortality rates are lower than in the pre Prostate Specific Antigen (PSA) 
era.6, 8, 150. This decline is likely to be at least in part due to the widespread use of PSA 
testing, and indeed, the efficacy of PSA screening in lowering Pca mortality has now 
been established in a randomised controlled trial102. The European Randomized Study 
of Screening for Prostate Cancer (ERSPC) demonstrated a 20% relative reduction in Pca 
mortality due to PSA screening after comparing the number of men who died from Pca 
in a screened population with that in a control population where screening was not 
recommended or performed on a systematic basis102.
Despite the ERSPC study design recommending no screening in the control popula-
tion, opportunistic PSA testing occurred in 8-29% of men in the control populations in 
participating European countries106-107. The level of contamination was even higher in 
the Prostate, Lung, Colorectal and Ovarian (PLCO) trial in the United States, with 52% 
of men in the control population also undergoing PSA screening97. The outcomes of 
both these studies will have been weakened by the considerable level of Pca screening 
in the control populations, which may have resulted in an underestimation of the true 
benefits of Pca screening, and indeed, may have contributed to the lack of difference in 
Pca mortality between the two arms of the PLCO study.
One of the possible methods of estimating the true effect of PSA screening is apply-
ing a secondary analysis using the Cuzick-method: effect of screening in men actually 
screened104, 151. Another method is the selection of a control population with a very low 
intensity of screening. In Northern Ireland (NI), PSA screening is not recommended 
and there is a well documented low level of PSA testing (6% of men >50 years old)152. 
Further, men tended not to proceed to prostate biopsy until PSA levels were >10.0ng/
ml, with few men with low PSA levels having a prostate biopsy152. In the current study, 
we compared the characteristics and outcomes of a population participating in the 
ERSPC, section Rotterdam, with men in Northern Ireland (NI) during a time period when 
asymptomatic PSA screening was infrequent152.
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5.2 MATERIALS ANd METHOdS
5.2.1 Intervention cohort
Between December 1993 and December 1999, a total of 42,376 men, aged 55-74 years, 
were randomized in the Rotterdam section of the ERSPC. All men with a prior diagnosis 
of Pca were excluded. In the current study, men randomized to the intervention arm 
between 1997 and 1999 were included. This inclusion criterion allowed an equal time of 
follow-up in the intervention and control population and still more than half of the men 
included in the intervention arm of the Rotterdam section of the ERSPC since most men 
were randomized in the year 1997 and 1998. Up to May 1997, men were screened with 
an interval of four years by PSA measurement, digital rectal examination (DRE) and tran-
srectal ultrasound examination (TRUS). Sextant biopsy was initially offered to men with 
PSA ≥4.0 ng/ml and/or suspicious finding on DRE and/or TRUS. After November 1997 a 
biopsy was prompted by PSA ≥3.0 ng/ml only. Treatment decisions were made by local 
urologists and individual patient preference. Details of the screening methodology were 
reviewed by Roobol et al96. Cancers diagnosed clinically between the two screens or due 
to opportunistic screening, transurethral resection of the prostate (TURP) for benign dis-
ease, and cystoprostatectomy specimens, were identified and included in this cohort as 
interval cancers. These interval cancers were identified by means of linkage the national 
cancer registries. Follow-up in this respect was complete until December 31, 2006. Grad-
ing of the cancers was done using the Gleason grading system and classified according 
to the 1992 TNM classification. When an isotope bone scan was not performed, men 
with stage T1c disease and serum PSA concentration <10.0 ng/ml at diagnosis were 
classified as M0 and men with serum PSA concentration ≥100.0 ng/ml were classified 
as M1. In men with a PSA >10 ng/ml and <100 ng/ml at diagnosis, the metastatic status 
was considered as unknown. Pca mortality was based on the consensus of a Causes of 
Death Committee (CODC)153. This committee reviewed medical records of all men who 
were deceased with a Pca using a predefined decision tree153.
5.2.2 Control cohort
Data on 133,287 men, aged 55-74 years between 1 January 1998 and 31 December 1999, 
in NI were included in the control cohort. Men with a prior diagnosis of any other type 
of cancer, except non-melanoma skin cancer, were excluded since in the ERSPC almost 
no men with another type of cancer participated. NI has a stable and homogenous 
population with little migration (0.7% annually)152. For this reason the group of men 
who were extracted from the NI population register was followed up as a cohort. All 
men diagnosed with Pca in NI are routinely registered by the Northern Ireland Cancer 
Registry (NICR). Details of the NICR PSA database and matching process have previously 
been described152.Using unique identifiers (name, date of birth, and address), the NICR 
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links Pca data to their database of all PSA tests performed throughout Northern Ireland 
and to the Registrar General’s Office (Northern Ireland) database of deaths. Causes of 
death were obtained from official national death certificates, ICD, 9th revision from 1994 
until 2000 and 10th revision onwards (World Health Organization, 1992)154. Patients were 
considered to have died from Pca only if Pca (185 or C61) was coded as the primary 
cause of death on the death certificate. Grading of the cancers was done using the Glea-
son grading system. Initial treatment data were extracted from medical charts. Cancers 
were classified according to the 1992 TNM classification with M0 or M1 status based 
on the result of isotope bone scans. Where bone scans were not performed, men with 
serum PSA at diagnosis <10.0 ng/ml were classified as M0, men PSA >10 and <100 ng/
ml at diagnosis as unknown, whilst men with serum PSA concentration ≥100.0 ng/ml 
at diagnosis were classified as M1. Diagnostic and mortality data were checked until 
December 31, 2006.
5.2.3 Validation of cause of death data in Northern Ireland
To validate the cause of death data from death certificates in NI, a random sample of 
136 men who had Pca and subsequently died were identified (7.6% of total, median age 
77 years). All available information from General Practitioner and hospital charts was 
extracted and reviewed independently by two authors (PVL, DC). Using the predefined 
ICOD flowcharts153, a cause of death was assigned in each case. In cases where there 
was a discrepancy in the assigned cause of death, the notes were reassessed until a 
consensus was reached. In 119 men (87.5%), the death certificate data matched that of 
the performed review. Four men (2.9%) had insufficient information to assign a cause 
of death. Of the 13 inaccurate recorded causes of death, six were incorrectly recorded 
as primary cause Pca and seven incorrectly recorded as due to intercurrent disease. This 
resulted in a death certificate accuracy of 90.4% (SD 2.19).
5.3 STATISTICAL ANALySIS
The chi-square (χ2) and the Mann-Whitney U tests were used to assess the relationship 
between categorical and continuous variables, respectively, between the intervention 
and the control cohort. Pca metastasis and mortality risk ratios between the two popula-
tions were estimated using a Poisson regression analysis. For both groups the number of 
man-years were calculated from the date of their study entry up to their date of death or 
December 31st, 2006 when still alive. The Nelson-Aalen analysis was used for the graphi-
cal estimation of the Pca mortality and Pca metastasis cumulative hazards155, cumulative 
survival percentages are presented. In both cohorts the survival time was defined as 
the time from study entry until Pca death, with censoring at the date of an intercur-
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rent death or December 31, 2006. For Pca metastasis the survival time was defined as 
the time from study entry until Pca metastasis with censoring at date of death if death 
occurred prior to a metastasis or December 31, 2006. A two-sided p value <0.05 was 
considered to be statistically significant. All analyses were performed with STATA: Data 
Analysis and Statistical Software, version 10.0.
5.4 RESULTS
In the intervention cohort, 11,970 men, median age 63 years, were included, with 1,153 
(9.6%) of these diagnosed with Pca during the follow-up period. In the control cohort 
133,287 men were included, with 3,962 (3.0%) diagnosed with Pca with identical follow-
up. Baseline patient characteristics are presented in Table 1. Median age at inclusion 
was similar, however the age distribution at inclusion was different for both groups 
(p=0.184 and p<0.001 respectively). Age at diagnosis was higher in the control cohort 
(median 70 vs. 67 years, p<0.001) with a higher median PSA at diagnosis (18.0 vs. 5.1 
ng/ml, p<0.001). Median follow-up was 8.53 years in the intervention population and 
8.72 years in the control population. In the intervention cohort 100% of Pca diagnoses 
were confirmed histologically by prostate biopsy (99.7%), cystoprostatectomy specimen 
(0.1%) or TURP (0.2%). In the control cohort 68.2% of men were diagnosed by prostate 
biopsy; 18.1% and 13.7% were diagnosed by TURP or on the basis of clinical opinion only 
(no histological confirmation), respectively.
In the intervention cohort 11 men (0.1% of total) and in control cohort 862 men (0.6% 
of total) had Pca metastasis at diagnosis (p<0.001). There was a significant reduction 
of 53% in Pca metastasis during observation in the intervention population relative to 
the control population: RR 0.47 (95%CI, 0.35-0.63, p<0.001). Pca metastasis cumulative 
hazard is graphically illustrated in Figure 1. As shown, the cumulative Pca metastasis 
hazard starts to differ after two years of observation and becomes statistically significant 
after five years. Furthermore, as demonstrated in Figure 1, this difference in metastatic 
disease is likely to increase with longer follow-up.
In the intervention cohort 35 (0.29%) men and in the control cohort 627 (0.47%) men 
died due to Pca or to a Pca intervention related procedure. This equated to a reduc-
tion in Pca mortality of 37% in the intervention population relative to the control 
population: RR 0.63 (95%CI, 0.45-0.88, p=0.008). The Pca specific cumulative hazards are 
graphically illustrated for both cohorts in Figure 2. The difference in Pca specific mortal-
ity, expressed by a cumulative hazard, becomes statistically significant six years after 
the start of observation. After a median follow up of 8.5 years, the absolute rate of Pca 
mortality was 0.36 per 1,000 person-years in the intervention cohort compared to 0.58 
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Table 1. Baseline characteristics at study start, diagnosis, and primary treatment modalities
Median follow up 8.5 years
Control cohort
Northern Ireland N
(% of total)
Intervention cohort ERSSC 
Rotterdam N
(% of total)
P value
Total participants included 133 287 11 970
Age (yr), median 63 63 0.184
 55 – 60 52 104 (39.1) 4 310 (36.0) <0.001 
 61 - 65 33 013 (24.8) 3 153 (26.3) 
 66 - 70 23 423 (17.6) 2 723 (22.7) 
 71 - 74 24 747 (18.6) 1 784 (14.9) 
Total patients diagnosed, 3962 1153 <0.001
% of total participants (3.0) (9.6) 
Age (yr) at diagnosis, median 70 67 <0.001
 55 – 60 348 (8.8) 175 (15.2) <0.001 
 61 - 65 790 (19.9) 314 (27.2) 
 66 - 70 1069 (27.0) 379 (32.9) 
 71 - 75 1108 (28.0) 265 (23.0) 
 ≥ 76 647 (16.3) 20 (1.7) 
PSA at diagnosis (ng/ml), median 18.0 5.1 <0.001
 0.0 – 2.9 193 (4.9) 134 (11.6) <0.001 
 3.0 – 4.9 168 (4.2) 435 (37.8) 
 5.0 – 9.9 740 (18.7) 361 (31.3) 
 10.0- 19.9 1 003 (25.3) 126 (10.9) 
 ≥ 20.0 1 799 (45.4) 89 (7.7) 
 Not known or not performed 59 (1.5) 8 (0.7) 
Disease extent
 Not metastasized (M0) 2 718 (68.6) 1 119 (97.0) <0.001 
 Metastasized (M1) 862 (21.8) 11 (1.0) 
 Not known or not performed 382 (9.6) 23 (2.0) 
Histological differentiation
 Gleason 2 – 6 1 638 (41.3) 790 (68.6) <0.001 
 Gleason 7 850 (21.5) 247 (21.4) 
 Gleason 8 – 10 932 (23.5) 51 (4.4) 
 Not known or not performed 542 (13.7) 65 (5.6) 
Initial treatment
 Radical prostatectomy 277 (7.0) 416 (36.1) <0.001 
 Radiotherapy 1 106 (27.9) 442 (38.3) 
 Watchful waiting 419 (10.6) 233 (20.2) 
 Androgen-deprivation therapy 1 248 (31.5) 48 (4.2) 
 Not known or other treatment 912 (23.0) 14 (1.2) 
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per 1,000 person-years in the control cohort; the absolute risk difference was 1.8 deaths 
per 1000 men (1.8 per 1000 men = 627 Pca deaths/133,287 men control population - 35 
Pca deaths/11,970 men intervention cohort), which correspond to 555 (1000/1.8) men 
needed to be screened to save one Pca death156. Additional Pca diagnosed by screening 
resulted in an increase in cumulative incidence with respect to the control population of 
67 per 1000 men, i.e. 37 (555/1000*67) cases had to be treated (NNT) in order to prevent 
one death from Pca156. These estimates are all cumulative and therefore interpreted as 
the probability, or risk, that an individual will have during the 8.5 years of observation157.
During follow-up, 1,676 men (14.0% of total) died in the intervention cohort, which 
was significantly lower than the overall mortality of 27,083 men (20.3% of total) in the 
control cohort: RR 0.70 (95%CI 0.66-0.73 p<0.001).
5.5 dISCUSSION
The ERSPC study demonstrated a 20% decrease in Pca mortality due to PSA screening, 
whilst the PLCO trial did not find any Pca specific mortality reduction97, 102. A weakness 
in both these trials, more so in the PLCO trial, was the level of opportunistic screen-
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Figure 1. Incidence of prostate cancer distant metastasis in the intervention and control population.  
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ing in the control populations. Given the high level of PSA testing and the high rate of 
screen-detected Pca in many countries throughout the world, any randomized trial will 
have similar difficulties with contamination of the control population, which may lead 
to an underestimation of the true value of screening. In the current study, we assessed 
retrospectively the rate of Pca metastasis and Pca specific mortality in men who did not 
undergo systematic screening or early investigation, and compared this with men who 
were prospectively screened for Pca. Our aim was to estimate the true benefits of PSA 
screening from a Pca screening trial, when there is a low level of contamination in the 
control population.
The main finding is the absolute mortality reduction of 1.8 deaths per 1000 men in 
favour of the screened population, which corresponds to a relative risk reduction of 
37%, after a median follow-up of 8.5 years. These results compare favorably to the ERSPC 
study that found an absolute mortality reduction of 0.71 per 1000 men after an average 
follow-up of 8.8 years, and a relative reduction of 20%102. In the present study, 555 men 
needed to be screened and an additional 37 men needed treatment to prevent one 
Pca related death, which again, is lower than the ERSPC findings (1410 screened and 
48 treated respectively)102. The trends in prostate specific mortality in both studies are 
however similar; there is overlap in the survival curves in the early part of observation, 
which then diverge with time. In the current study, this divergence happens earlier (4 
years vs. 7 years in the ERSPC) and becomes more pronounced over time (Figure 2), 
leading to a greater overall benefit due to screening, although the mortality difference 
did not become statistically significant until after six years of observation. By the end 
of observation, the mortality rate rose more slowly in the intervention population and, 
given the changes noted in the rates of distant metastasis (Figure 1), this trend is likely 
to continue with further follow-up. Therefore, there are few benefits of screening in the 
initial years after PSA testing, but these benefits are likely to increase over time; there 
is a difference in the rate of distant metastasis in favour of screening after five years, 
which leads to a disease specific mortality benefit after six years of observation. Hence, 
screening will only be beneficial in men with a life expectancy from at least another six 
to eight years.
Although the absolute benefit in terms of deaths prevented by screening might increase 
after longer follow up, the life-years saved per death prevented might tend to be smaller 
after more years of follow up. Based on the data of current study we assume an average 
of 5 years saved per death prevented in current study. Consequently, we expect that 
the benefit in terms of the number of life years gained will become smaller after longer 
follow up when the patients become older and will have limited life expectancies. How-
ever, for evaluation of the screening studies, these estimates are less used because they 
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are confusing and difficult to understand. Furthermore, the life years gained should be 
corrected for quality of life, making it quality of life adjusted life years (QALY’s) gained.
Another important observation is the screening induced increase in the Pca incidence. 
The intervention cohort had a 3.2 fold increased rate of Pca diagnosis, with a cumulative 
incidence increase of 67 per 1000 men. These results compare to 34 per 1000 men in 
the ERSPC and 12.5 per 1000 men in the PLCO studies, again highlighting the degree of 
contamination in the control arms of these studies, and the advantages of the control 
population in the present study97, 102. In the current study, the increased incidence rate 
was much greater than the observed decrease in mortality between the two groups (67 
vs. 1.8 per 1000 men respectively), leading to the potential for overdiagnosis (and over-
treatment) of the majority of men diagnosed by screening. As the life expectancy of men 
at end of observation is approximately 10 years, further follow-up will determine how 
many additional men are diagnosed with Pca and how many die from Pca or concurrent 
disease, giving more definitive data on overdiagnosis due to PSA screening.
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The main limitation is the lack of randomisation, meaning the current study is more akin 
to studies which have compared rates of prostate cancer diagnosis and prostate specific 
mortality in areas with high and low rates of PSA screening and radical treatment, such 
as in Seattle-Connecticut158 and in the Tyrol region of Austria159. The current study has 
advantages over previous studies as the difference in PSA testing and treatment is more 
pronounced in the current populations, and will more accurately estimate the potential 
benefits of PSA screening. Further, as there are individualised data in each population in 
the current study, survival analyses can also be performed as opposed to simply assess-
ing differences in prostate cancer incidence and mortality rates.
Due to the lack of randomisation, the rates of Pca or Pca mortality may have been 
different in both groups at the beginning of observation. At inclusion, the incidence of 
Pca in both countries was very different (86 vs. 62 per 100,000 persons in the Nether-
lands and NI respectively)160-161. This difference was mainly due to the early use of PSA 
testing in the Netherlands, with Pca rates increasing significantly from a baseline of 62 
per 100,000 persons in the end-1980s to over 90 per 100,000 by 2002160-161. In NI, there 
was an equal baseline incidence of 63 per 100,000 persons, but this remained stable 
until 2000, when the rates started to increase. In contrast, the Pca mortality rates in both 
countries were remarkably similar, with a slow increase in mortality until its peak in 1995 
(34.4 per 100,000 persons in Netherlands vs. 28.5 in NI)160-161, with a subsequent decrease 
in both countries. As men in both populations had similar ethnic backgrounds (virtually 
all white) and had an equivalent median age at inclusion (63 years), they should have a 
similar baseline risk of Pca. However, the higher level of PSA testing in the Dutch general 
population before 1995 means that many men have been pre-screened using PSA and 
will have already been diagnosed with Pca, especially more advanced Pca, and so will 
not have been offered inclusion into the screen-detected population. This, and the fact 
that many more men in the Dutch population had underwent PSA testing prior to inclu-
sion in the study population (on average 14% vs. 4%) will bias outcomes in favour of 
the screened group. Further, it is likely that a small number of men in the NI population 
may also have undergone PSA screening (9.1% of cancers diagnosed with PSA <5.0ng/
ml). There is therefore some degree of contamination in the control population of the 
present study, although the magnitude of this will be much less than in the ERSPC and 
PLCO studies97,  102. The method of inclusion i.e. men in Rotterdam signing informed 
consent whilst those in NI being identified retrospectively, also resulted in a healthy 
screening bias with generally healthier men of higher socio demographic level agreeing 
to participate in the ERSPC162. This resulted in a large difference in overall mortality: RR 
0.75 (95%CI 0.73-0.76 p<0.001) in favour of the intervention group. As men in the control 
cohort died sooner, they were more likely to die from a co-morbid cause as opposed to 
Pca, decreasing the Pca mortality relative to that in the intervention group. Finally, dif-
ferent treatments in both cohorts will have affected outcomes, with men diagnosed and 
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treated with curative intent at an earlier stage likely to have a better outcome54, 163-164. In 
both groups, following diagnosis, men were free to choose treatment in collaboration 
with their local urologist. As outlined in Table 1, men in NI had a higher PSA at diagnosis 
and a higher rate of metastatic disease, they were therefore less likely to undergo pros-
tatectomy and more likely to have androgen deprivation therapy. These differences in 
treatment are inherent in any study with a wide difference in the intensity of screening.
A number of criteria must be met before population-based screening can be justified60. 
Little is known about the screening risks, side effects of overtreatment and health re-
lated quality of life benefits of earlier treatment. Further, given the very large number 
needed to screen and needed to treat, it seems likely that cost of population-based PSA 
screening will be considered prohibitive in many countries.
5.6 CONCLUSION
Men undergoing systematic PSA screening had a 3.2 fold increased diagnosis of Pca. 
After 8.5 years, the rate of Pca metastasis was 53% lower in the intervention popula-
tion. Further, a significant reduction in Pca specific mortality of 37% was observed in 
the intervention cohort, however 555 men needed to be screened and 37 men needed 
treatment to prevent one Pca related death. Longer follow up is likely to demonstrate 
an increasing mortality benefit in favour of PSA screening, although the impact of 
overdiagnosis, quality of life benefits and cost-effectiveness need to be assessed before 
population-based PSA screening can be recommended.
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AbSTRACT
background: The benefits of prostate cancer (Pca) screening on an individual level 
remain unevaluated.
Methods: Between 1993 and 1999, a total of 43,987 men, aged 55-74 years, were includ-
ed in the intervention arm of the European Randomized Study of Screening for Prostate 
Cancer (ERSPC) section in the Netherlands, Sweden and Finland. A total of 42,503 men, 
aged 55-74 years, were included in a clinical population in Northern Ireland. Serum PSA 
(<20.0ng/ml) was measured in all men at study entry. All men were followed for Pca 
incidence and causes of death until December 31, 2006.
Results: The adjusted absolute difference in Pca specific mortality between the inter-
vention population and the clinical population increased with increasing PSA level at 
study entry, i.e. 0.05 per 10,000 person-years for men serum PSA 0.0-1.9 ng/ml and 8.8 
per 10,000 person-years for men serum PSA 10-19.9 ng/ml. The risks of early detection, 
i.e. the number needed to investigate (NNI) and number needed to treat (NNT) to save 
one death from Pca were increased with the decreasing PSA levels at study entry, i.e. the 
NNI for men serum PSA 0.0-1.9 ng/ml was 24,642 men, and for men serum PSA 10-19.9 
ng/ml 133 men; the NNT for men serum PSA 0.0-1.9 ng/ml was 724 men and for men 
with a serum PSA 10-19.9 ng/ml 60 men.
Conclusions: For men with a low serum PSA, the benefits of aggressive investigation 
and treatment may be limited since they are associated with a large increase in cumula-
tive incidence and potential overtreatment.
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6.1 INTROdUCTION
Prostate cancer (Pca) screening has been subject to much controversy for many years. 
Recently, the European Randomized Study of Screening for Prostate Cancer (ERSPC) 
showed a 20% reduction in Pca mortality in the screened population relative to the 
control population98. Secondary analysis of the ERSPC showed that the mortality effect 
among men was increased to approximately 30% after adjusting for the diluting effect 
of nonattendance and contamination105, 165.
The results of the ERSPC did not include patient individual risk stratifications. As blood 
was not collected at randomization from men in the control group, stratified analysis 
between the two arms of the ERSPC according to serum PSA on study entry to assess 
whether the mortality reduction was limited to men with PSA in a particular range was 
not possible. These analyses are important as the 20% relative reduction in Pca mortality 
was associated with a considerable increase in the cumulative excess incidence, with 
screening of 1410 men and treatment of 48 additional cases required to prevent one 
death from Pca98.
For this reason, we compared the Pca incidence and Pca specific mortality rates strati-
fied by individual serum PSA level that was measured at study entry in men participating 
in the intervention arm of the ERSPC and men in Northern Ireland, in whom screening 
and early detection of Pca was not routinely performed.
6.2 MATERIALS ANd METHOdS
6.2.1 Intervention population
Between December 1993 and December 1999 a total of 63,153 men, aged 50-74 year, 
were randomized into the intervention arm of the ERSPC section the Netherlands, 
Sweden and Finland. For the current study, only men aged 55-74 years, who did not 
have Pca and were actually screened by PSA, were included. Men with a baseline serum 
PSA ≥20.0 ng/ml at study entry were excluded since the main focus of this paper was 
the potential value of early detection. Although legal requirements with respect to ran-
domized trials were different in the Netherlands, Finland and Sweden, written informed 
consent was required for those who were randomly assigned to the intervention arm of 
the study92, 94, 96.
In the Netherlands, men were screened by PSA measurement, digital rectal exami-
nation (DRE) and transrectal ultrasound examination (TRUS) between 1993 and 1997. 
Sextant biopsy was initially offered to men with PSA ≥4.0 ng/ml and/or suspicious 
finding on DRE and/or TRUS. After May 1997 a biopsy was prompted by PSA ≥3.0 ng/
ml only. In Sweden, a sextant biopsy was indicated for men with a level of PSA ≥3.0 ng/
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ml. In Finland, men with PSA ≥4.0 ng/ml were defined as screen positive, and men with 
PSA 3.0-3.9 had an ancillary test (DRE until 1998, free/total PSA ratio with a cut-off ≤ 0.16 
from 1999 onwards). In Finland, sextant biopsy was initially offered to the screen posi-
tive men, however in 2002 a biopsy procedure with 10-12 biopsy cores was adopted as a 
general policy. In Sweden men were screened with an interval of two years until the age 
of 70 years in contrast to men in the Netherlands and Finland who were screened with 
an interval of four years until the age of 74 years and 71 years respectively. The screening 
algorithms used in the centers have been extensively described previously92, 94, 96.
In all centers the treatment decisions were made by a local urologist and based on 
individual patient preference. Cancers diagnosed between the two screening intervals 
or after the maximum screening age, clinically or due to opportunistic screening, trans-
urethral resection of the prostate (TURP) for benign disease, and cystoprostatectomy 
specimens, were considered as well and defined as interval cancers. These interval 
cancers were routinely identified by means of linkage to the national cancer registry. 
Cancers were classified according to the 1992 TNM classification. Men with stage T1c 
disease and serum PSA concentration <10.0 ng/ml were classified as M0 and men with 
serum PSA concentration ≥100.0 ng/ml were classified as M1, when an isotope bone 
scan was not performed. In men with a PSA ≥10.0 and <100.0 ng/ml in whom an iso-
tope bonescan was not performed the metastatic status was considered unknown. Pca 
mortality was based on the consensus of an independent Causes of Death Committee 
(CODC) in Sweden and the Netherlands and on accurately validated official causes of 
death certificates in Finland143,  153. Diagnostic and mortality data was available until 
December 31, 2006.
6.2.2 Clinical population
Data on men, aged 55-74 years, who had a first serum PSA between January 1994 and 
December 1999 in Northern Ireland, were included. Men with a prior diagnosis of Pca or 
a baseline serum PSA ≥20.0 ng/ml at study entry were excluded. Data were retrospec-
tive obtained from a population-based database of the Northern Ireland Cancer Registry 
(NICR) that included all routinely performed PSA tests since 1994. The NICR maintains 
this confidential electronic database of all PSA results for Pca surveillance purposes. 
No personal identifiable information was removed from the database and no patient 
contact was made during this study. During the years of observation, the clinical popula-
tion was not systematically screened, because in Northern Ireland early detection and 
screening was not recommended and the population had a well documented low level 
of PSA testing (6% of men >50 years old)152. Further, men tended not to proceed to 
prostate biopsy until PSA levels were >10.0ng/ml, with few men with low PSA levels 
having a prostate biopsy152. No individual data on reason for PSA testing was available 
but recent evidence showed that during the period of 1994-1998 less than 20% of PSA 
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testing was in asymptomatic men166. The NICR registers all Pca cases and links these to 
their PSA data. Causes of death were obtained from accurately validated official national 
death certificates, ICD, 9th revision from 1994 until 2000 and 10th revision onwards (World 
Health Organization, 1992)105, 154. Cancers were classified according to the 1992 TNM clas-
sification with M0 or M1 based on the result of isotope bone scans. Where bone scans 
were not performed, men with serum PSA concentration <10.0 ng/ml were classified 
as M0 whilst men with serum PSA concentration ≥100.0 ng/ml were classified as M1. In 
men with a PSA ≥10.0 and <100.0 ng/ml at diagnosis in whom an isotope bonescan was 
not performed, the metastatic status was considered unknown. Diagnostic and mortal-
ity data was available until December 31, 2006.
6.3 STATISTICAL ANALySIS
For both groups the time of follow up was measured from the date of their first PSA test 
up to their date of death or December 31, 2006. Baseline serum PSA was stratified into 
four categories, PSA 0.0-1.9, 2.0-3.9, 4.0-9.9 and 10.0-19.9 ng/ml. A multivariate Poisson 
regression analysis was used with the time of follow-up (divided into 2-years intervals) 
until either the event of interest or censoring. The following model was used: Log [E(Y)] 
= log(exp) + β0 + β1x1 + ...... + β5x5; a generalized linear model with log link function and 
Poisson distributed errors where E(Y) is expected number of Pca deaths, log(exp) is 
the logarithm of the follow up time, (x1, x2,..., xp)
T are the predictive variables, i.e. PSA 
(categories), age (continue), study population and the time interval since first screening 
visit (2-years intervals). The βi is the coefficient corresponding to xi. The term log(exp) 
was an offset with the parameter estimate constrained to 1 which enables the interpre-
tation of the parameter estimates as rate ratio’s. Comparisons between the observed 
and predicted data of this multivariate model showed the predictions to be accurate. 
In addition, the number needed to investigate (NNI) and the number needed to treat 
(NNT) to save one death from Pca were calculated156, based on the adjusted absolute 
rate differences. In both populations for baseline serum PSA and age adjusted cumula-
tive hazards were graphically estimated for different PSA categories at study entry using 
a cumulative hazard method. All analyses were performed with the commercially avail-
able STATA package: Data Analysis and Statistical Software, version 10.0; the cumulative 
hazard figures with Statistical Package for the Social Sciences software, version 16.0.
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6.4 RESULTS
6.4.1 baseline characteristics
A total of 42,503 men were included in the clinical population and a total of 43,987 men 
were included in the intervention population. Participants had statistically significant 
differences in their baseline characteristics at study entry (Table 1); the median age 
and baseline serum PSA were higher in the clinical population. The median follow up 
time was 8.8 (SD 3.1) and 9.1 (SD 2.2) years for the clinical and intervention population 
respectively.
Table 1. Characteristics of men at study entry
Intervention group N
(% of total)
Clinical group N
(% of total)
P value
Total participants included 43987 42503
Age (yr), median 61 65 <0.001†
PSA at study entry (ng/ml), 
median 1.18 1.60 <0.001† 
0.00– 1.99 32035 (72.8) 25555 (60.1) <0.001‡ 
2.00 – 3.99 7467 (17.0) 8703 (20.5) 
4.00 – 9.99 3927 (8.9) 6493 (15.3) 
10.00 – 19.99 558 (1.3) 1752 (4.1) 
† Mann-Whitney U test, ‡ Chi-square test
6.4.2 Prostate Cancer diagnosis
Pca was diagnosed in 1,522 men (3.6%) in the clinical population and in 4,339 men (9.9%) 
in the intervention population, adjusted rate ratio (RR) 4.61 (95%CI, 4.33-4.91). Patients in 
the clinical population were diagnosed at an older age and with a higher median serum 
PSA (Table 2). The number of men with a positive result on an isotope bonescan (or a 
PSA value of more than 100.0 ng/ml in those without bonescan results) at diagnosis was 
6.1 per 1000 men in the clinical group and 1.2 per 1000 men in the intervention group 
(p<0.001). The median time to a Pca diagnosis was lower in the intervention group than 
in the clinical group, 4.1 vs. 5.3 years respectively, p<0.001.
The Pca incidence rates increased with increasing baseline PSA level in both study popu-
lations (Table 3). The adjusted absolute rate differences on a cancer diagnosis between 
the intervention group and the clinical group increased with the increasing baseline PSA 
levels (Table 4).
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6.4.3 Prostate Cancer mortality
By the end of 2006, the overall mortality was 25.5% in the clinical group and 14.5% 
in the intervention group, adjusted RR 0.79 (95%CI, 0.77-0.82). In total 236 men (0.6%) 
died from a Pca related cause of death in the clinical population and 109 men (0.2%) 
died from a Pca related cause of death in the intervention population. This resulted in 
Table 2. Patient characteristics at diagnosis
Intervention group N
(% of total)
Clinical group N
(% of total)
P value
Total patients diagnosed,
% of total participants
4339
(9.9)
1522
(3.6)
<0.001‡
Age (yr) at diagnosis, median 66 71 <0.001†
PSA at diagnosis (ng/ml), median 5.0 12.8 <0.001†
Disease extent at diagnosis
% of total participants
 Not metastasized (M0)
 Metastasized (M1)
 Not known
4285 (9.8)
54 (0.1)
0
1129 (2.7)
 261 (0.6)
 124 (0.3)
<0.001‡
† Mann-Whitney U test, ‡ Chi-square test
Table 3. Adjusted rate ratio of prostate cancer incidence for serum PSA at study entry
 
 
PSA at baseline
Intervention population Clinical population
N at 
risk
N 
diagnosis
Rate ratio (95%CI) P value N at 
risk
N 
diagnosis
Rate ratio (95%CI) P value
PSA 0.0 – 1.99 32009 980 * 25555 243 *
PSA 2.0 – 3.99 7467 1553 6.80(6.27-7.37) <0.001 8703 313 3.66(3.09-4.33) <0.001
PSA 4.0 – 9.99 3889 1472 12.62(11.62-13.71) <0.001 6493 611 9.56(8.22-11.12) <0.001
PSA 10.0 – 19.99 539 334 21.67(19.09-24.59) <0.001 1752 355 21.48(18.18-25.38) <0.001
N: Observed number of men at risk. * Reference group to which other groups are compared. The reference 
group per definition has a rate ratio of 1.
Table 4. Adjusted absolute difference in prostate cancer incidence between the intervention population 
and the clinical population
 
PSA at baseline
Observed Pca incidence
Intervention
Observed Pca incidence
Clinical
Absolute difference
PC incidence
PSA 0.0 – 1.99 23.47 11.52 35.59
PSA 2.0 – 3.99 235.95 43.21 214.32
PSA 4.0 – 9.99 431.29 144.71 377.40
PSA 10.0 – 19.99 709.80 253.04 561.76
* Pca: Prostate cancer. Pca incidence in rates per 10,000 man-years. Absolute difference as rate per 10,000 
man-years.
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for age and baseline serum PSA (continue) adjusted non-significant relative reduction 
in Pca specific mortality of 20% in the intervention population relative to the clinical 
population, RR 0.80 (95%CI, 0.63-1.02).
The Pca mortality rates increased with increasing baseline PSA level in both groups 
(Table 5). Relative to the men with a baseline serum PSA <2.0 ng/ml at study entry, men 
with a higher baseline serum PSA had a significant increased adjusted RR of dying from 
Pca in both groups. The absolute difference in Pca specific mortality was 0.05 per 10,000 
person years in men with a baseline serum PSA 0-1.9 ng/ml and 8.88 per 10,000 person 
years in men with a baseline serum PSA 10-19.9 ng/ml, increasing with the increasing 
baseline PSA level (Table 6).
The age adjusted cumulative hazard graphs for Pca specific death by baseline PSA and 
study group are presented in Figure 1-4. Relative to the lowest PSA category, the main 
absolute difference in Pca mortality was observed for the PSA categories 4.0-9.9 ng/
ml and 10.0-19.9 ng/ml at study entry. Furthermore, non or a small difference in the 
cumulative hazard in Pca death was observed for men with a PSA 0.0-1.9 ng/ml and 
2.0-3.9 ng/ml at study entry.
Table 5. Adjusted rate ratio of prostate cancer specific mortality for serum PSA at study entry
Intervention population Clinical population
 
PSA at baseline
N at 
risk
N Pca 
deaths
Relative risk (95%CI) P value N at risk N Pca 
deaths
Relative risk (95%CI) P value
PSA 0.0 – 1.99 32009 26 * 25555 29 *
PSA 2.0 – 3.99 7467 26 3.97(2.29-6.87) <0.001 8703 44 3.39(2.5-6.29) <0.001
PSA 4.0 – 9.99 3889 38 10.78(6.46-17.99) <0.001 6493 89 10.09(6.59-15.43) <0.001
PSA 10.0 – 19.99 539 19 37.17(20.13-68.62) <0.001 1752 74 31.05(20.03-48.11) <0.001
N: Observed number of men at risk. * Reference group to which other groups are compared. The reference 
group per definition has a RR of 1.
Table 6. Adjusted absolute difference of prostate cancer specific deaths between the clinical population 
and the intervention population, adjusted NNI and NNT to save one men from prostate cancer death
 
 
PSA at baseline
Proportion 
study 
population
Median 
follow-up in 
years
Observed 
Pca deaths 
Intervention
Observed 
Pca deaths
Clinical
Absolute 
difference
PC mortality
NNI NNT
PSA 0.0 – 1.99 66.6% 8.9 0.92 1.37 0.05 24642 724
PSA 2.0 – 3.99 18.7% 9.0 3.95 6.07 0.47 2393 427
PSA 4.0 – 9.99 12.0% 8.9 11.13 16.71 2.34 492 152
PSA 10.0 – 19.99 2.7% 8.7 40.38 52.75 8.88 133 60
Pca deaths in rates per 10,000 man-years. Absolute difference as rate per 10,000 man-years. NNI: number 
needed to investigate to save one death from prostate cancer. NNT: number needed to treat to save one 
death from prostate cancer
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6.4.4 Potential harms early detection
Table 6 summarized the adjusted magnitude of early detection and treatment for the 
baseline PSA categories in terms of the NNI and NNT to save one men from Pca death. 
NNI and NNT decreased with increasing baseline PSA level. NNI varied from 24,642 men 
for men with a baseline serum PSA 0.0-1.9 ng/ml to 133 for men with a baseline serum 
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PSA 10.0-19.9 ng/ml. NNT varied from 724 men for men with a baseline serum PSA 0.0-
1.9 ng/ml to 60 for men with a baseline serum PSA 10.0-19.9 ng/ml.
 
 
Figure 3. Prostate cancer specific death in men serum PSA 4.0-9.99 ng/ml 
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6.5 dISCUSSION
Early detection and screening for Pca has potential harms. Pca screening increases the 
incidence, which might cause needless worry and expense for a lot of men who may be 
getting treatment for tumours growing too slowly to do any harm129. However, screen-
ing and early detection has potential benefits as well. These benefits are a reduction in 
Pca mortality and a decrease in the number of men that suffer from the complications 
of advanced disease98, 105. In current study the potential balance between these harms 
and benefits is demonstrated using the measures NNI and NNT. The NNI equals one di-
vided by the absolute mortality reduction and the NNT equals 1 divided by the absolute 
mortality reduction multiplied by the excess Pca incidence. Consequently, the NNI and 
NNT show, on the one hand the effectiveness of early detection in terms of the reduction 
in Pca mortality, and on the other hand the harms of early detection in terms of the 
percentage of men that is diagnosed with a potential overdiagnosed Pca.
This study provides additional information on how the harms and benefits of screening, 
early detection and treatment are distributed in relation to the baseline PSA levels. It 
demonstrated that the yield of Pca increased with the increasing baseline serum PSA at 
study entry. The benefits of early detection might be small for men with a baseline serum 
PSA 0-3.9 ng/ml at study entry. Despite the short follow-up, especially for men with a 
baseline serum PSA <2.0 ng/ml at study entry aggressive investigation and treatment 
yielded little or no mortality reduction while a significant increase in the cumulative inci-
dence of Pca was observed. These observations are in line with studies that show a strong 
correlation between the lower baseline PSA values and the detection of cancers with 
potential indolent tumour characteristics152, 167-169. These results were confirmed in current 
study, men with relatively low serum PSA at study entry were more often diagnosed with 
Pca with a favorable tumour stage and pathological characteristics (data not shown).
The main purpose of this study was to add information to the existing results of the 
ERSPC by providing a PSA risk stratification that would avoid misuse and maximization 
of PSA testing. Our results suggest that, assuming that the risk distribution according 
to the different PSA levels in this study was similar to the ERSPC, most of the absolute 
reduction in Pca mortality is achieved in men who had a moderately elevated PSA at 
study entry. In other words, the greatest benefits of early detection programs may be 
when men, aged 55-74 years, are diagnosed and treated when their serum PSA is in the 
range 4.0-9.9 ng/ml or 10.0-19.9 ng/ml. Furthermore, following research efforts that rec-
ommend more intensive PSA based screening by lowering the PSA cut-off, may greatly 
increase the number of men that need additional investigations and treatment, whilst 
having little effect on the reduction of Pca mortality.
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Our second main observation is that a large cumulative excess incidence was observed 
in men with a low baseline serum PSA at study entry in the intervention group. For men 
with a baseline serum PSA of 0.0-1.99 ng/ml at study entry, the increased risk of being 
diagnosed with Pca was increased more than 4 fold. In contrast, the Pca specific mortal-
ity difference was small, meaning that the potential harms were greater. The NNT to save 
one man from Pca death was 724 and 427 respectively when the baseline serum PSA 
was in the range of 0.0-1.9 or 2.0-3.9 ng/ml at study entry, respectively. Consequently, 
in these men the aggressive investigation and treatment was associated with extensive 
overtreatment and increase in costs. Furthermore, these observations suggest that for 
men with lower PSA levels, a screening protocol as currently performed in the ERSPC, 
may not be a proper tool to reduce Pca mortality. A simultaneous decrease in the quality 
of life may result. However, since all results are cumulative and the overall mortality is 
still low, longer follow-up is needed to confirm this early conclusion.
The significant excess incidence rates were mainly a result of repeated systematic 
screening using a lateralized sextant biopsy technique. A recent review showed that 
sextant biopsy, either classical or lateralized, will miss 23% or 19% of biopsy detectable 
Pca with extended biopsy schemes, respectively170. Therefore, the excess incidence 
might be even higher if the currently clinical accepted extended biopsy schemes were 
used for repeated screening.
The observations of the present study can be compared with the results of the Scan-
dinavian Control Group Prostate (SCGP-4) study since current data included the effect 
of early detection as well as the effect of early aggressive treatment. The SCGP-4 study 
showed that radical prostatectomy decreased Pca mortality compared to expected man-
agement for men with favourable localised clinically diagnosed disease after a median 
follow up of 10 years54. In the SCGP-4 study, 52% of the patients were diagnosed with 
Pca having a PSA ≤10 ng/ml. In patients with PSA ≤10 ng/ml at diagnosis the difference 
in the cumulative incidence of Pca death between radical prostatectomy and watchful 
waiting was smaller and was observed after more years of follow-up than in the patients 
diagnosed with a PSA >10 ng/ml171. Although the present study is not a randomized 
controlled trial, the trends in Pca mortality of the SCGP-4 study are similar. In this study 
the difference in the cumulative risk of death from Pca was observed earlier for men with 
a baseline serum PSA 10.0-19.9 ng/ml at study entry (Figure 4). Furthermore, for men 
included in the intervention and clinical cohort, an overlap in the cumulative hazard 
curves during the first five years was observed for men with baseline serum PSA 4.0-9.9 
ng/ml and eight years for men with baseline serum PSA 2.0-3.9 ng/ml at study entry 
(Figure 2 and 3).
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The main limitation of this study is the absence of randomisation, which necessar-
ily results in different patient characteristics at study entry. Statistical adjustment was 
needed for the difference in age and serum PSA at study entry. Furthermore, the large 
difference in all cause mortality might have biased the outcomes. Obviously the optimal 
study design would be the comparative evaluation of the intervention and control arm 
of the ERSPC. However, since serum PSA was not collected nor PSA measured at study 
entry in the control arm of the ERSPC, the present study design is an alternative method. 
The main limitations of the individual study populations and the present study design 
have previously been described105, 152.
Furthermore, different treatments in both cohorts might have affected the outcomes, 
with men diagnosed and treated with curative intent at an earlier stage likely to have 
a better outcome54, 163-164. In both groups, following diagnosis, men were free to choose 
treatment in collaboration with their local urologist. As outlined in Table 2, men in 
Northern Ireland had higher PSA levels at diagnosis and a higher rate of metastatic 
disease, they were therefore less likely to undergo prostatectomy and more likely to 
have androgen deprivation therapy105. These differences in treatment are inherent to 
any study with a large difference in the intensity of screening and early detection. The 
distribution of different treatments in the two study groups are published before105.
Another limitation that might have biased the study is the different PSA assays used. 
Several assays were used in Northern Ireland which differs from the same PSA assay 
used in the ERSPC. Cluster analyses that were performed for the different laboratories in 
Northern Ireland showed that there was no systematic difference in PSA values provided 
by the different laboratories and that the laboratory of origin did not affect the results. 
Finally, it could be argued that this study is plagued by a methodological bias, i.e. lead 
time. Generally, lead time is defined as the time between the detection by screening and 
the clinical diagnosis if there had been no screening. However, since in current study the 
observation time is defined as the time difference between the time of death and the 
time of first PSA measurement, lead time is unlikely to have influenced the outcomes. 
Nevertheless, it remains unknown if men with a specific age and PSA in a screening 
population compares equally to men with the same age and PSA in the selected clinical 
population.
The strong aspect from this study is the risk stratification based on baseline PSA and age. 
To the best of our knowledge, our study is the first report on a population based study 
cohort that showed the Pca incidence and mortality in two populations with a different 
intensity of screening and early detection stratified by baseline age and PSA. Currently, 
the interpretation of the balance between the risks and benefits is subjective, meaning 
it is a matter of personal judgement for which PSA level the benefits outweigh the harm. 
However, the final purpose of current study design is to risk stratify men at baseline 
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(based on age and PSA) into groups that require no further screening and men that 
have a higher risk of Pca mortality that should continue screening and early treatment. 
Currently longer follow-up is needed to give these clinical recommendations.
6.6 CONCLUSIONS
Baseline serum PSA before diagnosis is a strong predictor for Pca mortality in screen 
and clinical detected Pca. In the absence of standardized early detection programs, PSA 
might be used for a risk assessment that balances the harms and benefits of early detec-
tion in men aged 55-74 years. Current analyses suggest that the significant reduction 
in disease specific mortality with screening and early detection may be limited to men 
with baseline elevated PSA levels. In men with a low baseline serum PSA the benefits 
of continued aggressive investigation and treatment may be limited, whilst they are 
associated with a large increase in cumulative incidence, overtreatment and costs.
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AbSTRACT
Setting: In addition to disease-specific mortality, a randomized controlled cancer screen-
ing trial may be evaluated in terms of excess mortality. Excess mortality is calculated in 
the cancer patients in both study arms and is defined as the difference between the 
observed and expected mortality. The observed mortality can be estimated accurately 
by record linkage with the population registry. Thus the method critically hinges upon 
the assessment of the expected mortality. This issue is of special importance in the 
case of prostate-cancer screening. Attendees have a lower mortality rate and a higher 
probability of a prostate cancer diagnosis than non-attendees. Both issues affect the 
expected mortality in the screening arm patients.
Materials and methods: The effect of accounting for attendance is studied in a prostate 
cancer screening trial (ERSPC).
Results: Non-attendees had roughly twice the mortality rate of attendees. Approximately 
twice as many cancers were detected in the screening arm compared to the control arm, 
primarily in attendees. Unless the difference in mortality rate between attendees and 
non-attendees is taken into account the expected mortality is overestimated by 0.9 - 3.6 
deaths per 1000 person-years . The latter figure corresponds with a high non-attendance 
proportion.
Conclusions: Attendees have a lower all-cause mortality rate (are healthier) and a 
higher probability of a prostate cancer diagnosis than non-attendees and than men 
randomized to the control arm. If attendance is not accounted for, the excess mortality 
(= observed – expected mortality) is underestimated. The between-arm mortality rate 
ratio is overestimated (screening is considered more effective than it actually is). These 
effects may be considerable, notably if non-attendance is common.
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INTROdUCTION
A randomized study of screening for cancer typically focuses on the effect of screen-
ing on disease-specific mortality. To do so, the cause of death has to be determined. In 
the European Randomized Study of Screening for Prostate Cancer (ERSPC, an ongoing 
prostate-cancer screening study in 8 European countries172), all deaths in prostate-
cancer patients were reviewed by an independent committee. This committee labeled 
each death in cancer patients as prostate cancer death, possible prostate cancer death, 
intervention related death or other cause of death153. The involvement of human experts 
at such a critical stage in the evaluation of a study and the potential for error prompted 
the search for alternatives. An alternative that does not require the human judgment of 
the cause of death uses the excess mortality rate difference between the screened and 
the control population145.
Excess mortality rate is defined as the difference between the actually observed and 
the expected rate of death. An unbiased estimate of the expected mortality is of crucial 
importance in a study of excess mortality as is a correct labeling of the cause of death in 
a study of the disease-specific mortality.
In a previous paper173 we used identical age-specific mortality rates for calculating the 
expected mortality for both the screening and the control arm. Also, within the screen-
ing arm, no distinction was made in age-specific mortality rates between men who 
actually attended a screening visit and men who did not.
The above described method of calculating the expected mortality, however, may well 
be biased. E.g. not attending a screening visit may have a health-related reason. On the 
other hand, attendees may have a healthier life style (e.g. non- smokers) or have easier 
access to medical care. Not accounting for these facts may lead to a biased estimate of 
the expected mortality in the screening arm.
Studying this putative effect is the topic of this paper. We explicitly do not focus on 
the effectiveness of prostate-cancer screening in terms of a between- arm difference 
in excess mortality rate, that will be carried out and discussed in a separate paper. We 
used the material presented in a previous analysis augmented with material from the 
Finnish94, the Italian95 and the Swedish92 ERSPC centers. These centers are of special 
interest because the number of non-participants in the screening arm is high. They used 
pre-consent (i.e. up-front) randomization. This means that the men were enrolled into 
the study on the basis of the population registry without being aware of this. This results 
in 100% participation in the control arm and a variable rate of non-attendance in the 
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screen arm (effectiveness trial, focusing on the effect of screening under real life condi-
tions). In contrast, the participants in the Dutch region of ERSPC were randomized after 
giving informed consent (efficacy trial, which estimates the maximal effect of screening).
MATERIALS ANd METHOdS
We studied 149066 participants enrolled in the ERSPC (centers Finland, Italy, Sweden, 
aged 55-69, and the Netherlands, aged 55-74 at randomization, studied over the period 
1993-2006)68, 172, 66311 men were randomized to the screening arm and 82755 to the 
control arm. The randomization was 2 to 3 in the Finnish center (more men were ran-
domized to the control arm) and 1 to 1 in the other centers.
In order to study the effect of not accounting for attendance status we have calculated 
the excess mortality twice, once taking attendance status into account and once ignor-
ing attendance status, using the same baseline data.
The method uses the mortality rate in participants without prostate cancer to calculate 
the expected mortality in cancer patients. Subsequently, the excess mortality in cancer 
patients (difference between the expected and observed mortality) is calculated. The 
excess mortality in participants without prostate cancer is zero, by definition. Hereunder 
the method is discussed in detail.
For all participants, for all centers, the total follow-up period was subdivided into yearly 
intervals until either death, emigration or censoring (censoring date for all centers Dec 
31, 2006). For each interval the attained age equaled the age in the previous interval for 
the same individual plus 1 year (age at the initial interval = age at randomization). Each 
interval in the screening arm was subdivided into an episode of attendance and an epi-
sode of non-attendance. Attendance was defined as “being screened” at least once. At 
the moment of randomization, the status of a participant was defined as non-attendee. 
It changed to attendee at the moment of first attendance (status retained until death 
or censoring). For both study arms, each yearly interval was subdivided into a period 
without and with prostate cancer.
For each attained age, for all episodes in which no cancer was diagnosed, the number of 
deaths were added separately for each of 5 selections of participants without prostate 
cancer. These five selections were : attendees, non-attendees, men randomized to the 
screening arm, men randomized to the control arm and men randomized to either arm 
of the study. By dividing the respective total number of deaths by the respective num-
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ber of person-years, crude estimates of the all- cause mortality rates for each of the five 
selections were obtained for each attained age.
These crude estimates were smoothed by fitting a Poisson model to the number of 
deaths with attained age centered at 65 years as sole predictor. The logarithm of the 
number of person-years at risk was added as an offset to the model constant.
The crude and smoothed mortality rates were compared with the country-specific 
mortality rates as obtained from the Human Mortality Database.
For each attained age, the total number of person-years in men in whom prostate cancer 
was diagnosed was calculated for attendees, non-attendees and patients randomized to 
the control arm, for all study centers.
The number of person-years for each attained age in attendees with prostate cancer was 
multiplied with the age specific mortality rates in, 1) attendees without prostate cancer, 
2) screen arm participants without prostate cancer and 3) participants randomized to 
either arm without prostate cancer. In this way for each attained age three expected 
numbers of deaths were calculated. One with attendance status, screening arm and 
study center accounted for, one with study arm and study center accounted for and one 
with only the study center accounted for.
The same was done for non-attendee cancer patients. The three multiplication rates 
used in this case are similar to those used above (but then for non-attendees without 
prostate cancer). Subsequently the expected number of deaths in cancer patients in the 
screening arm were calculated by adding the expected number of deaths in attendees 
and non-attendees.
The expected number of deaths in men randomized to the control arm was calculated 
by multiplying the person-years in cancer patients for each attained age with the age 
specific crude mortality rate in control-arm participants without cancer.
Men in whom prostate cancer was found at autopsy were excluded from the calculations 
of the excess mortality, this was not done in the previous study173.
For all centers, for all calculated expected deaths, for each attained age the excess num-
ber of deaths was calculated as the difference of the observed and expected number of 
deaths in cancer patients.
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For all centers, for all calculated excess number of deaths, for each attained age, the 
excess mortality rates were calculated by dividing the excess number of deaths by the 
total number of person-years (i.e. in all participants irrespective of disease status) for 
that attained age. Additionally, the difference between the expected mortality rate cor-
rected for screening arm only and the expected mortality rate corrected for attendance 
status was calculated. The same was done for the excess mortality. The mean bias in the 
expected mortality was calculated for all centers as the sum of the differences between 
the expected number of deaths over all attained ages divided by the total number of 
person-years.
For each study center, the details of the calculation of the expected mortality rate (tak-
ing and not taking attendance status into account respectively) in a cancer patient with 
an attained age of 70 years are given. This information is supplied to support the details 
given in the appendix with actual data.
RESULTS
Table 1 contains a summary of the baseline data and the expected and excess numbers 
of deaths derived from these baseline data for all study centers.
Note that the excess numbers of deaths calculated directly from the mortality in non 
cancer participants typically differ from the corresponding reported excess deaths in the 
table. This illustrates the importance of using attained age- specific mortality rates. E.g. 
for the Finnish center, for the screening arm, the excess number of deaths derived from 
the person-years and deaths reported in the table equals 309 - (4695 / 269814) * 11016 
= 117.3 (considerably higher than the 56.9 listed).
The proportion of attendance is apparently strongly related to the type of randomiza-
tion. A much higher proportion (roughly 25%) of non-attendees were present in the Ital-
ian, Finnish and Swedish study centers (with up front randomization) . It is about 5 fold 
higher than in the Dutch center (5% non- attendees). On the other hand, in the Dutch 
center approximately 50% of the men invited for screening did not give consent68. The 
proportion of cancers detected in the screening arm is much higher than the proportion 
of cancers detected in the control arm. For all centers accounting for attendance status 
leads to higher estimates of the excess mortality (compare the excess mortality given 
in row 1 with the sum of the excess mortalities in the rows labeled A and NA for each 
center in Table 1).
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The expected number of deaths in the row labeled SC is much higher than the sum of the 
expected deaths in the rows labeled A and NA in Table 1. The results labeled with SC are 
obtained by accounting for the study center only (i.e. the method used in the previous 
paper173). The difference is especially large for the Finnish and the Swedish study centers.
Table 2 lists the excess mortality rates for men with an attained age of 70 for the four 
centers studied. The bias is the largest for the Swedish center where the “baseline mor-
Table 1: Summary of the baseline data and the expected and excess numbers of deaths derived from 
these baseline data for all study centers (age ranges at randomization given between brackets). The 
left panel contains a summary of the data used to calculate the expected mortality in non-cancer 
participants, the right panel lists the expected and excess mortality if the non-cancer participant mortality 
rate is applied to cancer patients. Subgroup is coded as follows : S : screening arm, C for control arm, SC 
screening or the control arm, A for attendee and NA for non-attendee. pYnc is the number of person-years 
in non- cancer patients, N is the number of men in that specific category, propN is the proportion of men. 
Note that the denominator of this proportion is the number of men randomized for S and C (proportion 
is 1 for SC) and the number of men randomized to the screening arm for A and NA. Ndnc is the number 
of deaths in non-cancer patients, Nc is the number of cancers, propC is the proportion of cancers. The 
denominator is the number of participants for S, SC and C and the number of cancers for A and NA, pYc is 
the number of person-years in cancer patients and Ndc is the number of deaths in cancer patients.
Used to derive the expected mortality no cancer patients Used to derive the expected and excess deaths
Center 
(age)
Sub-
group
N (propN) pYnc Ndnc Nc(propC) Sub-
group
pYc Ndc Expected 
deaths
Excess deaths
Finland
(55-69)
S 31970 (0.40) 269814 4695 2493 (0.08) S 11016 309 252.1 56.9
SC 80379 685203 11991 5125 (0.06) SC 11016 309 255.8 53.2
A 23774 (0.74) 193586 2300 2097 (0.84) A 9465 220 152.4 67.6
NA 8196 (0.26) 76228 2395 396 (0.16) NA 1552 89 68.3 20.7 (A+NA=88.3)
C 48409 (0.60) 415389 7296 2632 (0.05) C 9121 356 223.6 132.4
Italy
(55-74)
S 7265 (0.50) 58333 754 280 (0.04) S 1391 33 23.7 9.3
SC 14517 117049 1523 413 (0.03) SC 1391 33 23.3 9.7
A 5730 (0.79) 41889 475 246 (0.88) A 1251 21 18.8 2.2
NA 1535 (0.21) 16444 279 34 (0.12) NA 140 12 3.3 8.7 (A+NA=10.9)
C 7252 (0.50) 58716 769 133 (0.02) C 602 19 10.5 8.5
Rotterdam
(55-74)
S 21175 (0.50) 174641 3649 2152 (0.10) S 13451 428 361.4 66.6
SC 42318 358520 7399 3054 (0.07) SC 13451 428 354.7 73.3
A 19950 (0.94) 163316 3256 2104 (0.98) A 13246 412 339.8 72.2
NA 1225 (0.06) 11325 393 48 (0.02) NA 205 16 9.5 6.5 (A+NA=78.7)
C 21143 (0.50) 183879 3750 902 (0.04) C 3645 228 112.8 115.2
Sweden
(55-69)
S 5901 (0.50) 60361 1083 697 (0.12) S 4162 89 92.4 -3.4
SC 11852 123445 2213 1118 (0.09) SC 4162 89 91.7 -2.7
A 4466 (0.76) 39559 564 636 (0.91) A 3861 69 66.1 2.9
NA 1435 (0.24) 20802 519 61 (0.09) NA 300 20 11.4 8.6 (A+NA=11.5)
C 5951 (0.50) 63084 1130 421 (0.07) C 1847 71 42.6 28.4
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talities” between attendees and non-attendees are quite different combined with quite 
different proportions of person-years in “non- cancer attendees” and in cancer patients 
who had attended a screening visit (see appendix for an explanation).
In Figure 1 the bias that results in the expected mortality rate by not accounting for 
attendance status is plotted for all attained ages for all study centers.
The average difference in the “attendance status accounted for” and “attendance status 
not accounted for” expected mortality-rates is 3.6, 2.9, 1.1 and 0.9 for Sweden, Finland, 
Italy and the Netherlands per 1000 person-years respectively.
Table 2. Details for the calculation of the expected mortality rate in men with an attained age of 70 years 
(see appendix). All rates are given per 1000 person-years.
Center Mortality 
rate non-
cancer 
attendees
Mortality 
rate in non-
cancer non-
attendees
Proportion 
attender 
person-years 
in non-cancer 
participants
Proportion 
non-attender 
person-years 
in cancer 
patients
Expected 
mortality rate 
not accounting 
for attendance 
status
Expected 
mortality rate 
accounting for 
attendance 
status
Bias in the 
expected 
mortality 
rate
Finland 0.0200 0.0510 0.75 0.84 27.75 24.96 2.8
Italy 0.0156 0.0281 0.74 0.89 18.85 16.97 1.9
Rotterdam 0.0215 0.0374 0.94 0.99 22.45 21.66 0.8
Sweden 0.0206 0.0515 0.77 0.94 27.71 22.45 5.3
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Figure 1. 
 
fi ure 1. Bias in the expected mortality rate as a function of the attained age for the four centers studied. 
The bias is caused by not accounting for attendance status in the calculation of the expected mortality 
rate. The vertical line corresponds with the data given in Table 2. The line with the shortest age-range 
corresponds with Sweden (yellow), next is Finland (blue), than Italy (red) and the Netherlands (green). All 
rates are given per 1000 person-years.
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In Figure 2 the bias that results in the excess mortality rate by not accounting for at-
tendance status is plotted, for all attained ages, for all study centers. This plot enables 
studying the effect of “not accounting for attendance status” on the evaluation of the 
randomized study by means of a between-arm comparison of the excess mortality rate. 
The bias increases with increasing age.
The estimates of the expected mortality rates in men without prostate cancer in the 
different types of participants discerned in this study, as determined by the Poisson 
regression for the four centers, are given in Table 3. Non-attendees have a roughly 
twofold higher expected mortality rate than attendees. The expected mortality rates for 
the screening arm are comparable to the expected mortality rates for the control arm. 
For Sweden and Finland the expected mortality rates are higher than the mortality rates 
obtained from the Human Mortality Database (i.e. population-based). For Italy and the 
Netherlands they are lower.
dISCUSSION
A randomized controlled trial of screening for cancer is typically analyzed in terms of the 
between-arm difference in the disease-specific mortality rate. Thus the disease-specific 
mortality rate in the screening arm is compared with the rate in the control arm. This 
requires accurate information on the cause of death (i.e. human judgment). In addition, 
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figure 2. Bias in the excess mortality rate as a function of the attained age for the four centers studied. 
The line with the shortest age-range corresponds with Sweden (yellow), next is Finland (blue), than Italy 
(red) and the Netherlands (green). All rates are given per 1000 person-years.
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other effects of the screening process that affect mortality may be missed (e.g. detection 
of cardiovascular problems or diabetes). Both problems would be solved by carrying 
out an all- cause mortality analysis174. The reason that is mentioned in the literature for 
not doing precisely this is that the effect of screening on all-cause mortality is typically 
small. E.g., for prostate cancer, we assume that a third of the prostate-cancer mortality 
were avoided by screening. If the life time risk to die of prostate cancer were 3 % (chosen 
for ease of computation but close to the actual numbers) the effect of screening on all-
cause mortality would be 1%. This relative difference is much smaller than the assumed 
33% prostate-cancer specific mortality reduction. Showing a 1% effect instead of a 33% 
effect beyond a reasonable doubt (i.e. with statistical significance) requires prohibitively 
large numbers of trial participants. The precision of a study increases with the square 
of the number of events (proportional to the number of participants), thus a study that 
is twice as precise requires 4 times the number of participants. However, if we assume 
that a between-arm effect of a randomized controlled trial is confined to the patients in 
whom cancers are detected, an all-cause mortality analysis can be carried out without 
needing so many participants173.
Table 3. Example of the expected mortality rates per center for the four categories of participants 
discerned in this study for the attained age of 65.In the type column S stands for screening arm, A for 
attendee, NA for non-attendee and C for control arm.
Center Type Mortality rate in a 65 year old 
man (95%CI)
Mortality rate in the general male population 
(source Human Mortality Database)
Finland S 0.0179 (0.0174-0.0185) 0.0167 (2008)
A 0.0117 (0.0112-0.0122)
NA 0.0340 (0.0327-0.0354)
C 0.0181 (0.0176-0.0185)
Italy S 0.0109 (0.0100-0.0119) 0.0133 (2006)
A 0.0089 (0.0080-0.0100)
NA 0.0157 (0.0138-0.0178)
C 0.0115 (0.0106-0.0125)
Rotterdam S 0.0130 (0.0124-0.0136) 0.0138 (2008)
A 0.0122 (0.0116-0.0129)
NA 0.0236 (0.0206-0.0271)
C 0.0126 (0.0120-0.0132)
Sweden S 0.0171 (0.0160-0.0182) 0.0135 (2007)
A 0.0125 (0.0114-0.0137)
NA 0.0264 (0.0242-0.0288)
C 0.0170 (0.0160-0.0181)
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An excess mortality analysis can be applied as an alternative but preferably, at least, as 
an augmentation of a disease-specific mortality analysis. Given that excess mortality is 
the difference between the observed and the expected mortality and the possibility to 
obtain the former by database linkage (i.e. in theory flawlessly), an accurate determina-
tion of the expected mortality is of critical importance.
From a comparison of the expected mortality rates with the population mortality rates 
in Table 3 it is obvious why the latter was not used to estimate the excess mortality. It is 
lower than the expected mortality rate for Sweden and higher for Italy. A plot for all ages 
for the Netherlands of the expected mortality rate on the basis of the trial data and the 
Dutch population mortality rate in males (not shown) shows considerable differences 
despite the reasonable agreement at age 65 (Table 3). Thus, population-based mortality 
rates are apparently not specific enough to be used in this study. Therefore we have 
derived the expected mortality from within the trial, based on the participants in whom 
no cancer was yet detected.
In screening trials such as the ERSPC, an “intention to screen” based analysis is used. Thus 
the disease-specific screening arm mortality rate is compared with the corresponding 
control arm mortality rate, irrespective of actual screening attendance. This approach is 
conservative. If an effect of screening is detected in an “intent to screen” analysis it is very 
likely larger in individuals who are actually screened.
Non-attendees have a relatively high mortality rate (health-related,SES or education-
related). This can be appreciated from Table 3 (mortality rate in non-attendees is double 
the mortality rate for attendees in all four centers).
The appendix of this paper shows that not accounting for attendance status in the cal-
culation of the excess mortality may lead to a serious bias. It is affected by two factors. 
It increases if the ratio attendees/non-attendees in the cancer patients in the screening 
arm differs more strongly from the ratio attendees/non-attendees in the non-cancer 
participants. Intuitively this can be understood as follows. Men who show up for screen-
ing are healthier (i.e. less likely to die) than men who do not show up. Due to screening, 
cancers are primarily detected in these men. The bias also increases if the difference 
in the mortality rates between attendees and non-attendees (both without prostate 
cancer) increases. If attendance status is not accounted for, the expected number of 
deaths is overestimated and therefore the excess number of deaths is underestimated. 
The same holds for the expected and excess mortality rates. Therefore, since this effect 
occurs in the screening arm, the excess mortality rate difference between the two arms 
is overestimated. The screening program appears to be more effective than it actually is.
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The data presented in this paper illustrate the reality of this problem. For the Swedish 
study center, the excess mortality in the screening arm is negative if attendance status 
is not accounted for. This is an unlikely observation since the excess mortality is deter-
mined in cancer patients. The largest bias is observed in the three centers with upfront 
randomization (the related high percentage of non-attendance makes a bias more likely 
in an intention to screen analysis).
The relation between disease-specific and excess mortality is cancer type dependent. 
E.g. smoking causes both lung cancer and cardiovascular deaths. The excess mortality 
is related to both causes and therefore both an excess and a disease-specific mortal-
ity analysis should be done. Furthermore, the excess incidence in the screening arm 
consists of two parts, early diagnosis (cancer is found sooner but would have surfaced 
anyway) and overdiagnosis (cancer would not have surfaced during a patient’s life 
time). Both add to the expected mortality bias if attendance is not properly accounted 
for. The amount of overdiagnosis (and thus the bias) strongly depends on the type of 
cancer. Correcting for attendance is likely more important in prostate cancer screening 
(relatively high overdiagnosis) than in breast cancer screening with the same follow-up.
There is some opportunistic screening in the control arm of the ERSPC, very likely 
predominantly in healthy men. Correction for this fact is impossible, it requires informa-
tion about opportunistic screening at the level of the individual patient (which is not 
available). Thus the expected mortality for the control arm is estimated too high and the 
excess mortality too low (using the same logic as given above for the screening arm). 
This means that if a screening study is evaluated by a between arm study of the excess 
mortality rates the outcome is conservative (at least if attendance status is accounted 
for for the screening arm). The actual effect of screening on the excess mortality rate is 
in reality very likely slightly larger than the calculated value.
Figure 1 shows that the effect of accounting for attendance status on the expected mor-
tality is roughly constant at each attained age. The effect on the excess mortality rate, 
however, depends on the attained age (Figure 2) because incidence increases with age. 
The observed mortality is associated with incidence. Thus bias in the excess mortality 
rate increases with increasing age.
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CONCLUSION
Correcting for attendance status is very important in the calculation of the excess mor-
tality rate that can be used in conjunction with a disease-specific mortality analysis in a 
randomized controlled cancer screening trial.
APPENdIx
Let us look at an age group for a period of time in the screening arm. The expected 
mortality of the prostate-cancer patients will be based on person-years of those with-
out prostate cancer until the end of the period, death or diagnosis of prostate cancer, 
whichever comes first. The expected mortality rate without regard to the participation 
(attendance) status is :
 rs = was ras + (1 − was)rns, (1)
where was = pyas / pys = proportion of the participants’ person-years pyas out of all  person-
years pys, and ras and rns are the mortality rates in the participants and non-participants, 
respectively. When the participation status of the prostate-cancer patients is accounted 
for, the expected mortality rate is :
 rps = wap ras + (1 − wap) rns, (2)
where wap = pyap / pyp is the proportion of the participated prostate-cancer patients’ 
person-years pyap out of all prostate-cancer patients’ person-years pyp.
It is easy to see that rs = rps, if either was = wap or ras = rns.
There are no other solutions. Equations (1) and (2) represent lines in the space spanned 
by ras and rns.
These lines are equal if they intersect (rs = rps) or if they are on top of each other 
(was = wap).
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AbSTRACT
Objectives: To study the difference between the disease specific and excess mortality 
rate in the European Randomized Study of Screening for Prostate Cancer (ERSPC) sec-
tion Rotterdam.
Methods: A total of 42,376 men were randomized to systematic screening or usual care. 
The excess number of deaths was defined as the difference between the observed num-
ber of deaths in the prostate cancer (PC) patients and the expected number of deaths 
up to December 31, 2006. The expected number was derived from mortality of all study 
participants before a possible diagnosis with PC. The disease specific mortality rate was 
based on the number of men who died from PC. The excess mortality rate based on 
the arm-specific excess number of deaths and the disease specific mortality rate were 
compared between the two study arms.
Results: The overall mortality rate was not significantly different between the interven-
tion and the control arms of the study: RR 1.02 (95%CI 0.98-1.07). The disease specific 
mortality rate was 0.42 men per 1000 person-years in the intervention and 0.48 men per 
1000 person-years in the control arm: RR 0.86 (95%CI, 0.64-1.17). The excess mortality 
rate was 0.40 per 1000 person-years in the intervention arm and 0.61 men per 1000 
person-years in the control arm, and the RR for excess mortality was 0.66 (95%CI, 0.39-
1.13).
Conclusions: In contrast to the disease specific mortality rates an increased difference in 
the excess mortality rates was observed between the two arms. This observation may be 
due to a systematic underestimation of the disease specific deaths, and/or an additional 
disease related mortality that is measured by an excess mortality analysis but not by a 
disease specific mortality.
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8.1 INTROdUCTION
The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown 
a significant reduction in prostate cancer (PC) mortality due to screening98. In the final 
analysis the ERSPC has compared the number of men who died from PC per unit time 
at risk in both arms of the study, i.e., the disease specific mortality rates. Although this is 
a generally used endpoint of a randomised controlled screening trial, an alternative to 
this approach exists. It comprises the estimate of the excess mortality rate in the cancer 
patients in both arms of the study145. This excess mortality rate is based on the actually 
recorded number of cancer patient deaths in excess of the number expected on the 
basis of a cohort of cancer free individuals per unit of time.
No differences in the disease specific mortality and excess mortality rates are expected 
to be found. This is conditional on PC being the only factor affecting differences in 
mortality, the accurate ascertainment of the disease specific mortality and an accurate 
estimate of the expected mortality. However, if for example screening for PC has non-PC 
related effects on the life expectancy of cancer patients, or the cause of death is not 
accurately assessed, the outcome of the two mortality analyses may differ. Therefore the 
question whether the disease specific mortality rate differs from the excess mortality 
rate in men who are systematically screened for PC and in men who were not systemati-
cally screened is relevant. The absence of a discrepancy confirms the established effect 
of screening on PC mortality, the presence of a significant discrepancy warrants further 
research.
8.2 MATERIALS ANd METHOdS
8.2.1 Study Population
After signing an informed consent, a total of 42,376 men, aged 55-74 year, were ran-
domized in the Rotterdam section of the ERSPC between 1993 and 200068. Men were 
allocated to the intervention and the control arm by individual randomisation based 
on the outcome of a random number generator. Men with a prior diagnosis of PC were 
excluded. Between December 1993 and May 1997 men in the intervention arm were 
screened with an interval of four years by PSA measurement, rectal examination (DRE) 
and transrectal ultrasound examination (TRUS). A sextant biopsy was initially offered to 
men with PSA ≥4.0 ng/ml and/or a suspicious finding on DRE and/or TRUS. After May 
1997 a biopsy was prompted by PSA ≥3.0 ng/ml only. Treatment decisions were taken 
by the local urologist and at patient’s preference. Details of the screening methodology 
were reviewed by Roobol et al96. Cancers diagnosed between the screening intervals 
or after the age of 74 years clinically or due to opportunistic screening, transurethral 
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resection of the prostate for benign disease, and cystoprostatectomy specimens, were 
included as well. These cancers were identified by means of linkage to the national 
Comprehensive Cancer Registry160, 175. Follow-up in this respect was complete up to and 
including 2006. Men in the control arm were not subject to screening and received usual 
care if diagnosed with PC. The men with PC in the control arm were identified through 
the same linkage with the Comprehensive Cancer Registry.
8.2.2 Mortality data
Mortality data of participants who died in the period up to December 31, 2006 were 
obtained by linking the trial database with the Causes of Death Registry of Statistics 
Netherlands176. Linkage to the Causes of Death Registry of Statistics Netherlands was 
possible by using the personal administrative number of each participant as a linkage 
key.
8.2.3 Length of follow-up
Diagnostic and mortality data were available until December 31, 2006. Consequently, 
the date of censoring was at emigration or December 31, 2006.
8.2.4 disease specific mortality
For all PC cases in the study who were known to have died, all available information was 
gathered and anonymised. Subsequently all deceased PC cases were reviewed by a na-
tional independent causes of death committee (CODC) using predefined flow charts or 
by an international committee if no consensus was reached153. Patients were determined 
to have died from PC if they were classified as either “definitely PC death”, as “possible 
PC death” or as “PC intervention related death”153. The disease specific mortality was 
calculated for the both arms of the study.
8.2.5 Excess mortality
The excess mortality was calculated for the both arms of the study and was based on 
arm-specific excess numbers of deaths of the PC patients. In both arms, the observed 
number of deaths in PC patients diagnosed during the trial was compared with an 
expected number of deaths. The expected number of deaths was calculated on the 
assumption that the patients would have had the same mortality by age at and time 
since randomization as the study population (intervention and control arms) combined 
before any diagnosis of PC. The excess number of deaths was defined as the difference 
between the observed and expected numbers. The excess numbers of deaths were used 
as numerator data, and the number of person-years per study arm was used as denomi-
nator in calculating the excess mortality rates for the both arms of the study.
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8.2.6 General population mortality
The age specific mortality rates obtained from the study participants were graphically 
compared with the age specific mortality rates obtained from nationwide population 
life tables based on men in the general Dutch population177. The mortality rates were 
expressed in deaths per 1000 person-years at risk per year.
8.3 STATISTICAL ANALySIS
The excess mortality rates were compared between the study arms as shown in the 
Appendix 1. The disease specific mortality rates were compared between study arms 
using a Poisson regression analysis with an indicator of study arm as a predictor and the 
logarithm of the number of life years as an offset term (predictor with a coefficient of 
one)178. In this paper a two-sided p value <0.05 was considered statistically significant. 
All analyses were performed with the commercially available STATA package: Data 
Analysis and Statistical Software, version 10.
8.4 RESULTS
8.4.1 baseline characteristics
A total of 42,317 men of the 42,376 men who signed an informed consent were included 
in the study (59 men were excluded because of a PC diagnosis before randomization). 
The median age at randomization was 63 years for the both study arms (Table 1).
Table 1. The study arms by age at randomization
Intervention arm
N= 21,175
Control arm
N= 21,142
Age (yr), median 63.0 63.0
 55-59 8,142 8,033
 60-64 5,511 5,565
 65-69 4,746 4,820
 ≥ 70 2,776 2,724
The cumulative PC incidence in the intervention arm was 2.4 fold higher than in the 
control arm, i.e., 2,153 (10.2%) men were diagnosed with PC in the intervention arm 
and 901 (4.3%) men were diagnosed with PC in the control arm (Table 2). The median 
age at diagnosis differed significantly between the two groups (p<0.001); men in the 
intervention arm were diagnosed at an earlier age. Up to the end of 2006, a total of 4,077 
(19.2%) men died in the intervention arm (21.67 men per 1000 person years) and a total 
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of 3,977 (18.8%) died in the control arm (21.20 men per 1000 person years). This resulted 
in a cumulative all cause mortality that was not significantly different between the two 
arms: RR 1.02 (95%CI 0.98-1.07), Table 3.
Table 3. Mortality outcomes in the intervention and control arm ERSPC-Rotterdam
Randomization 
arm
Numb. 
of men
Numb.
PC
All cause 
mortality 
rate
RR (95%CI) PC 
death 
rate
RR (95%CI) Excess 
mortality 
rate
RR (95%CI)
Intervention 21,175 2,153 21.67 1.02
(0.98-1.07)
0.42 0.86
(0.64-1.17)
0.40 0.66
(0.39-1.13)Control 21,142 901 21.20 0.48 0.61
PC: prostate cancer, Rates as the ratio of deaths to 1000 person-years of exposure, RR: rate ratio
8.4.2 disease specific mortality rate
Up to the end of 2006, in the intervention arm 0.42 men per 1000 person years and in 
the control arm 0.48 men per 1000 person years died from a PC related cause of death 
according to the CODC. This resulted in a non-significant reduction in PC mortality rate 
of 14% in the intervention population relative to the control arm: RR 0.86 (95%CI, 0.64-
1.17), Table 3.
8.4.3 Excess mortality
Up to the end of 2006, the excess mortality rate was 0.40 men per 1000 person-years 
in the intervention arm and 0.61 men per 1000 person-years in the control arm. This 
resulted in a non-significant reduction in the excess mortality rate of 34% in the inter-
vention population relative to the control population: RR 0.66 (95%CI, 0.39-1.13), Table 3.
8.4.4 disease specific mortality versus excess mortality
The excess mortality rate was slightly lower than the disease specific rate in the interven-
tion arm of the study. The absolute risk difference was 0.02 men per 1000 person years. 
The excess mortality rate was considerable higher than the disease specific rate in the 
Table 2. Prostate cancer patients by age at diagnosis
Intervention arm
N= 2,153 (10.2% of men 
randomized)
Control arm
N = 901 (4.3% of men 
randomized)
P value
Age (yr), median 68 71 < 0.001 †
 55-59 165 (7.7) 23 (2.6) < 0.001 ‡
 60-64 458 (21.3) 122 (13.5)
 65-69 716 (33.2) 236 (26.2)
 70-74 650 (30.2) 274 (30.4)
 ≥ 75 164 (7.6) 246 (27.3)
† Mann-Whitney U test, ‡ Chi-square test
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control arm of this study. The absolute risk difference was 0.13 men per 1000 person 
years. The difference between disease specific and excess mortality rate in the control 
arm of the study was most evident for the older ages at randomization (Table 4).
8.4.5 Mortality rates study population versus general population
The age-specific mortality rates among study participants were favourable compared 
to men in the general population (Figure 1). The mortality rates increased with increasing 
attained age in both populations. The mortality ratio was about 1.4 fold higher among 
men in the general population for all ages.
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 Figure 1. The age specific mortality rate per 1000 person-years, for men in the general Dutch population and all 
men participating in the ERSPC (Rotterdam) 
 
 
 
 
 
 
 
 
 
 
 
 
 
figure 1. The age specific ortality    e rs, for men in the general Dutch population 
and all men participating in the E SPC (Rotterdam).
Table 4. Mortality outcomes according to age at randomization
Age No. of men
I arm
No. of men
C arm
PC death rate 
I arm
PC death rate 
C arm
Excess Mortality 
rate I arm
Excess Mortality 
rate C arm
55-64 13,653 13,598 0.19 0.25 0.18 0.27
65-74 7,522 7,544 0.83 0.89 0.80 1.19
PC: prostate cancer, I: Intervention, C: Control, Rates as the ratio of deaths to 1000 person-years of 
exposure, RR: rate ratio
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8.6 dISCUSSION
The ERSPC was initiated to detect the effect of population-based PC screening on PC 
specific mortality. The ERSPC (all centers included) was designed with a power of 0.86 
to detect a 25% intervention effect in men actually screened if the contamination re-
mained limited and the follow-up was complete up to the end of 2008179. As a result, a 
20% relative reduction in PC mortality with a significance level of p=0.04 was reported 
by the ERSPC based on the data up to the end of 2006; the relative reduction in the 
men actually screened was 27%98. The focus in this first report was the difference in PC 
specific mortality rates98. In the current report we have studied the excess mortality in 
addition to the disease specific mortality in the Rotterdam section of the ERSPC. The 
excess mortality rate was notably higher than the disease specific mortality rate in 
the control arm. As a result, in comparison to the disease specific mortality rates, an 
increased difference in the excess mortality rates was observed between the two arms 
of the ERSPC Rotterdam. Neither of the relative reductions were statistical significant. 
Therefore results after longer follow-up and complementary data of the total ERSPC are 
needed to confirm these observations.
Any difference between the excess and disease specific mortality rate could be due 
to a violation of the appropriateness of the basic assumptions (accurate estimation of 
expected mortality in case of excess mortality, accurate classification of cause-of-death 
in the case of disease specific mortality, and the absence of an intervention related ef-
fect on the life expectancy that is unrelated to PC in case of excess mortality)145. Since 
a difference was observed, this difference will be discussed based on the basis of the 
above three possible explanations.
8.6.1 Accurate estimation of expected mortality
Typically, in relative survival analysis, the expected mortality is estimated from nation-
wide population life tables stratified by age, sex and period180. In this screening setting, 
the general population may not be suitable as a reference population since the people 
who participate might well be healthier and of higher socioeconomic classes, i.e., subject 
to healthy screenee bias181-182. For this reason, in the present study, it seemed appropri-
ate to obtain the expected mortality from all participants before a possible diagnosis 
of PC. A comparison of the mortality rates from the Dutch national statistics 177 with the 
rates derived according to the procedure outlined above, indicated that the mortality 
rates were considerably lower among study participants than among men in the general 
population (Figure 1). These results are consistent with a study on socioeconomic status 
patterns among study participants, which showed that men who participated in the 
study had higher income levels and lower poverty or deprivation status162. Therefore, 
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the national population is not an appropriate reference group for the estimation of 
the excess mortality in a PC screening trial. Additionally, an excess mortality could be 
overestimated if PC patients would have characteristics which are related to PC but also 
carry an increased risk of death other than from PC. For example, patients diagnosed 
with smoking-related cancers will experience excess mortality, compared to the refer-
ence population, due to both the cancer and other smoking related conditions. Such a 
relation is not known for PC, however, it could be that there is an unknown factor related 
to clinical diagnosed PC in particular that is carrying a higher risk of death from other 
causes. In principal, such a confounding effect could be of influence on the observed dif-
ference between the disease specific mortality and excess mortality rates in the current 
study. Therefore, this has to be considered as an explanation for the observed difference.
8.6.2 Random variation excess mortality
The confidence interval of the rate ratio of the two excess mortality rates between the 
two study arms was estimated by the delta method, Appendix 1183-184. To examine the 
appropriateness of the assumptions made in this approach, the confidence interval was 
also estimated by means of a computer simulation (bootstrap procedure)185. Using a 
bootstrap procedure has the benefit of not making assumptions about the distribution 
of the coefficients. The procedures consist of a repeated sampling with replacement 
from the dataset under study and carrying out the modelling for each sample thus 
obtained. The rate ratio of the two excess mortality rates between the two study arms 
obtained from the bootstrap equaled 0.68 (95%CI 0.28-1.08).
8.6.3 Accurate classification of cause-of-death
In the present study the causes of death of every PC patient is ascertained by a commit-
tee153. Such committees are based on the experience in breast cancer screening trials 
where independent committees have reviewed causes of death to ensure a correct 
interpretation of the mortality results published133. It is assumed to be the most optimal 
method, especially in PC where death on the death certificates differs often from the 
clinical picture135, 137. However, it is in practice impossible to blind the arm of the study 
entirely before the committee reviews the records of deceased men. The records are for 
example not blinded for stage at diagnosis although this is a very suggestive parameter 
for the arm of the study186. It remains possible that the lack of adequate blinding of the 
records with respect to study arm has resulted in a bias in the cause of death ascer-
tainment. Efforts have been made to optimise the accuracy of the assessment of the 
cause of death, e.g. all PC deaths are reviewed by three persons independently without 
exchanging opinions153. However, despite these efforts, it might be possible that the 
reviewers have underestimated the PC mortality by being too cautious in stating that 
a patient has died from PC in the control arm of the study, in order not to overestimate 
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the study outcomes. Furthermore, it might be that due to the study protocol more 
information could be gathered from patients diagnosed with PC in the intervention 
arm. Consequently, the CODC made a more valid decision for the deceased men who 
were participating in the intervention arm. Therefore, this potential biases might be an 
explanation for the observed difference in both mortality rates in the control popula-
tion. Finally, any algorithm used for the review of causes of deaths is bound to be based 
on some arbitrary definitions which are needed to ascertain comparability of decisions 
but which may lead to discrepancies with the excess mortality.
8.6.4 Absence of an intervention related effect on life expectancy that is 
unrelated to PC.
Assuming that the observed difference in outcomes between the two mortality rates 
is not due to the two previously described explanations, the difference may be due 
to the theoretical difference of the two mortality analyses. Disease specific mortality 
is included in excess mortality but is not identical to it, i.e. disease specific mortality 
refers to mortality due to only one particular cause of death such as disease progres-
sion and treatment related mortality and excess mortality measures both the direct and 
indirect mortality due to the cancer of interest, e.g. including cachexia, uraemia, suicide 
depression and loss of interest in life. For this reason, a screening study may reduce 
the disease specific mortality but side effects of the screening procedure (anxiety) may 
cause an increased death of other causes. In such a case the excess mortality is higher 
than the disease specific mortality. On the other hand, the screening procedure may 
detect health problems unrelated to the disease under study which may lead to effec-
tive medical treatment. In this case the excess mortality will be less than the disease 
specific mortality. These latter considerations may thus explain the differences between 
the mortality rates in the intervention arm of the study (Table 3).
Based on the observation that the excess mortality rate exceeds the disease specific 
mortality rate in the control arm of the study, the life expectancy of more men may 
be negatively influenced than estimated on the basis of a disease specific mortality 
analysis. Possibly, in a number of cases, PC specific mortality has failed to esthablish to 
which extent PC is a contributary factor for death. This is a known phenomenon since 
only 50-85% of men with advanced PC die from their disease, depending on age and 
the extent of the disease at diagnosis187. As a result, in these men with advanced disease 
who did not die from PC, the advanced disease could have shortened the patient’s life 
by making the patient more susceptible for other causes of death. For example, the 
death of patients who are physically affected by PC but eventually die from a secondary 
infection, will be classified as an intercurrent cause of death. In such a case the question 
remains if the patient would have died when the disease of interest was absent. Based 
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on our results this may, amongst others, explain the observed discrepancy between the 
two types of mortality rates, especially in the control arm since the control arm contains 
more men with a clinically advanced disease.
The main difference between the excess mortality and disease specific mortality rate 
in the control arm was observed for the older age group at randomization (Table 4). 
This observation is in good agreement with the previous excess mortality studies on 
mammography screening for breast cancer that also observed a more pronounced 
discrepancy between the excess mortality and disease specific mortality analysis for the 
older ages188-189. In line with suggestions made in the previous publications, this could 
be the result of a more uncertain individual cause of death determination in these age 
groups since the overall mortality in these older ages was higher.
8.6.5 Overall mortality
This study and the total ERSPC were not designed to detect a statistically significant 
effect in overall mortality98, 179. We estimated that if the effect of screening were the only 
between arm difference in the mortality pattern a 30% disease specific mortality reduc-
tion would translate into a 0.7 % overall mortality reduction. In order to show this effect 
of screening on overall mortality at the two-sided 5% level of statistical significance, 
more than 3 million study participants have to be randomized (assuming a median of 
9 year follow-up and a 15% overall mortality over the 9 year period)190. Therefore, if PC 
screening has an impact on the overall mortality, this will be very small.
8.6.6 Limitations
This study was performed by a single centre of the ERSPC. However, this centre was not 
powered to analyze the effect of a significant difference in disease specific mortality 
alone179. Consequently, final conclusions can only be made after confirmative results 
based on data of the total ERSPC.
8.7 CONCLUSIONS
For the evaluation of PC screening, a study of the excess mortality analysis is of indepen-
dent additional value to a disease specific analysis since it measures the effect of screen-
ing in the presence of all competing risks. The between arm difference in the excess 
mortality rates was more than twofold the between arm difference in the disease specific 
mortality rates. Two possible explanations for the observed discrepancy outlined in this 
paper are: 1) a systematic underestimation of deaths from PC by the CODC in the control 
arm of the study; 2) an additional disease related mortality that is measured by an excess 
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mortality analysis but not with a disease specific mortality. Furthermore, although the 
effect in terms of excess mortality was larger than the disease specific mortality, PC 
screening might have no or a very small effect on the overall mortality.
In any randomised study with a disease specific mortality reduction as an endpoint, 
an additional excess mortality study should be mandatory as it may reveal additional 
important information. In the present study it may imply that the effects of PC screening 
on mortality is considerably larger than reported in the initial analysis that focussed on 
disease specific mortality only.
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APPENdIx 1.
Statistical comparison between the two excess mortality rates of the two study arms
The two excess mortality rates are presented as mi = ei/ni, where i = 1, 2 is the study arm 
(i= 1: intervention arm and i= 2: control arm), ei =arm-specific excess number of deaths 
and ni = arm-specific number of observed person-years. In this study, the quantities n1 
and n2 are regarded to be constants since the total numbers of death in the arms are 
large.
The ei are not regarded as constants, since ei depends on Ni = number of prostate cancer 
cases per study arm and the chances of patient survival (a source of extra random varia-
tion). Furthermore, each ei is also a difference between two numbers of deaths among 
the Ni patients:
 ei = di − di *,
where di = the observed number of deaths per study arm and di* = the expected number 
of deaths per study arm. Neither one of them is regarded to be constant as they depend 
on Ni, a Poisson-distributed random variable.
In this calculation, the di and di* are mathematically related to the Ni as:
di = Niqi and di* = Niqi*,
where the qi and qi* are death proportions, observed and expected respectively. The qi* 
is regarded to be fixed as it is based on the large total numbers of deaths in the study 
population. The qi is assumed to be the parameter of a binomial distribution with radix 
Ni.
In this comparison the quantity of interest is:
 Rate ratio (RR) = m1/m2 and, ln(RR) = ln(m1) − ln(m2).
The variance of the RR is estimated by the delta method183-184 as:
 var (ln(RR)) = var (m1)/m1
2 + var (m2)/m2
2.
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The 95% confidence limits for ln(RR) based on the delta method are calculated as ln(RR) 
+1.96 sqrt (var (ln(RR))) as the upper bound and ln(RR) − 1.96 sqrt (var (ln(RR)) ) as the 
lower bound , where sqrt = square root. Consequently, the confidence limits for the RR 
are obtained by an exponentiation of these upper and lower bounds.
The var (m1) and var (m2) are calculated as:
 mi = ei/ni = (di − di*)/ni = Ni (qi - qi*)/ni.
var (mi) = var (numerator)/ni
2, with var (numerator) = var (Ni) (qi − qi*)
2 + Ni
2 var (qi − qi*)
 = Ni (qi − qi*)
2 + Ni
2 var (qi).
Now the Poisson assumption of Ni, constancy assumption of qi* and the delta method 
for variance of a product have been made use of. A binomial assumption for qi further 
gives:
 var (qi) = qi (1 − qi)/Ni
and
 var (numerator) = Ni (qi − qi*)
2 + Niqi (1 − qi) = Ni ((qi − qi*)
2 + qi (1 − qi)).
This can be inserted into the formula of var (mi), i=1,2, in order to give the confidence 
interval for the RR.
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AbSTRACT
Objectives: To study the excess mortality rate in the European Randomized Study of 
Screening for Prostate Cancer (ERSPC).
Methods: A total of 141578 men, age 55-69 years, were randomized to systematic screen-
ing or usual care in the ERSPC sections Finland, Italy, the Netherlands and Sweden. The 
excess number of deaths was defined as the difference between the observed number 
of deaths in the prostate cancer (PC) patients and the expected number of deaths up 
to December 31, 2006. The expected number was derived from mortality of all study 
participants before a diagnosis with PC adjusted for study centre, study arm and study 
attendance. The excess mortality rates were compared between the two study arms.
Results: The PC incidence rate was 9.25 per 1000 person-years in the intervention arm 
and 5.49 per 1000 person-years in the control arm, RR 1.69 (95%CI 1.62-1.76). The excess 
mortality rate was 0.29 per 1000 person-years in the intervention arm and 0.37 men per 
1000 person-years in the control arm; the RR for excess mortality was 0.77 (95%CI, 0.55-
1.08). The absolute risk reduction in the excess mortality was 0.08 per 1000 person-years. 
The overall mortality rate was not significantly different between the intervention and 
the control arms of the study: RR 0.99 (95%CI 0.96-1.01).
Conclusions: Although the reduction in excess mortality was not statistically significant, 
the between-arm reduction in excess mortality rate was in excellent agreement with the 
previously report 20% reduction in the disease-specific mortality. This finding corrobo-
rates that PSA-based screening reduces the rate of excess deaths from PC. Estimation 
of excess mortality can be used in studies to evaluate the effects of PC screening on 
mortality.
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INTROdUCTION
Randomized studies have shown that Prostate Specific Antigen (PSA)-based screening 
for prostate cancer (PC) causes a significant reduction in PC specific mortality in men 
aged 55-69 years at invitation for screening[1, 2]. The effect was studied by comparing 
the number of deaths from PC in the screened and unscreened population of the trials. 
The cause of death of all men who died and were diagnosed with PC was labeled as 
either “death from” or “death with” PC by independent committees in each of the partici-
pating countries[3]. No effect of screening was found on the all-cause mortality.
There have been debates on the issue of whether disease-specific death should be 
the endpoint of a cancer screening trial[4-6]. All-cause mortality is potentially a more 
valid outcome than disease-specific mortality since all-cause mortality analyses are 
superior in discovering the ineffectiveness and, in some cases, the side-effects of an 
intervention. For example, a screening program can reduce the disease-specific mortal-
ity whereas the side effects of the screening procedure (anxiety, depression or even the 
treatment for the disease being screened for itself ) cause an increased risk of death of 
other causes. In such a case the disease- specific mortality decreases while the overall 
mortality increases. In clinical trials, such effects are known from fibrates for cholesterol 
reduction[7], antiarrhythmics following myocardial infarction[8, 9], and liberal red cell 
transfusion in the critically ill[10].
However, for evaluation of a screening trial, disease-specific mortality remains the 
best surrogate endpoint since screening trials would require millions of subjects to have 
the statistical power to detect a reduction in all-cause mortality. In a recent study we 
have presented an alternative to assess the total effect of screening on the mortality in a 
randomized trial[11]. It comprises a comparison of the estimates of the excess mortality 
rate in the cancer patients in both arms of the study. These excess mortality rates are 
based on the actually recorded number of cancer patient deaths in excess of the number 
expected on the basis of a cohort of cancer free individuals per unit of time. To study the 
use of excess mortality in prostate cancer screening further this study is based on data 
of the four largest centres of the European Randomized Study of Screening for Prostate 
Cancer (ERSPC).
STUdy dESIGN
The ERSPC was designed as a randomized, multicenter trial of screening for PC, with the 
rate of death from PC as the primary outcome[12]. As complementary approach to the 
primary outcome, it was planned to calculate the ‘excess mortality’ in PC patients (i.e. 
patients diagnosed after randomization)[13].
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In the present study, data from the four largest ERSPC centres are analysed to have 
robust estimates of the excess mortality. The procedure of recruitment and randomiza-
tion differed among centres. In Finland, Italy, and Sweden men underwent randomiza-
tion before written informed consent was provided by those allocated to the screening 
arm (population-based effectiveness trial). In the Netherlands, men provided informed 
consent before randomization (efficacy trial). In Finland a total of 80377 men aged 55-
69 were randomized, in Italy a total of 14517 men, in Sweden a total of 11852 men, 
and in the Netherlands a total of 34832 men. In Italy, Sweden and the Netherlands the 
study was performed based on randomization in a 1:1 ratio to the screening group or 
the control group. In Finland, the size of the screening group to the control group was 
approximately 1:1.5.
Screening tests and indications for biopsy
In Sweden a PSA cut-off value of 3.0 ng/ml was used as an indication for biopsy[14]. In 
Finland, a PSA value of 4.0 ng/ml or more was defined as positive test by which men 
were referred for biopsy; those with a value of 3.0 to 3.9 ng/ml underwent an ancil-
lary test (digital rectal examination until 1998 and calculation of the ratio of the free 
PSA value to the total PSA value (biopsy indication if FT-ratio < 0.16) starting in 1999) 
and were referred for biopsy if either of the two tests was positive[15]. In Italy, a PSA 
value of 4.0 ng/ml or more was defined as positive, but men with a PSA value of 2.5 
to 3.9 ng/ml also underwent ancillary tests (digital rectal examination and transrectal 
ultrasonography)[16]. In the Netherlands, up to February 1997, a combination of digital 
rectal examination, transrectal ultrasonography, and PSA testing (with a cutoff value of 
4.0 ng per milliliter) was used for screening; in 1997, this combination was replaced by 
PSA testing only (biopsy indication if PSA >= 3 ng/ml)[17]. Centres used sextant biopsies 
guided by transrectal ultrasonography. In June 1996, lateralized sextant biopsies were 
recommended. In Italy, transperineal sextant biopsies were used. In Finland, a biopsy 
procedure with 10 to 12 biopsy cores was adopted in 2002 as a general policy for the 
two study groups. The screening interval in Finland, Italy and the Netherlands was 4 
years; Sweden used a 2-year interval. Treatment of PC was performed according to local 
policies and guidelines. The distribution of treatments that were applied to the screen-
ing group and the control group was comparable[18].
follow up data
Cancer incidence data were obtained by linking the trial database with the regional 
(Italy, Sweden) or national (the Netherlands, Finland) Cancer Registry. Mortality data of 
participants who died in the period up to December 31, 2006 were obtained by linking 
the trial database with the National Causes of Death Registry. Linkage was possible by 
using the personal administrative number of each participant as a linkage key. Causes 
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of death were evaluated in a blinded fashion and according to a standard algorithm or, 
after validation, on the basis of official causes of death[3]. Patients were determined to 
have died from PC if they were classified as either “definitely PC death”, as “probable PC 
death” or as “PC intervention related death”
STATISTICAL ANALySIS
Follow-up for diagnosis and mortality analyses began at randomization and ended at 
death, emigration, or date of censoring (December 31, 2006), whichever came first. 
Men who were randomized to the intervention arm were classified as attendees or non-
attendees using the following definition: after randomization all men in the intervention 
arm were considered as non-attendees until the date that they participated for the first 
time in the study by a PSA test, DRE or TRUS. At this date their status switched from non-
attendee to attendee. Men who were not screened during the study were considered as 
non-attendees during the complete follow-up.
The age-specific expected number of deaths for PC patients in the screening arm 
who attended a screening visit was calculated on the basis of the age-specific observed 
mortality rate in study participants randomized to the screening arm who attended a 
screening visit (and before any PC diagnosis.). The age-specific expected number of 
deaths for PC patients in the screening arm who did not attend a screening visit was 
calculated on the basis of the age-specific observed mortality rate in study participants 
randomized to the screening arm who did not attend a screening visit (and before 
any PC diagnosis). The age-specific expected number of deaths for PC patients in the 
control arm was calculated on the basis of the age-specific observed mortality rate in 
study participants who were randomized to the control arm of the study before any PC 
diagnosis. The excess mortality for the three groups of PC patients mentioned above 
was calculated by subtracting the appropriate expected number of deaths from the 
observed number of deaths for the group. Thus the expected number of deaths was 
calculated based on the assumption that the PC patients would have had the same 
age-specific mortality as the study population taking into account attendance status 
(attendees and non-attendees in the intervention arm and all men in the control arm 
before any diagnosis of PC).
For each study arm, the sum of the number of life years of all participants from the 
moment of randomisation until either censoring or death was calculated. This sum was 
divided by the number of men randomized to that arm which yields the average number 
of life-years until either censoring or death per study arm per participant. Subtracting 
the number of life years per participant in the control arm from the number of life-years 
per participant in the screening arm yields the life-time gained per participant.
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Poisson regressions (using the stata generalized linear model function glm) were 
used to calculate all rate ratios, confidence intervals of rate ratios and their associated 
p-values[19]. In this approach the observations (deaths or number of PC cases) are as-
sumed to be distributed according to a Poisson distribution. The natural logarithm of 
the expected value of this Poisson distribution is assumed to be a linear function of 
the study arm (coded as an indicator value, 1 for the screening arm, 0 for the control 
arm) with an added constant consisting of a fixed part (model constant) and the natural 
logarithm of the number of person-years. In this parameterization the exponentiated 
parameter associated with the study arm indicator yields the ratio of the hazard in the 
screening arm and the control arm (the hazard rate ratio) and the exponentiated model 
constant yields the hazard in the control arm. However, the excess mortality is modelled 
with a different link function. In the case of excess mortality the expected value of the 
Poisson distribution does not equal the natural logarithm of the number of deaths but 
the natural logarithm of the excess number of deaths (i.e. the difference of the observed 
and expected number of deaths). The 95% confidence interval of the excess mortality 
hazard rate ratio and its associated p-value were based on the delta method (account-
ing for attendance in the intervention arm and difference in randomization scheme in 
Finland) shown in the Appendix. A two-sided p value <0.05 was considered statistically 
significant. All analyses were performed with the commercially available STATA package: 
Data Analysis and Statistical Software, version 10.
RESULTS
baseline characteristics
A total of 141578 men, age 55-69 years at randomization, were included in the study. 
Of these men 62578 were assigned to the intervention group and 79000 to the control 
group. The PC incidence rate in the intervention arm was 1.69 fold higher than in the 
control arm, i.e., 5206 (8.3% of total) men were diagnosed with PC in the intervention 
arm and 3871 (4.9% of total) men were diagnosed with PC in the control arm (Table 1). 
Up to the end of 2006, 9673 (15.5% of total) men died in the intervention arm and 12309 
(15.6% of total) died in the control arm. This resulted in an all cause mortality that was 
not significantly different between the two arms: RR 0.99 (95%CI 0.96-1.01, p=0.274), 
Table 2.
disease-specific mortality rate
Up to the end of 2006, in the intervention arm 188 men and in the control arm 296 
men died from a PC-related cause of death according to the causes of death commit-
tee (CODC). The corresponding disease-specific mortality rate was 0.33 men per 1000 
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person-years in the intervention arm and 0.42 men per 1000 person-years in the control 
arm. This resulted in a statistically significant reduction in PC mortality rate of 21% in the 
intervention population relative to the control arm: RR 0.79 (95%CI, 0.66-0.95, p=0.014), 
Table 2.
Excess mortality
Up to the end of 2006, the excess mortality rate was 0.29 men per 1000 person-years in 
the intervention arm and 0.37 men per 1000 person-years in the control arm. This re-
sulted in a non-significant reduction in the excess mortality rate of 23% in the interven-
tion population relative to the control population: RR 0.77 (95%CI, 0.55-1.08, p=0.132), 
Table 2. This equaled with an absolute risk reduction in the excess mortality of 0.075 per 
1000 person-years. The life time gained per participant was approximately 23 days after 
a median follow-up of nine years.
Table 1. Number of subjects, deaths and results of screening according to study group, attendees and 
non-attendees.
Intervention Attendees Non-attendees Controls All
Number of men 62578 50242 12336 79000 141578
Age at randomization, median 59 60 59 59 59
mean 59.8 59.9 59.6 59.7 59.8 
Person-years 562521 437709 124813 705264 1267786
Number of PC 5206 4681 525 3871 9077
PC rates 9.25 10.70 4.21 5.49 7.16
Number of deaths 9673 6100 3573 12309 21982
Death rates 17.20 13.94 28.63 17.45 17.34
Number of PC deaths 188 126 62 296 484
PC death rate 0.33 0.29 0.50 0.42 0.38
Attendees: men randomized to intervention arm who attended screening, Non- attendees: men 
randomized to intervention arm who never attended screening, PC: prostate cancer, Deaths: Number of 
all cause deaths, Rates are expressed as number per 1000 person-years
Table 2. Effect of screening on prostate cancer incidence, overall mortality, prostate cancer specific 
mortality and excess mortality
Intervention* Controls* Relative risk 95% CI P value
PC rates 9.25 5.49 1.69 1.62 – 1.76 < 0.001
Death rates 17.2 17.5 0.99 0.96 – 1.01 0.274
PC death rate 0.33 0.42 0.79 0.66 – 0.96 0.014
Excess mort rate 0.29 0.37 0.77 0.55 – 1.08 0.132
*All rates are expressed as number per 1000 person-years
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dISCUSSION
Since the latest publications by the ERSPC trial[1, 2], there is growing consensus that 
PSA-based screening for PC reduces mortality from the disease. Some issues remain 
unresolved, most notably those regarding the cost-effectiveness of screening, as well 
the concerns about the quality of life related to screening. Nearly no concerns consist 
on the validity of PC-specific mortality as endpoint of a PC screening trial. Neverthe-
less, in the ERSPC trial, screening might have reduced the number of deaths from PC 
while side effects of the screening procedure (anxiety, depression) might have caused 
an increase in the death from other causes. Up to the present study these screening 
effects remained unknown. The present study showed a reduction in the rate in excess 
mortality as an effect of screening that is almost identical to the reduction in the rate in 
disease-specific mortality. This is an important observation since by definition disease-
specific mortality is included in excess mortality but is not identical to it. Disease-specific 
mortality refers to mortality due to only one particular cause of death such as disease 
progression and treatment related mortality and excess mortality measures both the 
direct and indirect mortality due to the cancer of interest, e.g. including cachexia, 
uraemia, suicide, depression and loss of interest in life. Although in this study the RR of 
excess mortality did not reach the formal limits of statistical significance, the present 
study strongly corroborates the finding that PSA-based screening reduces the direct 
and indirect mortality related to PC and strongly supports the fact that PSA-based 
screening reduces the rate of death from PC. The support provided by this analysis is 
obtained in an objective way since it does not require human expertise to determine a 
cause of death.
After a median of nine years follow up, the ERSPC as a whole showed an alpha spending 
adjusted RR for death from PC in the intervention group of 0.80 (95%CI, 0.65-0.98;p=0.04) 
based on data including 162243 men randomized in seven different countries[1]. Data 
in the present study showed a reduction in the PC specific mortality rate of 21%, RR 0.79 
(95%CI, 0.66-0.95;p=0.014). The PC related cause of death was based on the consensus 
of the CODC that evaluated all deceased cases in a blinded fashion according to a stan-
dard algorithm[3]. Such committees are assumed to be the most optimal method for 
cause of death ascertainment, especially in PC where death on the death certificates 
differs often from the clinical picture. Nevertheless, in practice it was impossible to blind 
the arm of the study entirely before the committee reviewed the records of deceased 
men. The records were for example not blinded for stage at diagnosis although this is 
a very suggestive variable for the arm of the study. Therefore it remained possible that 
the lack of adequate blinding of the records with respect to study arm had resulted in a 
bias in the cause of death ascertainment. Based on the findings in the present study this 
potential bias did not influence the study outcomes.
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The results are not completely in line with a previous study that compared the effect 
of screening on the disease-specific and excess mortality in the ERSPC section Rotter-
dam only[11]. The previous study showed in contrast to the disease-specific mortality 
rates an increased difference in the excess mortality rates between the two study arms. 
The main difference between the excess mortality and disease-specific mortality rate 
was observed for the older age group at randomization, i.e. 70-74 years, men that were 
not included in the present study. The results for men age 55-64 years at randomization 
in the present study were in line with the results presented before[11]. The effect for 
age is in good agreement with excess mortality studies on mammography screening for 
breast cancer that also observed a more pronounced discrepancy between the excess 
mortality and disease-specific mortality analysis for the older ages[19, 20]. As a result, 
the excess mortality analyses should be incorporated in the evaluation of the screening 
trial when longer follow up is included. In line with suggestions made in the previous 
publication, it could be that there is an increase in the uncertainty of individual cause of 
death ascertainment in older age groups when the overall mortality in these older ages 
is increased.
Excess mortality analyses are often limited by the validity of the expected mortality. 
Typically, in an excess mortality analysis, the expected mortality is estimated from na-
tionwide population life tables stratified by age, sex and period. However, in a screening 
setting, the general population does not seem to be suitable as a reference population 
since the people who participate are healthier and of higher socioeconomic classes, 
i.e., subject to healthy screenee bias[11, 21]. For this reason, in the present study, the 
expected mortality was based on all participants before a diagnosis of PC and adjusted 
for study arm and study participation. These adjustments were needed. This is shown in 
detail by Kranse et al[22]. This study showed that if the expected mortality were to be 
estimated without a correction for attendance status, an excess mortality analysis on PC 
screening would over-estimate the effect of screening since men that participate and 
attend in a screening trial have been shown to be healthier and have a decreased risk of 
death from other causes compared to men who do not attend. Additional adjustment 
by estimating the expected mortality with correction for noncompliance among men 
participating in the intervention arm with a biopsy indication might have optimized the 
excess mortality since men in the intervention arm who had a raised PSA but were not 
biopsied were likely to have higher all cause mortality than those with biopsy. Although 
this seems to have a very small effect on the final outcomes, it might be incorporated in 
future excess mortality analyses.
Population-based screening entails an intervention in a healthy population and, there-
fore, potentially should have a favorable harm-benefit trade-off, which at the moment 
is not yet proven. Therefore, although this study corroborates that PSA-based screening 
reduces the mortality, population-based PC screening cannot be recommended at the 
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moment. The PC incidence in the intervention arm was 1.69 fold higher than in the 
control arm. However, since PC is a leading chronic condition affecting men and the 
incidence of overdiagnosed PC is increasing rapidly, there is an urgent need to resolve 
these issues. Therefore additional studies are needed. The present study showed that 
the estimation of excess mortality can be used in future studies to evaluate the effects of 
screening on PC mortality. This is useful since disease-specific mortality requires reliably 
coded information on cause of death and assumes that cancer mortality is independent 
of competing risk mortality, an assumption which is especially for PC only approximately 
true.
In conclusion, the PSA-based screening seems to have benefit on the excess mortal-
ity. The estimated excess mortality reduction of 23% is in excellent agreement with our 
earlier results.
APPENdIx
Assessment of the 95% confidence interval of the excess mortality rate ratio for 
a single study centre by accounting for participation.
The calculation of the confidence interval of the excess mortality rate ratio without 
taking attendance in the screening arm of the study into account has been described in 
detail in Appendix of van Leeuwen et al [200]. 
The two excess mortality rates (xsmr) are presented as mi = ei/ni, where i = 1, 2 is the 
study arm (i= 1: intervention arm and i= 2: control arm), ei =arm-specific excess num-
ber of deaths and ni = arm-specific number of observed person-years. Ni = number of 
prostate cancer cases per study arm. qi and qi* are death proportions in prostate cancer 
patients, observed and expected respectively. 
Having introduced the basic method [200] and notation we can introduce a first 
refinement, accounting for attendance in the screening arm. Since the attendance issue 
only affects the screening arm the formula for index i =2 are unaffected. In the following 
formula the subscript 1p denotes attendees and 1n denotes non-attendees.
The excess mortality rate ratio (xsmrR), now accounting for participation (p) and non-
participation (n) in the screening arm becomes: 
xsmrR =
N1p (q1p – q1p*) + N1n (q1n – q1n*) n2 =
N2 (q2 – q2*) n1
num n2 , (1)
den n1
Using the delta method the variance of the logarithm of (1) can be calculated as in [11]
      n2    var(num)   var(den)
var(ln(xsmrR)) =  (---------)² (------------- + -------------).
      n1   (num)²   (den)²
The var(num) and var(den) are calculated as: 
var(num) = N1p ((q1p – q1p*)² + q1p(1– q1p)) + N1n ((q1n – q1n*)² + q1n(1– q1n)) 
var(den) = N2 ((q2 – q2*)² + q2(1– q2)).
Calculating the pooled excess mortality rate ratio over all study centers and its 
confidence interval.
The above section deals with the calculation of the confidence interval of the xsmrR, 
accounting for attendance in the intervention arm in one study center. In the present 
study we consider the four study centers combined. In three study centers the random-
ization is 1 to 1, in one center (the Finnish center) it is 2 to 3, for every two men random-
ized to the intervention arm, 3 are randomized to the control arm. Thus if we calculate 
the pooled xsmrR we have to account for the different randomization scheme used in 
Finland. Were this not done, the contribution of the Finnish center to the xsmr in the 
control arm would be different than the contribution of the Finnish center to the xsmr 
in the screening arm. In that case, an observed difference in the xsmrR can be attributed 
to either this imbalance or to a true difference between the intervention arm and the 
control arm excess-mortality rate (or any combination of the two). Thus correction for 
this imbalance is necessary to enable an unambiguous interpretation of the xsmrR. 
Let us denote the research centers by r = 1,2,3 and 4. Then we get: 
xsmrR =
N1pr (q1pr – q1pr*) + N1nr (q1nr – q1nr*)
N2r (q2r – q2r*) (n1r / n2r) 
=
numr .
denr (n1r / n2r) 
Overall,
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xsmrR =  
Σ
r-1
4
numr =
NUM
.
Σ
r-1
4
denr (n1r / n2r) DEN
Then,
var(ln(xsmrR)) = var(NUM) / (NUM)² + var(DEN) / (DEN)², 
in which,
var(NUM) = Σ
r-1
4
 var(numr) 
and,
var(DEN) = Σ
r-1
4
 (n1r / n2r)
2 var (denr).
The quantities var(numr) and var(denr) are given in the previous attachment as var(num) 
and var(den). Note that in practice to a very good approximation for this specific study 
n1r / n2r = 2/3 for the Finnish center and n1r / n2r = 1 for the other centers. 
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AbSTRACT
Objectives: To assess the cause specific mortality unrelated to prostate cancer (PC) itself 
in men with screen and clinically diagnosed PC.
Methods: Study among participants of the European Randomized Study of Screening 
for Prostate Cancer. Based on consensus of causes of death committee, all men who 
died from PC were excluded. In the intervention arm, cases were men with a screen 
detected PC, aged 55-74 years, between 1993-2001. These cases were matched to 2 
controls in whom no cancer was found after biopsy, and 2 controls in whom no cancer 
was suspected screening. In control arm, cases were men with clinically diagnosed PC, 
aged 55-74 years, between 1993-2001. These cases were matched to 4 controls without 
PC. Matching was done with respect to date of birth, -screening and/or -diagnosis. Men 
were followed up to December 31, 2007.
Results: No statistically significant difference in overall mortality between cases and 
controls in the intervention arm was observed: RR 1.26 (95%CI0.96-1.65; p=0.102) and 
RR 1.13 (95%CI0.86-1.47; p=0.381). In the control arm, the overall mortality was statisti-
cally significantly higher in cases relative to controls: RR 1.43 (95%CI1.03-2.00; p=0.033). 
This difference was due to an increased risk of dying from neoplasms and disease of the 
circulatory or respiratory system among cases: RR 1.61 (95%CI1.12-2.29; p=0.009). The 
study was limited by the relatively small size.
Conclusions: Increased mortality unrelated to PC itself was observed in men with 
clinically diagnosed PC, but not in screen detected PC. The excess mortality in men with 
clinically diagnosed PC seems due to significantly increased risk of dying from neoplasm 
and disease of the circulatory or respiratory system. Results have to be studied more 
thoroughly in further clinical trials.
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10.1 INTROdUCTION
Prostate cancer (PC) has become the most common non-cutaneous diagnosed cancer 
in men in Europe and the United States5. Currently, only a small percentage of men with 
predominantly localized PC die from a PC related cause of death. Cardiovascular disease 
(CVD) is the primary or secondary cause of death in most PC patients144.
Recent evidence has suggested that there might be a positive correlation between in-
creased cardiovascular risk and the PC incidence, progression and treatment for PC191-196. 
Furthermore, some methods to reduce the risk for CVD seem to be similar to methods to 
reduce the risk for high risk PC197-199. In addition, recent evidence has suggested that the 
excess mortality is lower among men who were diagnosed with screen detected PC in 
comparison to men with clinically diagnosed PC, possibly due to the use of medications 
for CVD and/or the change to a healthier lifestyle of men with a screen detected PC200. 
The current study was designed to quantify the excess mortality measured in the study 
by van Leeuwen et al.200.
Previously we have demonstrated that CVD mortality is not increased among men 
diagnosed with prostate cancer in the Rotterdam section of the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) compared to the general Dutch popula-
tion201. However, no distinction was made between screen detected and symptomati-
cally detected patients, and to socioeconomic class which is known to be higher in men 
participating in the ERSPC in comparison to the general population. Making use of the 
detailed information on each individual participant in the ERSPC Rotterdam, we com-
pared the incidence of overall mortality and non-prostate cancer causes of death among 
men without PC and men with screen-detected PC on the one, and unscreened men 
with symptomatically diagnosed PC on the other hand. With this analysis we have the 
aim to assess whether men with screen detected and symptomatically diagnosed PC are 
at an increased risk of death and of which particular causes. The comparison group for 
men with screen detected PC consisted of men who were screened for PC but in whom 
no PC was detected. Unscreened men in the control arm with symptomatically PC were 
compared with men participating in the control population of the ERSPC Rotterdam 
who were not diagnosed with PC.
10.2 MATERIALS ANd METHOdS
10.2.1 Study Population
All men were participants of the Rotterdam section of the ERSPC. All men signed an 
informed consent before randomization to systematic screening (intervention arm) and 
usual care (control arm).
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Men in the intervention arm were screened with an interval of four years by PSA 
measurement, rectal examination (DRE) and transrectal ultrasound examination (TRUS) 
between December 1993 and May 1997. A sextant biopsy was initially offered to men 
with PSA ≥4.0 ng/ml and/or a suspicious finding on DRE and/or TRUS. After May 1997 a 
biopsy was prompted by PSA ≥3.0 ng/ml only. All cancers were classified according to 
the 1992 TNM classification. Men who were diagnosed with PC were treated by the local 
urologist. Details of the screening methodology were reviewed by Roobol et al96.
10.2.2 design
The current study is designed as a prospective cohort study including cases and controls 
where case subjects were men diagnosed with PC (screen-detected or symptomatically) 
and control subjects were men who were not diagnosed with PC until death or the 
cut-off date December 31, 2007. Matching was performed to ensure equal risks of non-
prostate cancer death among the case and control subjects.
10.2.3 Selection of screen-detected cases and matched controls
All males, aged 55-74 year, in the intervention arm of ERSPC Rotterdam diagnosed with 
a screen detected PC between January 1, 1995 and December 31, 2004 were eligible 
as case subject (case intervention arm) and were actually selected if the tumour was 
diagnosed at screening and was localized (defined as stage T1C, N0, M0 and serum PSA 
< 20.0 ng/ml). Cases were excluded if they were determined as PC related cause of death 
before December 31, 2007. These inclusion criteria were made to select only screen 
detected PCs. Only T1c cancers were included since T1c PC is the disease diagnosed in a 
patient at screening without any clinical sign they have the disease. The date of diagno-
sis of the case was the index date. The control subjects were randomly selected from the 
intervention arm, alive at the date of diagnosis of the case and were matched to the case 
subjects by month and year of birth, self reported health status (i.e., good, moderate or 
poor) and month and year of screening. Each time a case subject was included in the 
study, we randomly selected four controls; two control subjects in whom no cancer was 
found after a prostate biopsy and two control subjects who had a normal PSA value (PSA 
< 3.0 ng/ml) and did not undergo prostate biopsies or were not suspicious for having 
cancer. If there was no match in respect to the previous mentioned variables, then a 
control subject was selected who was born 1 month before or after the case subject. 
If that still did not lead to a match, then a control subject was selected born 2 months 
after the case subject and then, if necessary, 2 months before the case subject was born, 
and so forth, until a match was found with a maximum difference of 6 months. Two most 
optimal groups were chosen since both might be criticisable for a reason. The aim of 
the current study design was to indentify controls who were in the absence of PC. We 
selected men with a PSA < 3.0 ng/ml at a screening visit although it is known that there 
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is no PSA value where below PC is not detectable72, and men with no cancer found at a 
sextant biopsy although it is known that a sextant prostate biopsy misses a substantial 
percentage of PC170.
10.2.4  Selection of unscreened symptomatically diagnosed cases and matched 
controls
These case subjects, aged 55-74 year, were all men randomized to the control arm of 
the ERSPC, section Rotterdam, who were clinically diagnosed with PC, defined as stage 
>T1c, N0/N1, M0/M1 and serum PSA > 0 ng/ml, between January 1, 1995 and December 
31, 2004 (case control arm). Cases were excluded if they were determined as having died 
from a PC related cause before December 31, 2007. T1c cancers were excluded since 
T1c PC is the disease diagnosed in a patient at screening without any clinical sign they 
have the disease. The controls were randomly selected from the control arm, alive at the 
date of diagnosis of the case, and matched to the case subjects on month and year of 
diagnosis with respect to month and year of birth, self reported health status (i.e., good, 
moderate or poor) and month and year of randomization. Each time a case subject was 
included in the study, we randomly selected 4 controls. Control subjects were men who 
were randomized to the control arm of the ERSPC, section Rotterdam, alive at the time 
of diagnosis of the case, and not diagnosed with PC. If there was no match in respect 
to the previous mentioned variables, the same complementary matching process was 
performed as described before.
10.2.5 Mortality data
Mortality data of case and control subjects in both the intervention and the control arm 
that died in the period up to December 31, 2007 were obtained by linking the trial data-
base with the Causes of Death Registry of Statistics Netherlands. Causes of death were 
based on the national certificates coded according to the International Classification 
of Diseases (9th revision [ICD9]; 1995) and ICD10 (from 1996 onward), and the causes of 
death grouping was based on the tabulation list for main primary causes of death of 
Statistics Netherlands154. For all case subjects in the study who were known to have died, 
all available information was gathered and anonymised. Subsequently, cases classified 
as having died from PC related death by the independent causes of death committee 
(CODC) of the ERSPC Rotterdam were excluded from the study. The CODC reviews all 
deceased PC cases using predefined flow charts. Patients were determined to have died 
from PC if they were classified as either “definitely PC death”, “possible PC death” or as “PC 
intervention related death”153.
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10.3 STATISTICAL ANALySES
The mortality rates were compared between cases and controls using a Poisson regres-
sion analysis with an indicator of study arm as a predictor and the logarithm of the 
number of person years as an offset term (predictor with a coefficient of one)178. For the 
cases and controls, the time of follow-up was measured from the date of randomization 
up to date of death or December 31, 2007. P-values <0.05 were considered statistically 
significant. All analyses were performed with the commercially available STATA package: 
Data Analysis and Statistical Software, version 11.
10.4 RESULTS
10.4.1 baseline characteristics
A total of 372 cases and 1488 controls participating in the intervention arm of the ERSPC 
section Rotterdam were included in this study, and a total of 221 cases and 884 controls 
participating in the control arm of the ERSPC section Rotterdam. The age at diagnosis 
and tumor characteristics of the cases are presented in Table 1. The median age at diag-
nosis differed significantly between the two groups (p<0.001); cases in the intervention 
arm were diagnosed at an earlier age.
10.4.2 Case and Control Subjects Intervention Arm
The median follow up from time of diagnosis up to either death or end of follow up was 
8.9 years for the cases. Up to the end of 2007, a total of 82 (22.0%) cases died (26.2 men 
per 1000 person years). A total of 139 (18.7%) controls died in whom no cancer was 
found after biopsy, and a total of 155 (20.8%) controls in whom no cancer was suspected 
(Table 2). This resulted in an all cause mortality that was not significantly different be-
tween cases and controls: RR 1.26 (95%CI 0.96-1.65; p=0.102) for the cases relative to 
the controls in whom no cancer was found after biopsy; and RR 1.13 (95%CI 0.86-1.47; 
p=0.381) for the cases relative to the controls in whom no cancer was suspected. In 
addition no significant difference was found between the cases and all controls in the 
intervention arm; RR 1.19 (95%CI 0.93-1.52; p=0.168).
With respect to CVD, a total of 26 (7.0%) cases died from CVD (8.3 men per 1000 person 
years) and a total of 47 (6.3%) controls in whom no cancer was found after biopsy, and a 
total of 53 (7.1%) controls in whom no cancer was suspected. Consequently, no statisti-
cally significant difference in CVD was observed between the cases and controls; RR 1.18 
(95%CI 0.73-1.90; p=0.503) for the cases relative to the controls in whom no cancer was 
found after biopsy; and RR 1.04 (95%CI 0.65-1.67; p=0.854) for the cases relative to the 
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controls in whom no cancer was suspected. The RR on CVD was 1.11 (95%CI 0.72-1.70; 
p=0.643) for all cases relative to all the controls.
10.4.3 Causes of death intervention arm
The six most frequent causes of death among the cases and controls in the interven-
tion arm are presented in Table 2. Neoplasms were the most frequent cause of death, 
followed by CVD. Despite all PC related deaths based on the consensus of the CODC 
were excluded, in 3 cases the primary cause of death was PC (3.6% of all deaths). The 
mortality from neoplasms, CVD and diseases of the respiratory system together was 
not statistically significant different in the cases relative to the controls; RR 1.20 (95%CI 
0.92-1.58; p=0.180).
Table 1. Baseline characteristics at diagnosis
Cases Intervention arm, N
(% of total)
Cases Control arm, N
(% of total)
P value
Total participants included 372 221
Age (yr), median 66.6 68.5 <0.001
 55 – 60 68 (18.3) 19 (8.6) <0.001
 61 - 65 107 (28.8) 56 (25.3)
 66 - 70 115 (30.9) 79 (35.8)
 71 – 74 82 (22.0) 67 (30.3)
PSA at diagnosis (ng/ml), median 4.7 11.6 <0.001
Tumour Stage
 T1c 372 (100.0) -
 T2 - 141 (63.8)
 T3 - 76 (34.4)
 T4 - 4 (1.8)
Histological differentiation
 Gleason 2 – 6 293 (78.8) 90 (40.7) <0.001
 Gleason 7 70 (18.8) 77 (34.8)
 Gleason 8 – 10 9 (2.4) 30 (13.6)
 Not known or not performed - 24 (10.9)
Primary Treatment
 Surgery 156 (41.9) 59 (26.7) <0.001
 Radiotherapy 131 (35.3) 116 (52.5)
 Watchful waiting 83 (22.3) 13 ((5.9)
 Hormone - 30 (13.6)
 Other 2 (0.5) 3 (1.3)
Adjuvant Treatment
 Hormone 4 (1.1) 28 (12.7) <0.001
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10.4.4 Case and Control Subjects Control Arm
For the cases the median follow up from time of diagnosis up to either death or end of 
follow up was 6.1 years. A total of 47 (21.3%) cases died (34.2 men per 1000 person years) 
and a total of 134 (15.2%) controls (Table 3). This resulted in an all cause mortality that 
was statistically significantly different between cases and controls: RR 1.43 (95%CI 1.03-
2.00; p=0.033). The CVD was not statistically significantly different between the cases 
and controls (Table 3). A total of 11 (5.0%) cases died from CVD (8.0 men per 1000 person 
years) and a total of 30 (3.4%) controls died from CVD; RR 1.50 (95%CI 0.75-2.99; p=0.250) 
for cases relative to the controls.
10.4.5 Causes of death Control Arm
The six most frequent causes of death among the cases and controls in the control arm 
are presented in Table 3. Neoplasms were the most frequent cause of death followed by 
CVD and diseases of the respiratory system. Based on data of the Causes of Death Reg-
istry of Statistics Netherlands, a total of 6 death cases were recorded as primary cause 
PC, although all PC related deaths based on the consensus of the CODC were excluded 
(12.8% of all deaths). The mortality from neoplasms, CVD and diseases of the respiratory 
system together was statistically significantly higher among the cases relative to the 
controls; RR 1.61 (95%CI 1.12-2.29; p=0.009).
Table 2. Causes of death in the intervention arm stratified by study group
Study Group
Cases
N (%)
Controls:
All
N (%) RR (95%CI)
Controls:
No PC after 
biopsy
N (%) RR (95%CI)
Controls:
No PC 
suspected
N (%) RR (95%CI)
Total included 372 (100) 1488 (100) 744 (100) 744 (100)
Total no. of deaths 82 (22.0) 294 (19.8) 1.19 (0.93-
1.52)
139 (18.7) 1.26 (0.96-
1.65)
155 (20.8) 1.13 (0.86-
1.47)
Total CVD deaths 26 (7.0) 100 (6.7) 1.11 (0.72-
1.70)
47 (6.3) 1.18 (0.73-
1.90)
53 (7.1) 1.04 (0.65-
1.67)
Neoplasms 40 (10.7) 118 (7.9) 54(7.2) 64 (8.6)
Respiratory system 1 (0.2) 20 (1.3) 7 (0.9) 13 (0.5)
Digestive system 2 (0.5) 7 (0.5) 4 (0.5) 3 (0.4)
Endocrine and 
metabolic
1 (0.3) 10 (0.7) 5 (0.7) 5 (0.7)
Abnormal clin or 
lab findings
3 (0.8) 11 (0.7) 7 (0.9) 4 (0.5)
Only the six most frequently recorded primary causes of death of Statistics Netherlands are presented; 
clin: clinical; lab: laboratory; RR: Relative Risks using a Poisson regression analysis with an indicator of 
study arm as a predictor and the logarithm of the number of person years as an offset term (predictor 
with a coefficient of one)
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10.6 dISCUSSION
In this study, men with clinically diagnosed PC were at an increased risk of dying from 
a cause unrelated to PC itself compared to men without PC, RR: 1.43 (95%CI 1.03-2.00; 
p=0.033) if all PC deaths based on the consensus of the CODC were excluded. This dif-
ference was based on an increased risk of dying from neoplasms and diseases of the 
circulatory and respiratory system, together: RR 1.61 (95%CI 1.12-2.29; p=0.009). Results 
are limited by a relatively small sample size. The observations are in line with previous 
findings of the ERSPC section Rotterdam in which a secondary mortality analysis showed 
that the excess mortality was higher than the disease specific mortality in the control 
arm of the ERSPC Rotterdam. This previous study suggested a possible underestima-
tion of deaths from PC by the CODC in the control arm of the study, or an additional 
disease related mortality that was measured by an excess mortality analysis but not 
with a disease specific mortality analysis200. The current study confirms that both these 
suggestions have a contribution to the observed excess mortality in the control arm of 
the study.
All cases in this study that were determined by the CODC to have died from a PC 
related cause of death were excluded from the study. For this reason, in theory, the 
overall mortality in cases and controls was expected to be similar. However, this was not 
the case in the control arm of the study. Based on data of the death certificates, 3 cases 
with a screen detected PC (0.81% of all cases) and 6 cases with a clinically diagnosed 
PC (2.71% of all cases) were recorded with PC being the primary cause of death. This 
observation, in spite of being based on small numbers, suggests that the accuracy of the 
Table 3. Causes of death in the control arm stratified by study group
Study Group Cases
N (%)
Controls:
N (%) RR (95%CI)
Total included 221 (100) 884 (100)
Total no. of deaths 47 (21.3) 134 (15.2) 1.43 (1.03-2.00)
Total CVD deaths 11 (5.0) 30 (3.4) 1.50 (0.75-2.99)
Neoplasms 26 (11.8) 62 (7.0)
Respiratory system 5 (2.3) 15 (1.7)
Digestive system 2 (0.9) 4 (0.4)
Endocrine and metabolic 1 (0.4) 2 (0.2)
Abnormal clin or lab findings 0 (0.0) 6 (0.7)
Only the six most frequently recorded primary causes of death of Statistics Netherlands are presented; 
clin: clinical; lab: laboratory; RR: Relative Risks using a Poisson regression analysis with an indicator of 
study arm as a predictor and the logarithm of the number of person years as an offset term (predictor 
with a coefficient of one)
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cause of death determination is higher in screen detected than in clinically diagnosed 
PC. As suggested previously, it might be possible that the reviewers have underesti-
mated the PC mortality by being too cautious in stating that a patient has died from 
PC in the study and that the information to make a judgement is more limited in the 
control arm of the study. Furthermore, it might be that due to the study protocol more 
information could be gathered from patients diagnosed with PC in the intervention arm 
resulting in a higher accuracy of the death certificates.
What are the reasons why men with PC have an increased risk of dying from causes 
unrelated to PC itself. First, recently, Hemelrijck et al. observed an increased risk of 
nonfatal and fatal CVD in patients with PC receiving curative treatment, surveillance or 
especially androgen-deprivation therapy (ADT). Findings that are in line with previous 
studies; a systematic review of 4 studies showed that men who underwent ADT had a 
significantly increased risk of CVD (summary hazard ratio, 1.17; 95%CI, 1.07-1.29)202. ADT 
is also associated with osteoporosis and fractures, diabetes and with an increased risk 
of colorectal cancer203-205. Given the widespread use of ADT to treat especially locally 
advanced PC, treatment with ADT might result in an increased risk of death in patients 
with clinically diagnosed PC in particular. In the current study, 26.6% of the cases in the 
control arm received primary and/or adjuvant treatment with ADT in contrast to 1.1% 
of the cases in the intervention arm (Table 1). Secondly, the median age at diagnosis 
in men participating in the control arm was higher than men in the screening arm. 
Consequently, the increased risk of dying from causes unrelated to PC itself might be 
associated to the increasing age at diagnosis. However, no effect of age at diagnosis 
could be measured among men diagnosed with PC in the screening arm.
The risk of excess mortality in screen detected PC was suggested to be lower due 
to changes in medical regimen, medication and lifestyle unrelated to PC itself200. It is 
known that the incidence of clinically insignificant PC is large among men participating 
in a screening program129. Nevertheless a large percentage of these men obtain invasive 
treatment with curative intent. Consequently, after a PC diagnosis, the first contact with 
the urologist and/or radiation oncologist often involves screening of patients general 
health including the measures of the vital signs that lead to other interventions that 
might be associated with the decrease in non PC specific mortality. It has been proven 
that the use of these medications is increased in men and women diagnosed with PC or 
breast cancer subsequent to screening206-209. Further, the change in medical treatments 
is studied in detail by a study among 180 men with screen detected PC. This study 
showed among patients diagnosed with a screen detected PC a significant change in 
medical treatments and prescriptions unrelated to PC itself subsequent to their diagno-
sis209. In total 72% of men had a change in medical regimen after diagnosis, 61% had a 
change in medication and 29% received a new medical diagnosis. In total 24 (14%) had 
a multiple gated acquisition scan, treadmill or persantine thallium test, and 23 (13%) 
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had another treatment performed, most frequently a cardiac catheterization. Among 
the men with changes to their medical regimen 36 (59%) began a new or different 
medication, which in 67% was a beta-blocker209. Meta analyses including twenty-three 
randomized controlled trials showed a statistically significantly lower CVD and all cause 
mortality (relative risk 0.76, 95% CI: 0.68, 0.84) in the groups treated with beta-blockers 
than in the control groups after a mean of 1 year210. Other frequently new started 
medication were statins. A meta-analyses including nine studies showed that the use 
of statins for secondary prevention in elderly patients with documented coronary heart 
disease reduced all-cause mortality 22% and reduced coronary heart disease mortal-
ity 30% median use of 3 years211-213. Also relatively frequently new started medications 
were inhaled corticosteroid and long-acting beta-2 agonists for treatment for chronic 
obstructive pulmonary disease. Using the combination of inhaled corticosteroid and 
long-acting beta-2 agonist therapy more than 6 months have shown to be associated 
with a 20% reduced total mortality214. Although these medication effects are shown in 
large randomized controlled trials, we might suggest that they have at least contributed 
to the observed effect among men with screen-detected cancers in the present study.
Since there is emerging evidence that lifestyle factors can alter the rate of progression of 
indolent PC, many men frequently take on the responsibility of improving their general 
health by making lifestyle and dietary changes215-216. A small randomized clinical trial 
showed that intervention participants had significantly improved their lifestyle com-
pared with controls at 12 months217. Recommendations given to prevent progression of 
indolent PC include for example, choose nutritious foods, focus on fruits and vegetables, 
drink green tea, eat omega-3 rich foods, choose healthy fats, manage stress and take 
supplements. Consequently these recommendations might also have an effect on the 
non-PC related mortality, incidence and mortality rates of other neoplasms. Urologists 
might, therefore, be aware of positive effects of life-style modification and might give 
more attention to co-morbidities. Further urologists might develop programs in con-
junction with for example cardiologists to counsel asymptomatic men before initiating 
early PC treatment, in order to identify those who are at an increased risk of non-PC 
related mortality. However, the results presented in the present study have a low level of 
evidence, which should not automatically support the changes in medical treatment in 
men with screen detected PC. Therefore, this issue should be studied more thoroughly in 
further analyses or other clinical trials. For example, the effect of the change in medical 
treatments might be studied in detail to assess the specific effect of the various medica-
tions on the outcomes in men with screen-detected PC.
There are limitations in this study: The number of deaths was relatively small. Conse-
quently the CIs for the estimates of the cause specific death groups were rather wide. 
No data was available on smoking, BMI and serum lipid levels, although these are strong 
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risk factors for CVD. Although this study reached the optimal match between cases and 
controls that ensured an equal risk of non-prostate cancer death, it remains possible 
that especially the cases in the control arm were less healthy as part of their late diag-
nosed clinically significant PC (possibly these men refused the health system in general). 
In addition, the potential role of the use of medication that decreases the risk of CVD 
was not assessed in this study. Finally, data from this study after longer follow up is 
needed to confirm current observations. The strength of this study includes the validity 
of the control cases. In general, control cases are obtained from the general population 
although PC patients often have shown to be a selection of men considering general 
health and social economic class. Our study also has strong aspects. Participants were 
part of a randomized controlled trial and followed by regular matching with national 
cancer registries. Cases and controls were part of a homogeneous study population.
10.7 CONCLUSIONS
We concluded that men with clinically diagnosed PC have an increased risk of death un-
related to PC itself. This excess mortality was likely due to a significantly increased risk of 
dying from neoplasm and disease of the circulatory or respiratory system. No increased 
risk in all cause mortality unrelated to PC itself was observed among men diagnosed 
with PC subsequent to screening. Many effects might have influenced these observa-
tions, however, the relatively increased use of ADT in clinically diagnosed PC and the 
change of medical regimes and medication among men with screen detected PC may 
have had the most influence. These results should be studied more thoroughly in further 
clinical trials. The present study is limited by the relatively small sample size and small 
number of events. Finally, if changes in the medical regimens really do affect all cause 
mortality in men with PC, uro-oncologists should look carefully at the management of 
abnormal parameters of the circulatory and respiratory system, and should encourage 
PC patients to make lifestyle modifications.
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AbSTRACT
background: The rate of decrease in advanced cancers is an estimate for determining 
the prostate cancer (PCa) screening program effectiveness.
Objectives: To assess the effectiveness using a 2-or 4-years screening interval.
design, Setting, and Participants: Men, aged 55-64 years, were participants of two 
centres of European Randomized Study of Screening for Prostate Cancer (ERSPC): Go-
thenburg (2-year screening interval, n=4202) and Rotterdam (4-year screening interval, 
n=13301). We followed participants until date of PCa, date of death, last-follow up 
December 31, 2008, or up to a maximum of 12-years after initial screening. Potentially 
life-threatening (advanced) cancer was defined as cancer with at least one of following 
characteristics: clinical stage ≥T3a, M1 or N1, PSA >20.0ng/ml or Gleason score ≥8.
Interventions: We compared proportional total (advanced) cancer incidence (screen 
detected and interval cases), defined as the ratio of the observed number of (advanced) 
cancers to the expected numbers of (advanced) cancers based on the control arm of the 
study.
Measurements: The proportional cancer incidence from second screening round until 
end of observation was compared using a 2-years or 4-years screening interval.
Results and limitations: From screening round two until end of observation, propor-
tional cancer incidence was 3.64 in Gothenburg and 3.08 in Rotterdam; RR1.18 (95%CI 
1.04-1.33;p=0.009). Proportional advanced cancer incidence was 0.40 in Gothenburg 
and 0.69 in Rotterdam; RR0.57 (95%CI 0.33-0.99;p=0.048); the RR for detection of low 
risk PCa was 1.46 (95%CI 1.25-1.71;p<0.001). This study was limited by the assumption 
that PSA testing in the control arm was similar in both two centres.
Conclusion: A 2-year screening interval significantly reduced the incidence of advanced 
PCa, however increased the overall risk of being diagnosed with (low risk) PCa compared 
to a 4-year interval in men aged 55 to 64 years. Individualized screening algorithms have 
to be improved to provide the strategy for this issue.
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11.1 INTROdUCTION
The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown 
that screening reduces mortality from prostate cancer (PCa)98, 165, 218. Experience from cer-
vical and breast cancer screening programmes has demonstrated that the programme 
effectiveness can differ between centres and countries219-220. One of the main criteria 
used in evaluating and comparing the effectiveness of a screening is the change in the 
rate of disease diagnosed at an advanced stage221. This is reflected in the incidence and 
tumour stage distribution of interval cancers among those screened in the years follow-
ing a negative screening test and in the tumour stage distribution of cases diagnosed at 
second and subsequent screening rounds222.
Within the ERSPC, the screening intervals differed between the participating centres. 
Most centres used a 4-year screening interval while in Gothenburg, Sweden, a 2-year 
interval was used98. A previous study showed no difference in the rate of aggressive 
interval cancers between the Gothenburg (Sweden) and Rotterdam (the Netherlands) 
study223. However, the results might be inconclusive, since breast cancer screening stud-
ies have indicated that caution is required when comparing the absolute interval cancer 
rates in different countries220. Therefore, the proportionate interval cancer incidence is 
defined as the measure of choice for between-programme comparisons since it allows 
adjustment for geographical differences in cancer incidence221, 224.
11.2 MATERIAL ANd METHOdS
11.2.1 Characterization of the Study Population
Between December 1993 and December 1999 a total of 62,322 men, aged 50-74 year, 
were randomized, 42,376 men, age 55-74, in Rotterdam and 9,973 men, age 50-64, in 
Gothenburg. To obtain a similar age distribution between the two centers, only men 
who were aged 55-64 years at start screening in both study arms, were included in this 
study. The procedure of recruitment and randomization differed among the centres. In 
Gothenburg, men underwent randomization before written informed consent was pro-
vided (population-based effectiveness trial), in Rotterdam men gave informed consent 
before randomization (efficacy trial).
11.2.2 Screening
The screening protocol is described in detail in Schröder et al172. During the whole study 
period, in Gothenburg men were screened with an interval of two years until an upper 
age limit of 67-71 (mean 69) years, in contrast to men in Rotterdam who were screened 
with an interval of four years until an upper age limit of 71-74 (mean 73). Interval cancers 
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were defined as any case of PCa diagnosed up to 24 months (Gothenburg) or 48 months 
(Rotterdam) after participation in the first or a subsequent screening round. Cancers 
diagnosed in men after they refused a scheduled screening round or a biopsywere not 
considered as interval cancers. All cancers were classified according to the 1992 TNM 
classification. A potentially life-threatening advanced cancer was defined as a PCa 
with one of the following characteristics: clinical stage ≥T3a, N1 or M1, or a serum PSA 
>20.0ng/ml or Gleason score ≥8 at biopsy. A low risk PCa was defined as cancer with 
clinical stage T1c, Gleason score ≤6 and PSA ≤ 10.0 ng/ml at diagnosis.
11.2.3 The underlying rate of prostate cancer incidence
The underlying rate of PCa incidence was obtained from the population participating in 
the control arm of the study centre. This allowed an age, time period, and tumour stage 
specific estimate for the underlying incidence.
11.3 STATISTICAL ANALySIS
The time of follow up was measured from the date of first screening up to either the 
date of diagnosis, date of death or December 31, 2008. To achieve a comparable length 
of observation in the two study centers, the maximum length of follow-up was 12 years 
for every individual. Men with a longer follow-up were censored at 12 years after the 
date of first screening. The definitions of terms used in this study are summarized in 
Table 1. The following outcomes were calculated from the prevalence screen and sub-
sequent screening rounds: the number of (advanced) detected cancers (including both 
screen-detected and interval cancers) and the proportional incidence of (advanced) 
cancers. The proportional (advanced) cancer incidence was defined as the ratio of the 
observed number of cancers (including both screen-detected and interval cancers) to 
the expected number of cancers among survivors in the screening group during the 
period of observation. The number of expected (advanced) cancer was estimated by 
multiplying age and calendar period specific (advanced) PCa rates of the control popula-
tion to the age and calendar period specific person-years generated in the screening 
group. This allowed an estimate of the baseline PCa risk in Sweden and the Netherlands 
and thus adjustment for the difference in the baseline risk between the two countries225. 
Contamination (i.e. PSA-testing in the control population) was assumed to be similar in 
the two study centres.
Confidence intervals of proportional incidence ratio’s were calculated assuming that 
the observed number of events followed a Poisson distribution with the logarithm of 
the observed number of life years as offset term226. A Poisson regression model with the 
logarithm of the expected number of cancers as offset term was used to estimate rela-
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tive risks (RRs) of the centre of Rotterdam versus the centre of Gothenburg by modality 
of cancer occurrence and aggressiveness. All statistical tests were two sided. P values 
less than 0.05 were considered statistically significant. Analyses were performed with 
STATA package: Data Analysis and Statistical Software, version 11.0.
11.4 RESULTS
After age selection, i.e., of men who were aged 55–64 years at the time of first screening, 
4202 men from the intervention arm in Gothenburg and 13301 men from the interven-
tion arm in Rotterdam were included. During the study period (up to December 31, 
2008), men in Gothenburg had a maximum of six screenings with a median follow-up 
of 12.0 years. Men in Rotterdam had a maximum of three screening visits with a median 
follow-up time of 11.2 years. A total of 5950 men, age 55-64 years at randomization, 
were included in the control arm in Gothenburg and 13966 men, age 55-64 years at 
randomization, were included in the control arm in Rotterdam. Based on these data, the 
expected incidence rate for (advanced) PC was calculated for each year after randomiza-
tion.
Outcomes of the proportional advanced cancer and low risk cancer incidence are 
shown in Table 2,3 and 4. The data relate to the intervention (observed data) and control 
(expected data) population of the ERSPC Gothenburg and Rotterdam. During round 
2-6 the proportional screen detected cancer incidence was RR 3.64 (95%CI 2.92-4.53) 
in Gothenburg and RR 3.08 (95%CI 2.67-3.55) in Rotterdam. During round 2-6 the pro-
portional advanced cancer incidence was RR 0.40 (95%CI 0.22-0.71) in Gothenburg and 
RR 0.69 (95%CI 0.50-0.96) in Rotterdam. In Table 5 the differences in program effective-
ness are presented comparing the Gothenburg and Rotterdam centre. A statistically 
Table 1. Definitions of terms used in this study
Term Definition
Advanced cancer PC with one of the following characteristics: ≥T3a, N1, M1, PSA >20 ng/
ml, or Gleason score ≥8
Interval cancer PC diagnosed in a man who had a screening test with or without further 
assessment, which was negative for PC, either before the next invitation 
to screening, or within a time period equal to the screening interval in 
case the man had reached the upper age limit for screening.
Prevalence screen-detected cancer PC diagnosed in a man who had at first invitation a screening test with 
further assessment which was positive for PC.
Proportional (advanced) cancer 
incidence
The ratio of the observed number of (advanced) cancers and the for 
age and country specific expected number of (advanced) cancers in the 
absence of screening.
Screen detected cancer PC diagnosed in a man who had at second or subsequent round a 
screening test with further assessment which was positive for PC.
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Table 2. Number of men screened (NS), number cancers detected (DNC), observed person years (PY), 
Expected number cancers (ENC), proportional number detected cancers (RR).
NS DNC PY ENC RR 95% CI
Gothenburg, screen round
Screen 1 4202 130 8102 20 6.50 4.06-10.41
Screen 2 – 6 9487 371 18115 102 3.64 2.92-4.53
Rotterdam, screen round
Screen 1 13301 544 50418 142 3.83 3.18-4.61
Screen 2 – 3 17540 780 66138 253 3.08 2.67-3.55
Table 3. Number of men screened (NS), number advanced detected cancers (DNC), observed person 
years (PY), Expected number advanced cancers (ENC), proportional number advanced detected cancers 
(RR).
NS DNC PY ENC RR 95% CI
Gothenburg, screen round
Screen 1 4202 24 8102 11 2.14 1.07-4.45
Screen 2 - 6 9487 16 18115 40 0.40 0.22-0.71
Rotterdam, screen round
Screen 1 13301 165 50418 54 3.05 2.25-4.15
Screen 2 - 3 17540 64 66138 92 0.69 0.50-0.96
Table 4. Number of men screened (NS), number low risk detected cancers (DNC), observed person years 
(PY), Expected number low risk cancers (ENC), proportional low risk detected cancers (RR).
NS DNC PY ENC RR 95% CI
Gothenburg, screen round
Screen 1 4202 66 8102 5 13.20 5.32-32.76
Screen 2 - 6 9487 236 18115 25 9.44 6.25-14.26
Rotterdam, screen round
Screen 1 13301 270 50418 41 6.58 4.74-9.15
Screen 2 - 3 17540 472 66138 73 6.47 5.05-8.27
Table 5. Relative risk and 95% confidence intervals (CI) for the proportional (advanced) cancers in the 
Gothenburg (Goth) study relative to the Rotterdam (Rott) study
Cancers, round Relative Risk (RR) 95% CI P- value
Goth. vs. Rott.
Total cancer incidence, round 2 – 6 1.18 1.04-1.33 0.009
Advanced cancer incidence, round 2 – 6 0.57 0.33-0.99 0.048
Low risk cancer incidence, round 2 – 6 1.46 1.25-1.71 < 0.001
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significant reduction was observed in the proportional advanced cancer incidence after 
the first screening episode (round and interval 1) in favour of using a 2-year screening 
interval, RR 0.57 (95%CI 0.33-0.99; p=0.048). The likelihood for a PC to be diagnosed at 
repeated screening was increased using a 2-year relative to a 4-year interval, RR 1.18 
(95%CI 1.04-1.33;p=0.009); for the detection of a low risk PCa the RR was 1.46 (95%CI 
1.25-1.71; p<0.001).
11.5 dISCUSSION
In an intension to screen analysis, data on seven centres of the ERSPC showed that 
screening for PC produced a 20% relative reduction in PCa mortality, using a 4-year 
screening interval in 86% of the participants, nine years after the onset of screening98. 
The Gothenburg screening study, which is part of the ERSPC, showed that the relative 
reduction in PC mortality increased up to 44% fourteen years after onset of screening 
men every second year218. Based on the present study, the use of a shorter screening 
interval might have contributed to the relatively high reduction in PCa mortality. This 
study showed that screening with a 2-year relative to a 4-year interval significantly 
reduced the incidence of advanced cancer with 43% in men aged 55 to 64 years. Any 
difference in mortality between the two centers should be studied more thoroughly in 
further analyses when mortality data is available by an appropriate length in follow-up. 
At present, we can conclude that screening biannually decreases the risk of being diag-
nosed with advanced PCa, however, that the effect on PCa mortality remains uncertain.
Despite these observations, the optimal interval for PCa screening remained undefined. 
First, the effects of screening need also to be evaluated by means of an appropriate 
economic analysis. Biannually screening is likely to increase costs associated to the 
screening programme. In addition, simply shortening the screening interval would 
probably lead to more overdiagnosis. The likelihood for PCa diagnosed at repeated 
screening was increased using a 2-year compared to a 4-year interval, RR 1.18 (95%CI 
1.04-1.33;p=0.009). Moreover, the proportional low risk PCa incidence was significant 
higher in the program using biannually screening, RR 1.46 (95%CI 1.25-1.71;p<0.001). 
Since overdiagnosis remains the key limitation in the implementation of population 
based PC screening, other strategies are needed to define the optimal screening inter-
val. This is the first study that showed that some men might benefit from more frequent 
screening in terms of a reduced rate of advanced disease with potentially improved PC 
mortality outcomes. As a result, we should try to indentify the men who need a more fre-
quent screening program, which make individual screening intervals based on patient’s 
individual risks an urgent need. Studies have shown that a more individualized program, 
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that includes a combination of other diagnostics, is sensitive for the estimation of the 
future risk of PC227-228. Based on these studies, and studies that have related the interval 
to the initial PSA level, a candidate’s individual screening interval might be defined229-230. 
For example, Roobol et al. concluded that the screening interval of men aged 55-65 
years with a PSA of 1.0 ng/ml could be as long as 8 years with a minimal risk of missing 
aggressive PC at a curable stage231. Two more recent studies, that determined the poten-
tial benefit of screening stratified by the participant’s initial PSA, concluded that men 
with an initial PSA ≤1.0 and <2.0 ng/ml are unlikely to benefit from repeated screening 
since the cancer in these men is not likely to become life threatening if they remain 
unscreened232-233. This issue should be studied more thoroughly in further clinical trials.
The present study has limitations. Due to the design of the study, the time of observation 
from screening round 2 until the end of observation differed between the two study cen-
ters, i.e., 10 years in Gothenburg and 8 years in Rotterdam. In addition, the screening tests 
differed among the two centers in part of the initial screening round. Men in Gothenburg 
were screened by PSA only whereas men in Rotterdam were screened by a combination 
of PSA, DRE and TRUS up to 1997172. Consequently, this difference might have influenced 
the outcomes. In Rotterdam a more intense screening strategy at first screening round 
was used, resulting in a PCa detection rate at first screening round of 3.9% in Rotterdam 
versus 2.8% in Gothenburg (p=0.0006). To assess the potential consequence of the dif-
ference in study design, we also studied the proportional cancer incidence during the 
first 4 years and last 8 years of observation in Gothenburg and Rotterdam. This study 
showed a proportional cancer incidence of 7.65 in Gothenburg and 3.83 in Rotterdam; 
RR 2.00 (95%CI 1.71-2.33;p<0.001), and a proportional advanced cancer incidence of 
1.70 in Gothenburg and 3.05 in Rotterdam; RR 0.56 (95%CI 0.38-0.83;p=0.004) during the 
first four years after randomization. During the following eight years of observation, the 
proportional cancer incidence was 3.00 in Gothenburg and 3.08 in Rotterdam; RR 0.97 
(95%CI 0.84-1.11;p=0.696) and the proportional advanced cancer incidence was 0.32 in 
Gothenburg and 0.69 in Rotterdam; RR 0.46 (95%CI 0.24-0.88;p=0.019). This alternative 
analysis would not have changed our conclusions. One additional key observation was 
made. After two screening rounds no increase in the overall detection of PCa was found 
comparing the 2-year with the 4 year screening interval. The second limitation of our 
study is the difference in randomization procedure in the two centres. In Gothenburg, 
consent was obtained after randomization, with a response and participation rate at 
first screening of 64%. In Rotterdam, consent was obtained before randomization, with 
a response rate of approximately 55%, but participation rate of men randomized was 
95%. Thus noncompliant men were excluded before randomization in Rotterdam but 
not in the Gothenburg study. This so called healthy screenee bias, might have resulted in 
a relatively more favourable PCa distribution in the control population of the Rotterdam 
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study. Since in this study the proportional incidence of advanced interval cancers was 
used (a rate ratio related to the control population of the study) this potential bias could 
have overestimated the proportional incidence in favour of the Gothenburg study. 
Finally, contamination by PSA testing in the control population, and the percentage of 
men that had undergone PSA tests before randomization was assumed to be similar 
although no data was available to test this assumption.
11.6 CONCLUSIONS
This study compared the interval cancers in a population with a 2-year and a 4-year 
screening interval using the best possible control for sources of artefactual variation 
across the different populations. Both screening with a 2-year and a 4-year interval sig-
nificantly reduced the risk of being diagnosed with advanced cancer. A 2-year screening 
interval significantly reduced the incidence of advanced PCa up to 43% relative to a 
program that uses a 4-year interval in men aged 55 to 64 years. However, the screening 
programs that use more frequent screening showed to be associated with increased 
numbers of investigations and with an increase in the incidence of low risk PCa up to 
46%. Therefore the identification of men that can benefit from more frequent screening 
is needed to define the optimal patient-individual screening interval. Finally, the effects 
of screening need also to be evaluated by means of an appropriate economic analysis, 
not merely on evidence of effectiveness in terms of stage distribution and PC specific 
mortality, and needs to take into account the quality of life aspects of the screening 
program.
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AbSTRACT
Objectives: To assess the number of missed prostate cancers and the frequency of ag-
gressive disease when taking lateralized sextant prostate biopsies, irrespective of the 
total prostate volume (Pvol), during screening for prostate cancer.
Subjects and methods: Men participating in the European Randomized Study of 
Screening for Prostate Cancer, Rotterdam section, aged 55–74 years, with a prostate-
specific antigen (PSA) level of ≥ 3.0 ng/mL, and a negative sextant biopsy result at the 
initial screening round, were followed for 8 years. Cases of prostate cancer detected 
during the follow-up by screening, or detected clinically as interval cancers, were as-
sessed. Pvol at the initial screening round was related to the number of cancers found 
during the follow-up. Furthermore, the frequency of aggressive cancer (N1 or M1, PSA 
> 20.0 ng/mL, Gleason > 7 as evaluated using multivariate logistic regression analysis, 
including age, PSA level and Pvol.
Results: In the total of 1305 men, 152 prostate cancers were detected during 8 years 
of follow-up (11.6%); 23 were classified as aggressive (15.1%), and 50 (32.9%) were 
detected as interval cancers. There was a significant relation between a larger Pvol at 
the initial screening round and fewer cancers (odds ratio 0.1, P <0.001). In multivari-
ate logistic regression, the initial PSA level (odds ratio 3.21, 95% confidence interval, CI 
1.2–8.3) and smaller Pvol (0.08, 95% CI 0.03–0.26) were statistically significant predictors 
for all cancers and aggressive cancers (PSA odds ratio 70.37, 95% CI 13.5–366.2; Pvol 
odds ratio 0.03, 95% CI 0.01–0.35).
Conclusions: Men with a smaller Pvol and an initially high PSA level were at greater risk 
of cancer detection and of an aggressive cancer during the follow-up. The use in clinical 
practice of volume-adjusted biopsy schemes should not be implemented automatically 
in screening programmes with repeated screening.
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12.1 INTROdUCTION
PSA testing in combination with an efficient and accurate method of prostate biopsy 
represents the standard method for the early detection of prostate cancer. Systematic 
sextant biopsy was proposed and popularized by Hodge et al.29 and has been the stan-
dard protocol for many years. Later studies applying extended biopsy protocols showed 
that the sextant biopsy misses 10–30% of biopsy-detectable cancers 234-235. Prostate vol-
ume (Pvol) can affect the cancer detection rate, as a sextant biopsy might under-sample 
larger prostates236-237.
Although the effectiveness of prostate cancer screening is not confirmed by level I evi-
dence, screening is common and even recommended. Randomized multicentre studies 
are ongoing, including the European Randomized Study of Screening for Prostate Cancer 
(ERSPC), that is designed to study the effect of population-based screening for prostate 
cancer on prostate cancer mortality rates and quality of life and, if proven effective, to 
establish the optimum screening programme 238. In the ERSPC section Rotterdam, men 
are screened with an interval of 4 years by PSA testing and, when the PSA level is ≥ 3 ng/
mL, with a lateralized sextant biopsy, irrespective of the prostate volume. Obviously, due 
to this study protocol, biopsies are taken in a considerable number of men with an el-
evated PSA level produced by benign prostate enlargement. Furthermore, probably due 
to the standard use of the lateralized sextant biopsy scheme, a significant percentage 
of cancers remain undetected in men with large prostates. Consequently, these cancers 
might surface at repeated screening rounds, or as interval cancers with less favourable 
cancer characteristics.
We analysed whether men with larger prostates, who had a biopsy indication but with 
negative results at the initial screening round, were diagnosed with cancer more fre-
quently as interval cancers or at subsequent screening rounds, and whether these had 
less favourable tumour characteristics. We then considered whether more biopsy cores 
should be taken in men with larger prostates, for adequate prostate cancer screening, or 
that other baseline variables might be more predictive for detecting aggressive prostate 
cancers.
12.2 SUbJECTS ANd METHOdS
The ERSPC was designed to study the effect of population-based screening for prostate 
cancer on prostate cancer mortality rates and quality of life. Between December 1993 
and December 1999, in the Dutch centre of the ERSPC, 42 376 men aged 55–75 years 
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were randomized after providing informed consent. In all, 21 210 men were randomized 
to the intervention arm. Men with a previous diagnosis of prostate cancer were excluded. 
For the current analysis only those participants were included who were screened by the 
use of an exclusively PSA- based algorithm, between May 1997 and December 1999. 
In these men the PSA level as used as the only biopsy indication, applying a threshold 
of 3.0 ng/mL, irrespective of the findings on a DRE and TRUS. A detailed description of 
the methods of the screening trial is provided by Roobol et al.96. At 4 and 8 years after 
the initial screening, men were invited to undergo repeated screening, when aged 74 
years. Cancers diagnosed clinically between the screening intervals or by opportunistic 
screening, TURP for benign disease, and cystoprostatectomy specimens (i.e. ‘interval 
cancers’) were also considered. The serum PSA level was measured using the Hybritech 
Tandem-E assay (Beckman-Coulter, San
Diego, CA, USA). Pvol and transition zone (TZ) volume (TZvol) were measured by TRUS
(model 1846 mainframe, Bruel & Kjaer, Glostrup, Denmark) and a 7-MHz biplanar 
endorectal transducer. The lateralized sextant biopsy consisted of right- and left- sided 
lateral cores from the base, mid and apex of the prostate. An additional core biopsy was 
taken from any suspicious area on TRUS.
All cancers were classified according to the primary TNM classification of 1992, and 
graded using the Gleason grading system. Men with T1c and a serum PSA level < 10 ng/
mL were classified as M0, and men with a serum PSA level of ≥ 100 ng/mL were classified 
as M1, if an isotope bone scan was not taken. Aggressive cancer was defined as cancer 
that had at least one of the following characteristics at diagnosis: stage N1 or M1, serum 
PSA level > 20.0 ng/mL, or a Gleason score > 7.
For statistical analysis the Pvol at the initial screening round was stratified in groups 
(<40, 40–60, >60 mL) and related to the number of prostate cancers found at the second 
and third screening round, by screening or clinically, during the two intervals (0–4 and 
4–8 years). These results were analysed using the chi-square test and two-sided Fisher’s 
exact test. For additional statistical comparisons Pvol, TZvol and PSA values were loga-
rithmically transformed to obtain normal distributions. Subsequently, the total number 
of prostate cancers detected at, or before, the second and third screening round were 
statistically analysed using univariate logistic regression, to assess the correlation with 
the continuum of Pvol and TZvol at the initial screening round. In addition, multivariate 
logistic regression analyses were used to assess all screen and clinically detected cancers 
during the 8 years of follow up, including the initial screening round variables of log 
PSA value, age and log Pvol, using a backward stepwise method with variables rejected 
at a P < 0.05. For all tests, a two- sided P < 0.05 was considered to indicate statistical 
significance.
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12.3 RESULTS
During the first screening round, 10 754 men were invited for screening using a PSA level 
of ≥3.0 ng/mL as a biopsy indication, between May 1997 and December 1999; 10 191 
(94.8%) men actually had a PSA test. In all 2146 (21.1%) men had a PSA level of ≥3.0 ng/ 
mL, of whom 1849 (86.2%) were biopsied. Prostate cancer was detected in 541 (29.3%) 
men. Consequently, 1305 men, who all had a benign biopsy result and in whom the Pvol 
was measured, were included in the present study for further evaluation at repeated 
screening rounds. The baseline patient characteristics of these 1305 men are shown in 
Table 1. Figure 1 presents a flow diagram of the study including the following 8 years.
Table 1 The baseline characteristics of the 1305 subjects
Variable Median (range) or n (%)
Age, years 65 (55-74)
55-59 227 (17.4)
60-64 358 (27.4)
65-69 396 (30.3)
70-75 324 (24.8)
PSA, ng/mL 4.0 (3.0-46.7)
Pvol, mL 47.4 (13.1-207.7)
00.0 – 40.0 408 (31.3)
40.1 – 60.0 565 (43.3)
> 60.0 332 (25.4)
Tzvol, mL 29.1 (4.5-182.9)
00.0 – 20.0 305 (23.4)
20.1 – 30.0 372 (28.5)
> 30.0 618 (47.4)
Unknown/not done 10 (0.1)
At the second screening round after 4 years, 976 (74.8%) participants were invited 
between July 2001 and October 2004; 734 (75.2%) men had a PSA test, of whom 628 
(85.6%) had a serum PSA level of ≥3.0 ng/mL. Overall, 581 (92.5%) men were biopsied, 
of whom 62 (10.7%) had prostate cancer. In addition, 26 interval cancers were detected 
between the first and second screening round. Of all 88 cancers the median Pvol was 
43.4 mL at the initial screening round, by contrast with an initial median Pvol of 47.4 mL 
in all men with a benign biopsy result at the second screening round. Of 88 cancers, 12 
(13.6%) were aggressive; the total number of cancers and number of aggressive cancers 
in relation to Pvol the initial screening round for 1246 patients (who were alive at the 
second screening) are shown in Table 2. Statistically more cancers were detected in 
smaller prostates, but there was no significant difference for the total number of ag-
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gressive cancers and Pvol stratified in groups of < 40 mL and > 40 mL (Fisher’s exact 
two-sided, P = 0.545).
The total number of detected prostate cancers in relation to the total Pvol and TZvol 
(continues variables) was analysed using univariate logistic regression. This showed a 
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figure 1. A flow diagram of the study.
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significant relation for the total number of prostate cancers with the smaller Pvol (odds 
ratio 0.217, P = 0.02) and with TZvol (0.327, P = 0.02) at the initial screening round. There 
was no relation for the total number of aggressive prostate cancers with Pvol or TZvol at 
the initial screening round (P = 0.915 and 0.891, respectively).
At third screening round (4 years later), 652 (71.3%) men were invited for a PSA 
testbetween July 2005 and March 2008, and 291 (44.6%) were screened by PSA test-
ing, of whom 229 (78.7%) had a serum PSA level of ≥3.0 ng/mL. A biopsy was taken 
in 168 (73.4%) men, of whom 40 were diagnosed with prostate cancer (23.8%). In 24 
men an interval cancer was detected during the second 4 years of follow-up. Of all 64 
cancers the median Pvol was 40.0 mL at the initial screening round, by contrast with a 
median Pvol of 47.6 mL in men with a benign biopsy result at the third screening round. 
Of all 64 cancers, 11 (17%) were aggressive. After stratifying Pvol as in the previously 
defined groups, there was a significant relation between the total number of prostate 
cancers and smaller Pvol at the initial screening round (Table 2). Subsequently, there 
was a significant relation for the total number of aggressive cancers and Pvol (Table 
2). The predictive value of Pvol and TZvol (continuous variables) for detecting prostate 
cancer was assessed using univariate logistic regression. Men with, at the initial screen-
ing round, a small Pvol and/or small Tzvol were more often diagnosed with prostate 
cancer during the follow-up than men with high Pvol (odds ratio 0.05, P < 0.001) and 
TZvol (0.10, P < 0.001). However, there was no significant relation for aggressive prostate 
Table 2 Screen- and interval-detected prostate cancer during the First and second 4 years of follow-up
Pvol, ml
0-40 40.1-60 >40 >60 Total
First 4 years
Cancer, n (%) 37 (9.5) 36 (6.7) - 15 (4.7) 88 (7.1)
No cancer, n (%) 351 (90.5 505 (93.3) - 301 (95.3) 1157 (92.9)
P <0.005
Aggressive cancer, n (%) 4 (1.0) - 8 (0.9) - 12 (1.0)
No aggressive cancer / no cancer 384 (99.0) - 849 (99.1) - 1233 (99.0)
P 0.545
Second 4 years
Cancer, n (%) 31 (9.4) 23 (4.9) - 10 (3.5) 64 (5.9)
No cancer, n (%) 300 (90.6) 443 (95.1) - 275 (96.5) 1018 (94.1)
P <0.005
Aggressive cancer, n (%) 7 (2.1) - 4 (0.5) - 11 (1.0)
No aggressive cancer / no cancer 324 (97.9) - 747 (99.5) - 1071 (99.0)
P <0.005
Agressive prostate cancer; one of the following characteristics at diagnosis: stage M1 or N1, serum PSA 
level >20.0 ng/ml, or a Gleason score >7
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cancer with the continuum of Pvol and TZvol at the initial screening round (P = 0.066 
and 0.093, respectively).
Table 3 shows the results of the multivariate logistic regression analysis, with serum PSA 
level, Pvol and age at the initial screening round included. All 152 prostate cancers, in-
cluding 23 aggressive prostate cancers, all detected up to 8 years after the initial screen-
ing round, were included. A small Pvol, lower age and an increased baseline PSA level at 
the initial screening round were significant predictors for cancer (Table 3). In addition, a 
multivariate logistic regression analysis, with initial PSA, Pvol and age included, showed 
that an increased baseline PSA level and smaller Pvol were significantly predictive for 
detecting aggressive prostate cancer during the 8-year follow-up (Table 3).
12.4 dISCUSSION
In this study we showed that men with a smaller Pvol, who had, at the initial screening 
round, an indication for biopsy and a negative biopsy result, were at greater risk of being 
diagnosed with prostate cancer, and of aggressive prostate cancer, during the 8 years of 
follow-up. This was in contrast with our intuitive assumption which implied that using 
lateralized sextant biopsies irrespective of Pvol would result in more missed cancers in 
larger prostates, due to under-sampling. Our initial theory supported the need to obtain 
more biopsies because taking only six biopsy cores in men with large prostates might 
miss many aggressive cancers, and possibly affect the prostate cancer mortality rate. 
In line with this, the ideal endpoint for the present study would be the prostate cancer 
mortality rate. However, as no men in the current study died from prostate cancer until 
December 2006, the number of detected aggressive prostate cancers for different Pvol 
replaced the prostate cancer mortality rate as a surrogate endpoint.
In all, 23 aggressive prostate cancers were screen- or clinically detected during the 8 
years of follow-up. Stratifying the initial Pvol by groups with < 40 and > 40 mL resulted 
in 11 (2.7%) of 408 men and 12 (1.3%) of 897 men who were detected with an aggres-
Table 3 Predictive value of different predictors of prostate cancer and aggressive prostate cancer in 
multivariate analyses
Multivariate analyses, odds ratio (95% CI), P
Variable All cancers Aggressive cancers
Log Pvol 0.085 (0.028-0.259), <0.001 0.032 (0.003-0.345), 0.004
Log initial PSA 3.213 (1.242-8.313, 0.016 70.367 (13.522-366.191), <0.001
Age 0.957 (0.925-0.990), 0.011 1.010 (0.930-1.096), 0.817
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sive prostate cancer, respectively. This resulted in an increased risk for men with smaller 
prostates of developing a clinically significant cancer with an unfavourable perspective. 
Nevertheless, this relative risk stratification could be influenced by the unequal Pvol 
distribution over the different volume groups, as 68.7% of the men had a Pvol of > 40 mL 
at the initial screening round. Therefore, the percentage of aggressive cancers detected 
in larger prostates might be lower than in small glands because larger prostates are 
more often biopsied in previous screening rounds secondary to the increased serum 
PSA level that might be produced by benign prostate tissue. Consequently, men with 
smaller prostates and a PSA level of ≥3.0 ng/mL at the previous round were a priori at 
increased risk of cancer, as their elevated PSA level might not be produced by benign 
prostate tissue. However, even when the number of patients was normally distributed 
over Pvol groups of < 40 and > 40 mL, and the total number of detected aggressive 
prostate cancers was unaffected, there would be no significantly higher risk for larger 
Pvol, as in all, 11 and 12 aggressive prostate cancers were detected in men with a Pvol 
of < 40 and > 40 mL.
In ine with our initial hypothesis, it might be possible that better sampling of smaller 
prostates influenced the number of detected cancers. In addition, at the second and 
third screening round, lateralized sextant biopsies were taken irrespective of Pvol. 
For this reason we made a subanalysis including only the ‘clinically’ detected interval 
cancers during the 8 years of follow-up. In this analysis, eight (2.0%) of 408 men with 
an initial Pvol of < 40 mL, and 10 (1.1%) of 897 with a Pvol of > 40 mL had an aggressive 
prostate cancer. Consequently, this subanalysis showed no increased relative risk of an 
aggressive prostate cancer diagnosis for men with larger prostates.
By contrast with our initial theory, the current results have no implication for changing 
the study protocol by taking more biopsy cores in men with larger prostates. After 8 years 
of follow-up, more aggressive tumours were detected in small prostates than in larger 
prostates. These results were confirmed in multivariate analyses including age, baseline 
PSA level and Pvol. In addition, in multivariate analyses the baseline serum PSA level 
was a significant predictor for detecting aggressive prostate cancer. This implies that 
if there should be an adjustment of the study protocol, patients with smaller prostates 
and a significantly increased baseline serum PSA level with a benign biopsy result at 
the initial screening should be re-screened after a shorter interval. However, the current 
study design does not have the power to introduce this adjustment to the study pro-
tocol. Also, these results suggest that volume-adjusted biopsy schemes should not be 
implemented automatically in screening programmes with repeated screening rounds. 
Because men with larger prostates are at greater risk of a benign elevated serum PSA 
level, the introduction of a volume-based biopsy scheme validated in the clinical setting 
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into a prostate cancer screening programme will result in increasing over-diagnosis. 
Consequently, as over- diagnosis is one of the major concerns of prostate cancer screen-
ing, an increase in over-diagnosis could interfere with the effectiveness and public 
acceptance of a screening programme. For this reason there is a need for an adjusted 
prostate biopsy scheme particularly developed for a systematic screening situation, 
which might differ from clinical schemes used routinely.
The present study results are in line with those from studies that have focused on the 
relation of tumour grade and Pvol 239-241. These studies were published after the results of 
the Prostate Cancer Prevention Trial, showing that men with a smaller Pvol, treated with 
finasteride, were 25% less likely to be diagnosed with prostate cancer but 67% more 
likely to have high-grade disease (Gleason ≥7)72. Although these observations might be 
attributable to a biopsy artefact of gland size, whereby small glands are relatively over-
sampled, further studies showed that gland size not only affects the detection rate, but 
is also associated with the distribution of Gleason score. Three studies taken together all 
indicate that prostate cancer detection is greater in small glands and at increased risk of 
clinically significant upgrading after radical prostatectomy239-241.
The present study included a follow-up of 8 years. Possibly more (aggressive) prostate 
cancers will be detected after a longer follow-up. Consequently this could change the 
conclusions obtained from present study results in the future. However, the results 
show that during the more recent years of observation, the interval-detected aggressive 
prostate cancers were mostly diagnosed in small prostates. This makes it unlikely that a 
larger number of aggressive prostate cancers in larger prostates might be expected in 
the following years. Moreover, based on the estimated lead-time, most missed aggres-
sive prostate cancers at the initial screening round would be clinically detected during 
8 years of follow-up129, 242.
The number of biopsy cores taken affects the cancer detection rate. Several groups con-
cluded that the lateralized sextant biopsy method under-samples prostates and con-
sequently might fail to detect a significant proportion of clinically important tumours 
243-244. Recently, Schröder et al. 170 reviewed seven studies that compared the percentages 
of cancers detected in the clinical setting by extended and sextant biopsy schemes. 
This review reported that classical sextant and lateralized sextant biopsies would have 
missed 23% and 19% of the detectable cancers. It was also confirmed that a volume- 
adjusted, increased-core regimen significantly increases the positive biopsy rate, with 
no significant increase in morbidity of the procedure 245. The most comprehensive data 
of the European Prostate Cancer Detection Study resulted in the Vienna nomogram, and 
it was concluded that 8–18 biopsy cores should be taken, based on Pvol and age, to en-
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sure a 90% certainty of cancer detection 246. However, the optimum number of cores that 
should be taken as an initial strategy in a screening setting remains a controversial topic, 
especially for prostate cancer screening, as over-diagnosis is one of the major concerns 
of screening. The present study does not aim to provide an answer to this question.
In conclusion, currently Pvol-based biopsy schemes are routinely used in clinical practice 
to assure adequate sampling. However, the present study does not support the imple-
mentation of these same volume-based schemes for a screening setting. We found that 
when applying a volume-independent lateralized sextant biopsy scheme in a prostate 
cancer screening programme with repeated screenings, large prostates are not under-
sampled with respect to the number and aggressiveness of tumours found, compared 
to small prostates, during the 8 years of follow-up. The total number of cancers and 
number of aggressive cancers was higher in small prostates. For prostate cancer screen-
ing, the question of the validity of a sextant biopsy regimen for the balance between 
missed aggressive cancers and overdiagnosis remains.
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AbSTRACT
background: Competing causes of deaths in men with screen detected prostate cancer 
(PCa) are poor defined. Results of clinical diagnosed cases are inaccurate for predicting 
the outcomes since the survival of screen detected cancers are in principal lengthened 
due to an earlier diagnosis.
Objectives: Estimation of the survival based on a competing risk analysis stratified 
by age, stage, serum Prostate Specific Antigen (PSA) and histological findings for men 
diagnosed with clinically localized PCa who were managed by radical surgery.
Design, Settings and Participants: Total of 2234 participants of the European Random-
ized Study of Screening for Prostate Cancer (ERSPC), aged 55 to 74 years, were diagnosed 
due to screening between 1993 and 2000 with PCa (staged <T2c, not N1, not M1 and 
PSA <20.0 ng/ml). 990 of these men were treated with radical surgery and followed until 
the end of 2008 for overall and disease specific mortality.
Measurements: Estimates of the probability of dying from PCa or other causes of death. 
Results and limitations: Median follow-up was 9.9 years. 168 men died during follow-up, 
of which 23 due to PCa. Men with tumours with Gleason scores of ≤6, 7 and ≥8, face 
a 2.1%, 4.2% or 16.1% probability, respectively, of dying from PCa within 15 years of 
diagnosis. The main limitations of this study were the small number of PCa deaths. The 
risk of dying from Pca relative to the risk of dying from other causes was higher for the 
younger ages and advanced Gleason scores.
Conclusions: Men with a clinically localised PCa (PSA <20.0 ng/ml), treated by radical 
surgery, have a very heterogeneous risk of dying either from PCa or other causes de-
pending on their Gleason score, stage and age. These risk estimates might be used as 
preoperative information and counselling for patients diagnosed with a localized PCa 
due to screening.
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13.1 INTROdUCTION
Prostate cancer (PCa) is the most common form of cancer affecting men in the Western 
world126,  247. The International Agency for Research on Cancer projected that in 2008 
there were 382,251 new cases of PCa (22% of all adult male cancers) and 89,319 deaths 
(9% of all male cancer deaths) from PCa, resulting in an incidence/mortality ratio of more 
than 4:1 126. These numbers highlight the difference between the number of men who 
are diagnosed with PCa and the number of men who actually die from PCa. This is mainly 
due to the increased detection by Prostate Specific Antigen (PSA) testing, which started 
in the early nineties. PSA testing has resulted in PCa being diagnosed at an earlier age, 
when it is at a relatively earlier stage, and lower tumour grade and serum PSA. Many 
of these patients are treated with radical surgery; in the United States and Western 
European countries between 45% and 50% of patients with localized PCa are currently 
treated by radical prostatectomy248-249. Overall, these patients have a competing risk of 
dying either from PCa or other causes, depending on the aggressiveness and stage of 
the disease, co-morbidity and age.
This study was designed to estimate survival for men diagnosed with screen-detected 
clinically localized PCa and treated with radical surgery. The primary objective of the 
analysis was to estimate the probability of dying from PCa or other causes after radical 
treatment given a patient’s tumour histology, stage, PSA and age at diagnosis in the PSA 
era.
13.2 METHOdS
All men included in this study were participants of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC). The study was designed to study the effect of 
population-based screening for PCa on mortality and quality of life68. The study started 
in 1993 and randomized a total of 267,994 men in the age range of 50–74 years.
The inclusion criteria for the current study were: (1) randomization to the intervention 
arm; (2) diagnosis with screen detected clinically localised PCa between 1993 and 2000, 
aged 55-74 years; (3) treated by radical surgery. Patients undergoing a combination of 
radical surgery with radiation therapy, or patients initially followed by an active surveil-
lance program or treated initially with endocrine treatment were excluded to evaluate 
the outcomes among men treated by radical prostatectomy that were highly compa-
rable among each other.
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13.2.1 Clinical information
All cancers were classified according to the TNM classification of 1992. All men with a 
clinical PCa ≥cT2c and/or cN1 and/or cM1 disease or with a PSA ≥20 ng/ml at diagnosis 
were excluded. We defined these inclusion criteria to estimate the survival of men with 
PCa after screening in a low and favourable clinical stage, presuming that these cancers 
are currently most often diagnosed in communities with a high frequency of PSA test-
ing248. Men with T1c disease and serum PSA concentration less than 10.0 ng/ml were 
classified as M0, even through a bone scan was not performed. Men with PSA 10-20 ng/
ml and stage NX or MX were not excluded.
13.2.2 Pathological Evaluation
The pathological information was based on the prostate biopsy specimens. Due to the 
ERSPC screening protocol, most information was based on lateralized sextant biopsies. 
Grading of the cancers was done using the Gleason grading system. Standardization of 
pathology procedures was coordinated and achieved by the work of the international 
pathology committee98.
13.2.3 Treatment procedure
For all patients the treatment of PCa was performed according to the local policies and 
guidelines, in high and low volume centres. Radical surgery was performed by an open 
or a (robotic assisted) laparoscopic procedure. Comparing outcomes of different surgical 
techniques was not the aim of this study.
13.2.4 Mortality data
Mortality data of participants who died in the period up to December 31, 2008 were 
obtained by linking the trial database with the National Causes of Death Registry. 
Linkage to the National Causes of Death Registry was possible by using the personal 
administrative number of each participant as a linkage key. Causes of death were evalu-
ated in a blinded fashion and according to a standard algorithm or, after validation, on 
the basis of official causes of death153. Patients were determined to have died from PCa 
if they were classified as either “definitely PCa death”, as “probable PCa death” or as “PCa 
intervention related death”
13.3 STATISTICAL METHOdS
Follow-up for mortality analyses began at diagnosis and ended at death, emigration, 
or a uniform censoring date (December 31, 2008). The primary outcomes for this study 
were estimates of the probability of dying from PCa or other competing causes given a 
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patient’s age, PSA and tumour histology grade at diagnosis. The counts and cumulative 
survival estimates of men with each of the 3 outcomes of interest (alive, deceased from 
PCa, and deceased from other causes) are presented. To estimate the proportions of 
men who died from PCa, died from competing medical hazards, or were still alive 15 
years following diagnosis, we applied the 2 fitted rates to the proportion of men still 
alive at the beginning of each successive follow-up interval. Therefore, the following 
model was used: Log [E(Y)] = log(exp) + β0 + β1x1 + ...... + β5x5; a generalized linear model 
with log link function and Poisson distributed errors where E(Y) is expected number of 
PCa deaths, log(exp) is the logarithm of the follow up time, (x1, x2,..., xp)
T are the predic-
tive variables, i.e. age, Gleason score, serum PSA and the time since diagnosis. The βi is 
the coefficient corresponding to xi. The term log(exp) was an offset with the parameter 
estimate constrained to 1. All analyses were performed with STATA: Data Analysis and 
Statistical Software, version 11.0.
13.4 RESULTS
13.4.1 Study population
Between 1993 and 2000, a total of 2234 men were diagnosed with a histological proven 
localized PCa (clinical staged ≤T2c, NO, M0 and PSA < 20 ng/ml) in the intervention arm 
of the ERSPC. From all patients complete PSA, stage and pathology information was 
available at diagnosis. The primary treatment modalities are shown in Table 1. A total 
of 990 men were treated with radical surgery. A detailed description of these men is 
presented in Table 1. Median follow-up was 9.9 years (inter quartile range = 8.9-11.2 
years). A total of 23 men died from a PCa related cause of death, from which 4 cases were 
assessed as intervention related death. Men of older ages were at increased risk of an 
intervention related cause of death.
Table 1. Initial treatment modalities prostate cancer <T2c, not N1, not M1 and PSA <20.0 ng/ml)
Total number patients diagnosed 2234
Surgery 990 (44.3)
Radiotherapy 535 (24.0)
Active surveillance 506 (22.6)
Endocrine 59 (2.7)
Surgery and Radiotherapy 3 (0.1)
Surgery + Endocrine treatment 41(1.8)
Radiotherapy + Endocrine 75 (3.4)
Other or Unknown 25 (1.1)
182 Chapter 13
13.4.2 Relative risk prostate cancer mortality
In multivariate analysis the relative risk of PCa specific death for patients with Gleason 
score ≥8 was statistically significant increased relative to patients with a Gleason score 
≤6 tumours; RR 7.22 (95%CI 2.72- 19.15, p <0.001) (Table 2). No statistically significant 
difference was observed in the RR of dying from PCa for men with PSA 10-20.0 ng/ml 
relative to men with PSA < 10.0 ng/ml at diagnosis, RR 0.77 (95%CI 0.23- 2.61, p=0.676).
Table 2. Patient characteristics at diagnosis
Total participants included 990
Age (yr), median 63.0
 55 - 64 616 (62.2)
 65 – 74 374 (37.8)
PSA at diagnosis (ng/ml), median 5.3
 0.0  - 9.9 856 (86.5)
 10.0 - 20.0 134 (13.5)
Clinical stage
 T1 512 (51.7)
 T2 478 (48.3)
 N0 583 (54.4)
 NX 452 (45.6)
 M0 971 (98.1)
 MX 19 (1.9)
Histological differentiation
 Gleason 2 – 6 751 (75.9)
 Gleason 7 171 (17.2)
 Gleason 8 – 10 68 (6.9)
13.4.3 Mortality Outcomes by age and Gleason score
The distribution and outcomes of 990 patients treated by radical surgery for localized 
PCa are presented in Table 2. The patients are stratified by age and the histology of the 
biopsy specimen classified according to the Gleason score. Estimates of the cumulated 
probability of dying from either PCa or other causes are presented as a 15-year outcome 
in Table 3 and as function of time since diagnosis in Figure 1.
For men aged 55-64 years at diagnosis the PCa specific 10-years cumulated mortality 
estimates were 1.1%, 2.3% and 13.0% for Gleason scores ≤6, 7 and ≥8 respectively. The 
10-years PCa specific mortality estimates for men aged 65-74 years were 2.1%, 4.2% and 
7.7% for Gleason scores ≤6, 7 and ≥8 respectively.
Table 3 and Figure 1 demonstrate that few men with Gleason score ≤6 tumours 
identified by prostate biopsy had progression leading to death from PCa; 1.2% and 
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2.7% of men aged 55-64 and 65-74 years, respectively, died from PCa within 15 year 
of diagnosis (median 9.9 years). From all men aged 55-64 years at diagnosis that died 
within 15 years after diagnosis, 7.7%, 17.6% and 55.3% died from PCa if they harboured 
a disease with Gleason scores of ≤6, 7 and ≥8, respectively. For men aged 65-74 at 
diagnosis these percentages were 9.0%, 13.5% and 41.7% for Gleason scores ≤6, 7 and 
≥8, respectively.
Table 3. Multivariate relative risks prostate cancer specific mortality.
Characteristic Relative Risk 95% CI P - value
Age at diagnosis 1.01 0.91 – 1.12 0.818
PSA at diagnosis 1.00 0.90 – 1.11 0.993
Gleason score ≤ 6 *
Gleason score 7 2.01 0.68 – 5.79 0.199
Gleason score ≥ 8 7.22 2.72 – 19.15 < 0.001
* Reference group to which compared. The reference group per definition has a relative risk of 1.
Chapter 13. 
 
 
Figure 1. Estimated mortality from prostate cancer and other causes of death. 
 
 
 
 
 
 
 
 
 
figure 1. Estimated mortality from prostate cancer and other causes of death.
184 Chapter 13
13.4 dISCUSSION
Accurate predictions of outcomes in cancer specific and overall survival are useful for 
patients and clinicians before choosing treatment. Currently, there is limited survival 
data that is appropriate for the men diagnosed with localized PCa as a result of screen-
ing. The reported outcomes are primarily of the patients diagnosed with PCa in the pre 
PSA era55,  250-251. These outcomes are inaccurate for predicting the survival of patients 
with a screen detected PCa since the survival outcomes of these cancers are in principal 
lengthened due to a diagnosis at an earlier age252. This is called the lead-time which for 
screen detected PCa is estimated between the 6 and 12 years depending on age at diag-
nosis129. Considering treatment of men with a localized screen detected PCa, we realize 
that more information is needed than the outcomes of one single treatment modality. 
In our opinion, only prospective randomized data can solve the controversy supporting 
surgery, radiation or observation. No randomized controlled trials have been performed 
to solve this dilemma for men with a screen detected localized PCa. These studies are 
ongoing, however results are not expected soon 253-254.
This study provides risk stratifications for men diagnosed with a screen detected 
localised PCa who consider treatment with radical surgery. It demonstrates a large het-
erogeneity among patients with PCa clinical stage <T2c and PSA <20.0 ng/ml. Men with 
a localised disease and a Gleason score ≤6 in their biopsy specimen harbour a 2.1% PCa 
mortality risk while this risk in men with a Gleason score ≥8 disease was estimated to be 
16.1% after 15 years of observation. Our study showed that PCa remains a major cause 
Table 4. Observed counts and estimated cumulative percentage of men deceased from either prostate 
cancer or an intercurrent cause of death by age and Gleason score up to 15 years after diagnosis (median 
9.9 years).
Age 55-64 years at diagnosis
Gleason Score No.
at risk (%)
No.
Alive (%)
No. Deceased From 
Other Causes (%)
No. Deceased From 
Prostate Cancer (%)
% Prostate Cancer 
Deaths of all Deaths
≤ 6 495 (100) 437 (84.5) 52 (14.3) 6 (1.2) 7.7 %
  7 88 (100) 76 (83.0) 10 (14.0) 2 (3.0) 17.6 %
  8-10 33 (100) 25 (71.2)  4 (14.9) 4 (15.9) 55.5 %
  All 616 (100) 538 (83.3) 66 (14.5) 12 (2.9) 16.7 %
Age 65-74 years at diagnosis
Gleason Score No.
at risk (%)
No.
Alive (%)
No. Deceased From 
Other Causes (%)
No. Deceased From 
Prostate Cancer (%)
≤ 6 256 (100) 206 (70.0) 45 (27.3) 5 (2.7) 9.0 %
  7 83 (100) 60 (60.0) 20 (34.5) 3 (5.5) 13.5 %
  8-10 35 (100) 18 (46.0) 14 (31.5) 3 (22.5) 41.7 %
  All 374 284 (58.3) 79 (36.2) 11 (5.5) 13.2 %
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of death in particular in younger men with high-grade disease who were screened and 
treated with radical prostatectomy. Additionally, the relative contribution of the death 
unrelated to PCa itself to the overall mortality increased with increasing age at diagnosis 
and decreased with the Gleason scores.
More than an exponential increase in the risk of dying from PCa was observed for the 
increasing Gleason scores. This was reflected in the more than 2 fold higher RR for a man 
with a Gleason score ≥8 relative to a Gleason score 7, and the RR of 2.01 for a men with 
a Gleason score 7 relative to Gleason score ≤6, (Table 2). These observations are in line 
with studies showing that patients with a Gleason score 8-10 typically have a markedly 
higher PCa death rate compared with the lower scores251, 255-256. However, the difference 
in risk between the high and low Gleason scores might be larger in our population due 
to two effects.
First, screening detects a considerable part of insignificant cancers that would never 
have surfaced during the lifetime of a patient. In the current study these patients are 
included in the most favourable risk group, i.e., Gleason scores ≤6. As a result, the survival 
in this group is improved by an increase in the number of patients who would not have 
died of the disease in the first place, which highlights the possibility for active surveillance 
strategies (i.e., deferred curative treatment for low-risk prostate cancer until the per-
ceived disease progression). Observational single centre and retrospective population-
based cohort studies of active surveillance for localized prostate cancer have reported 
favourable outcomes, however studies that show longer follow up are needed41-42, 257-258. 
Nevertheless, for Gleason scores ≤6 PCa, we might conclude that cancer specific survival 
is very favourable, but that is in part due to a significant percentage of overtreatment.
Second, the increased PCa mortality risks for Gleason score 8 relative to Gleason score 
6 diseases is probably due to the limitation in the clinical staging of men with high risk 
Gleason scores. The clinical stage in most of our patients was based on the serum PSA, 
the findings by DRE, transrectal ultrasound (TRUS), and an isotope bonescan when 
indicated. As a result, 41% of our patients with Gleason 8-10 disease and clinical stage 
<T2c, NO, MO and PSA < 20 ng/ml had extraprostatic disease (i.e., ≥pT3) in their radical 
prostatectomy specimen (data not shown). This percentage is line with the outcomes 
of the Partin tables, a predictive model that has been developed to estimate the prob-
ability of extraprostatic extension, seminal vesicle invasion and lymph node invasion259. 
After we entered the clinical data of our patients with a Gleason score 8-10 disease in 
the Partin tables, the estimated probability of extraprostatic extension was 38% (95%CI 
30-47). In conclusion, a large percentage of patients with high Gleason scores might 
not harbour a localised disease, which we cannot assess due to the limitations of the 
currently used staging modalities.
The competing risks of dying from PCa in men with favourable Gleason scores are very 
low, i.e. 8% and 9% of all deaths for ages 55-64 and 65-74 years, respectively.
186 Chapter 13
In total 4 of the 990 men (0.4%) who were treated with radical surgery were determined 
as intervention related death. This is in line with 30-day mortality after radical prosta-
tectomy percentages presented in earlier series varying between 0.5% and 0.7%260-261. 
We observed no statistically significant association with age, although earlier series 
showed that radical prostatectomy complication rates were associated with increasing 
age and co-morbidity. Relative to other major surgeries in older ages262, intervention 
related mortality after radical prostatectomy is low and should be low considering 
the risk of overdiagnosis and overtreatment that is associated PCa. Overdiagnosis is 
estimated between 23-66% in screen-detected PCa. Therefore, as there is no evident 
reason to assume a different risk of intervention related deaths in overdiagnosed or 
non-overdiagnosed cancers, roughly 1 or 2 deaths in our group might be ascribed to 
overtreatment. Consequently, the risk of death associated to overtreatment is roughly 
estimated between 0.1 and 0.2% in this patient cohort. Although these risks seem to be 
low, especially in older people these risks might be worth to discuss when considering a 
radical prostatectomy in a patient with favourable characteristics.
Most studies that reported outcomes after radical prostatectomy are limited by the in-
clusion of patients diagnosed before the introduction of PSA, or by the use of surrogate 
endpoints (e.g. biochemical recurrence) rather than PCa specific mortality55, 250, 263-264. In 
2,578 men with localized PCa diagnosed and treated before the wide introduction of PSA 
testing, the 10-year cancer specific mortality was 6%, 20% and 23% for well, moderate 
and poorly differentiated cancer, respectively265. In 751 men diagnosed with clinically 
nonmetastatic PCa between 1971 and 1984 the 15-year cancer specific death was 4% 
to 5%, 8% to 9%, 12% to 13%, 23% to 26% and 30% to 32% for Gleason scores 2 to 4, 5, 
6, 7 and 8 to 10, respectively251. So, the cancer specific mortality estimates in the pres-
ent study compare favourable to earlier series across all Gleason scores. Corresponding 
10- and 15-year data in the current study was 1.1% and 2.1%, 2.3% and 4.2%, 13.0% and 
16.1% for the Gleason scores ≤6, 7 and ≥8, respectively. In comparison to the earlier 
series the percentage of cancer specific deaths was roughly 2 fold decreased for men 
with Gleason scores 8-10, 5 fold decreased for Gleason scores 7, and 6 fold decreased for 
Gleason scores ≤6. These results confirm that earlier studies are inaccurate for predicting 
the survival of patients with a screen detected PCa, that the survival of screen-detected 
cancers across all Gleason scores, especially lower scores, are lengthened due to a diag-
nosis at an earlier time, and that the survival is likely improved by detecting insignificant 
cancers that would not have been diagnosed in the absence of screening. To which 
extent the survival outcomes are diluted by these effects are impossible to establish in 
this study.
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There are studies reporting the outcomes after radical prostatectomy in patients diag-
nosed after PSA testing. In a study by Stephenson et al. the overall 15-year PCa specific 
mortality was 12% for patients treated in the PSA era, and the 15-year PCa specific mor-
tality for patients with a PSA <10 ng/ml, Gleason 6, T1c or T2a disease was 2%256. D’amico 
et al. reported the PCa specific mortality after radical prostatectomy for patients with 
clinically localised PCa diagnosed in the PSA era. The 10-year cumulative PCa specific 
mortality was < 1% for patients with a PSA < 10 ng/ml, Gleason score ≤ 6 and T1c or 
T2a disease, and 4% for patients with a PSA < 10-20 ng/ml, Gleason score 7 and T2b dis-
ease255. The additional findings were in line with ours. The relative contribution of deaths 
unrelated to PCa itself increased with advancing age, and high-grade PCa remained a 
major cause for patients who were treated with radical prostatectomy of all ages, but in 
particular the younger ages.
In comparison to studies 256 and 255, strength of our study is the prospective data col-
lection and the PCa specific mortality that was based on the consensus of a cause of 
death committee. In addition, the current study did not include only patients treated 
at high-volume centres, and thus may presents an estimate for those patients who are 
diagnosed in the PSA era and are treated in the community setting. Finally, all men were 
diagnosed in a defined screening program.
Our study has limitations. The number of PCa specific deaths was small, and thus the 
survival estimates have to be interpreted with caution. Additionally, no difference in 
outcome between men treated by either an open or (robot assisted) laparoscopic radi-
cal prostatectomy was obtained. The histological information was most often based on 
sextant biopsies. However, sextant biopsies are related to a significant under grading. 
Therefore, more extended biopsy schemes are performed in current clinical practise. 
No data on co-morbidity was included although co-morbidity is a known strong deter-
minant of survival among men with PCa. Despite these limitations, the results of this 
large prospective study of patients with localised PCa that were treated with radical 
prostatectomy provide useful information for patients and clinicians.
13.5 CONCLUSION
Men with a screen-detected clinically localised PCa, treated by radical surgery, have a 
very heterogeneous risk of dying either from PCa or other causes depending on their 
age and histology of the biopsy specimen. Men, aged 55- 74 years at diagnosis, with 
tumours that have Gleason scores of ≤6, 7 and ≥8, face a 2.1%, 4.2% or 16.1% probability, 
respectively, of dying from PCa within 15 years of diagnosis. The relative contribution 
of deaths unrelated to PCa itself increased with advancing age and decreasing Gleason 
scores. For men with high-grade PCa, Pca remained a major cause of death despite early 
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detection by screening followed by radical prostatectomy and screening. The present 
estimates on cancer specific mortality compare favourable to earlier series across all 
Gleason scores indicating that disease specific survival of screen-detected cancer is 
lengthened due diagnoses at an earlier point in time, and likely is increased by the 
treatment of men that likely would never have surfaced clinical symptoms of PCa in the 
absence of screening.
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14.1 INTROdUCTION
Prostate cancer (PC) is a disease that most frequently occurs in elderly men, and there is 
a progressive increase in PC detection and mortality rates with age7, 152, 266. Opportunistic 
PSA testing has resulted in increasing PC incidence with patients diagnosed at an earlier 
age8, 149. Mortality from PC remains the most common in patients 70 years of age or older. 
In 2008, the median age at the time of death from PC in the Netherlands was 80 years160. 
Approximately, 3.5% of patients die before reaching the age of 60, 28.4% die between 
60 and 74 years of age, and 68.1% die after the age of 75 years.
Demographic projections indicate that the number of men aged 65 years and older 
will increase from the current 2.5 million men to 4.5 million in the Netherlands during 
the next 30 years176. The factors contributing to this change include the low and high 
rates of fertility during certain eras (e.g., during the depression and after World War II), 
advancements in medicine and sanitation, and reduced mortality due to elimination of 
many infectious diseases across all age groups267-268. The aging of the Dutch population 
during the next 30 years will be driven by the “baby boom” cohort born between 1946 
and 1964. In 2011, the oldest individuals in this cohort will turn 65. By 2040, the percent-
age of persons in the age group 65 years and older will increase from the current 15% to 
26% of the population.
As PC is a disease that is associated with high mortality rates in elderly men, there is rea-
son for concern regarding the estimated increase in the number of men aged 65 years 
and older. An increase of at least 51% in the number of new cases of PC is estimated 
by the year 2035. The total mortality rate from PC is estimated to increase by 131%, 
from 2050 to 5855 PC deaths (Figure 1)269. As a result, PC will become a major health 
problem during the upcoming decades. Screening for PC might be a strategy to prevent 
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the increase in PC morbidity and mortality. This, and the key findings presented in parts 
I-IV, will be the subject of the general discussion of this thesis.
14.2 PARTS I ANd II
The results presented in chapters 5 and 6 will be discussed with respect to two large ran-
domised controlled trials based on screening for PC. The European Randomised Study of 
Screening for Prostate Cancer (ERSPC) reported that screening for PC has the potential 
to reduce disease-specific mortality172. The Prostate, Lung, Colorectal and Ovarian (PLCO) 
trial in the United States did not show a reduction in PC mortality resulting from screen-
ing270. The mortality outcomes for both of these studies, especially the PLCO trial, were 
biased by neglecting the considerable levels of PSA testing in the control populations271. 
The data discussed in chapter 5 showed that the adjusted benefit of screening on a 
population-wide basis was higher than the 20% relative reduction in PC mortality that 
was reported by the ERSPC after a median follow up of 9 years. The study in this thesis 
estimated a relative reduction in PC mortality of 37%105. Individual patient mortality 
results stratified by PSA were not obtained in the randomised controlled trials because 
no blood from the men in the control arm of the trials was collected and stored for PSA 
measurement at the end of the trials172, 270. Therefore, in chapter 6, the PSA-specific data 
from men participating in the intervention arm of the ERSPC were compared with the 
PSA-specific data men in Northern Ireland (NI). The data presented in Chapter 6 showed 
that baseline PSA was useful for developing a risk stratification scheme with the poten-
tial to increase the balance between the harm and benefit of PC screening232.
The data presented in chapters 5 and 6 and the data from the ERSPC as a whole were 
used to quantify the harm-benefit tradeoffs that were associated with PSA screening. 
The harm-benefit tradeoffs were demonstrated by the NNS/NNI* and NNT* to save one 
man from PC-related death. The NNS/NNI was calculated as (1/absolute reduction in PC 
mortality) and the NNT as ((1/absolute reduction in PC mortality) * excess incidence). 
As a result, diluted estimates of the absolute mortality reduction and excess incidence 
due to PSA testing in the control population were reflected by a modification of the 
harm-benefit tradeoffs. Furthermore, both the absolute mortality reduction and the 
excess incidence depend on the duration of the follow-up. This makes the harm-benefit 
tradeoffs a sub-optimal measure under the condition of a limited follow-up. Due to the 
reduction in absolute mortality, the increases in the excess incidence and the duration 
of follow-up were biased and limited by the data from the randomised controlled trails. 
In chapters 5 and 6, the harm-benefit tradeoffs will be discussed in more detail.
* Appendix 1 page 246
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The results described in chapter 5 showed that the excess PC incidence was largely un-
derestimated by the ERSPC and PLCO trials. After a median of 9 years of follow-up, 9.6% 
of the men were diagnosed with PC in the intervention arm of the ERSPC-Rotterdam, 
4.3% of the men were diagnosed with PC in the control arm of the ERSPC-Rotterdam, 
and 3.0% of the men were diagnosed with PC in NI272. In total, 6.0% of the men were diag-
nosed with PC in the control arm of the PLCO after a median follow-up of seven years97. 
It is unlikely that the difference in incidence between the control arm of the ERSPC and 
the NI is reflected by a difference in the natural risk of developing the disease (chapter 
4). This difference reflects the change in the frequency of PSA testing in the general 
population of the two study populations152. As shown in Figure 2, the PC incidence was 
equal in the Netherlands and NI in 1990; it started to increase in the Netherlands in 1992, 
but it remained stable in NI until 1999. Comparable trends in PC incidence were shown 
in Finland, Sweden, Italy, Spain and Switzerland, showing an increase in the PC incidence 
starting in the early 1990s9. The impact of PSA testing on incidence was first reported in 
the United States, where it was associated with a doubling in the rates of prostate cancer 
from 1986 to 1992147. PSA testing in the Netherlands, which has been available since the 
mid-1980s, remained limited until around 1993, perhaps due to recommendations that 
advised against its use in asymptomatic men. When we compared the incidence rates 
in the Netherlands and NI and the number of PSA tests performed in those countries, a 
close relationship between the use of PSA screening and cancer incidence was revealed. 
In 2000, the rate of PSA tests per 1000 men over 45 years of age was almost 140 in the 
Netherlands and around 50 in NI, which is consistent with the more rapid increase in 
incidence observed in the Netherlands during the 1990s.
The ERSPC estimated that serum PSA was measured in 20% of men from the control 
population of the study165. In total 52% of men in the control arm of the PLCO were 
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tested for PC by measuring the PSA270. PSA testing has resulted in an increase of the 
PC incidence in the control arm of the PLCO and a decrease of the excess incidence 
after seven years of follow-up270. A more robust estimate of the excess incidence was 
made in chapter 5, showing an increase in the cumulative incidence in the intervention 
population relative to the control population of 67 per 1000 men after a median of nine 
years of follow-up. The excess incidence was 34 per 1000 in the ERSPC as a whole and 13 
per 1000 in the PLCO172, 270. Taking into account the effect of PSA contamination on the 
excess incidence, the ERSPC underestimated the number of men (48 in total) that would 
receive additional treatment to prevent one man from PC after nine years of follow-up. 
Similar conclusions can be drawn from the data of the Gothenburg screening study, 
which presented a NNT of 12 after 14 years of follow-up218.
The results presented in chapter 5 show that the reduction in PC mortality was underes-
timated by the randomised controlled trials. For clear reasons, including PSA contamina-
tion in the control arm and intense pre-screening prior to randomisation in both arms, 
no effect on the mortality rate was found in the PLCO271, 273. A secondary analysis of the 
ERSPC showed that the relative reduction that was observed after 9 years of follow-up 
increased after adjustment for contamination and nonattendance from 20% to 29-
31%165. In this study, contamination was based on tumour stage specific data, assuming 
that 23.9% of the T1C cases, 11.2% of the T2 cases, 12% of the T3 cases and 9% of the T4 
cases in the control arm were detected as a result of PSA testing in asymptomatic men 
(Table 1)165. After a median of 9 years, the stage distribution of the cancers diagnosed in 
the control population of the ERSPC was 6.7% T1a/b cases, 42.7% T1C cases, 30.7% T2 
cases, 16.4% T3 cases and 3.5% T4 cases (Table 1)274. In contrast, of all of the cases of PC 
diagnosed in the Netherlands in 1993, in men aged 65-74 years, 12.4% had T1a/b-stage 
Table 1. Stage distribution of the control population of the ERSPC adjusted for contamination in 
comparison to the stage distribution of all cases diagnosed in the Netherlands in 1993. Data obtained 
from 169,271,280.
A B C D E
Control ERSPC
Stage distribution, 
%
Control ERSPC
Assumed 
contamination, %
Control ERSPC, 
adjusted for 
contamination
Stage distribution, 
%
The Netherlands 
1993
Stage distribution, 
%
The Netherlands 
1999
Stage distribution, 
%
T1a/b 6.7 0 8.1 12.4 6.2
T1c 42.7 23.9 39.1 3.9 16.0
T2 30.7 11.2 31.7 38.9 43.3
T3 16.4 12.0 17.2 12.9 12.3
T4 3.5 9.0 3.9 32.2 22.2
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disease, 3.9% had T1C, 38.7% had T2, 12.9% had T3 and 32.2% had a T4-stage disease266. 
A comparison is presented in Table 1, and the stage distribution of all of the cases di-
agnosed in the control arm of the ERSPC is presented in column A. Next, the estimated 
percentage of men diagnosed as a result of opportunistic PSA testing in the control 
arm is presented (column B), and the stage distribution of all cases diagnosed in the 
control population of the ERSPC after adjustment for contamination is given in column 
C. Finally, the stage distribution of all cancers diagnosed in the general population of 
the Netherlands in 1993 and 1999 is presented in the last columns (D and E). Comparing 
the adjusted stage distribution of the control population of the ERSPC with the stage 
distribution of the cases diagnosed in 1993-1999, the adjusted stage distribution seems 
to be more favourable. This suggests that the effect of contamination by the ERSPC as a 
whole is underestimated. Consequently, the relative effect of screening on the PC rate of 
mortality may be higher than 31% after 9 years of follow-up. In chapter 5, we estimated 
a relative reduction of 37% after 9 years of follow-up. Considering the other limitations 
described in chapter 5, the true relative reduction is likely to be between 31 and 37% 
after a median follow-up of nine years.
The data described in chapter 6 demonstrate that risk stratification based on baseline 
PSA values can be used to optimise the harm-benefit trade-off in a PC screening pro-
gramme. Men with low initial PSA values are unlikely to benefit from early detection. 
This observation has clear clinical consequences and allows for specific individualised 
risk stratifications after measuring men’s PSA baseline. As a result, men at high risk can 
be informed about their more favourable harm-benefit trade off with respect to the 
overall NNS and NNT presented by the randomised controlled trials. In contrast, men 
with a serum PSA <1.0 ng/ml (36% of all men) or men with PSA <2.0 ng/ml (67% of all 
men) can be reassured that even if they received a biopsy revealing detectable cancer, it 
is unlikely to become life threatening during their lifetime. Such risk stratification mea-
sures may lead to an increased acceptance of screening among men and might increase 
the compliance among those who are at high risk, if they are informed of their risk status 
and their individualised harm-benefit tradeoffs. The results presented chapter 6 are 
in line with a recent study by Vickers et al. who determined the relationship between 
concentrations of PSA at age 60 and subsequent diagnosis of clinically relevant PC in an 
unscreened population233. They showed that 60-year-old men with PSA concentrations 
below the median (≤1 ng/ml) were unlikely to have clinically relevant PC (0.5% risk of 
metastasis by the age 85 and 0.2% risk of death from PC). The risk of dying from PC for 
men with PSA levels lower than 1.0 ng/ml in Northern Ireland after 9 years of follow-up 
was 0.1%233. Because population-based screening is not a reasonable option for reduc-
ing a 0.2% risk of cancer-specific death after 25 years, systematic repeated screening 
should not be applied to men with low baseline serum PSA values.
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The data presented in chapter 6 illustrate the potential power of using risk stratifica-
tion in population-based screening programmes. The reductions in the relative and 
absolute mortality increased with the increasing serum PSA values at the start of the 
study. This influenced the NNS and NNT because the absolute mortality reduction 
was used as the denominator in the calculations of the NNS and NNT. As a result, the 
harm-benefit tradeoffs associated with PSA-screening were more favourable for men 
with higher PSA values at the start of the study. In other words, the benefits increased 
with the increase in PC mortality. As a result, the harm-benefit trade-offs are likely to 
differ between populations in Europe. The PC mortality rates in the Nordic European 
countries (Norway, Sweden, Denmark, Iceland, and Estonia) are five times higher than 
those reported in several Central and Eastern European countries. Based on the data 
presented in chapter 6 and in Vickers et al233, harm-benefit trade-offs are likely to differ 
between different European countries, with more favourable harm-benefit trade-offs in 
countries with higher PC mortality rates, such as Norway, Sweden, Denmark, Iceland and 
Estonia. These differences must be taken into account when applying the results of the 
randomised controlled trials to a specific population in Europe.
The results on mortality and excess incidence discussed in chapter 5 and 6 are limited 
by the short duration of the follow-up. With PC being a major cause of death in elderly 
men (the median age of PC-related death is 80 years) and a median age of 69 years at 
the end of the follow-up in the study described in chapter 6, most men were at risk 
of dying from PC during the years after termination of the follow-up period. Therefore, 
even if the relative reduction in PC mortality remains stable during the next years, the 
absolute reduction in the rates of mortality from PC will increase with longer follow up. 
The association between age and the relative and absolute reduction is illustrated in 
Figure 3. Applying a 20% relative reduction to the age-specific PC mortality rate shows 
 
Figure 3. Prostate Cancer (PC) mortality stratified by age at the time of death. The figure illustrates that with a 
constant relative reduction in PC mortality of 20%, the absolute reduction in the PC mortality rate will increase 
with the age at the time of death from PC.  
  
 
Figure 4. Interval-specific (conditional) estimates of relative survival for patients diagnosed with cancers of the 
stomach (left graph) and female breast (right graph) in Finland, obtained with permission from 145. 
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that the absolute mortality reduction will increase 6.4-fold from 0.13 per 1000 men aged 
65-69 years to 0.83 per 1000 men aged 80-84 years. Consequently, using the absolute PC 
mortality reduction as the denominator for the calculation of the harm-benefit tradeoff, 
this tradeoff will change favourably with a longer follow-up in an ageing population. In 
addition, as the excess incidence of screening depends on the duration of follow-up, the 
harm-benefit trade-off is also limited by the short-term estimate of the excess incidence. 
Following the principle of screening, the excess incidence is expected to decrease be-
cause the incidence in screened men is expected to drop to a much lower level than in 
unscreened men after men in the screening population have reached the optimal age 
for cessation screening275. Therefore, it would be more realistic to replace the numerator 
of the NNT calculation with an estimate of the incidence of overdiagnosis. Draisma et al. 
estimated the frequency of overdiagnosis in the Rotterdam section of the trial and found 
it to be as high as 44-55% of the screen-detected cases129. The rate of overdiagnosis of 
screen-detected cases in the US population of men aged 50-84 years between 1985-
2000 was estimated to be 23-42%276. Assuming a 20% relative PC mortality reduction 
and an overdiagnosis frequency between 23 and 55%, the NNT to save one man from PC 
death is estimated to be between 19 and 5 men.
Finally, the relative reduction in PC mortality is expected to increase with longer follow-
up. This prediction is based on the cumulative incidence in mortality in both study arms 
of the ERSPC as a whole, the Gothenburg screening study and the results described in 
chapter 5. Further, as shown in chapters 5 and 6 and by the ERSPC as a whole, it takes 
several years for the benefits of PC screening to become evident. Therefore, the steady 
state for the reduction of the relative mortality rate, which is the final effect of screening, 
remained undefined in these studies. An estimate of the steady state for the reduction 
of the relative mortality rate was made by Hanley et al. who showed in a time-specific 
re-analysis of the ERSPC that the relative mortality reduction is expected to increase. 
The time-specific re-analysis of the PC-related deaths that occurred in the first 12 years 
of follow-up suggested that if screening were to be carried out for several years, and if 
the follow-up were pursued into the window where the reduction in mortality becomes 
manifest, the relative mortality reduction would be 50–60%277.
14.3 PART III
A randomised controlled trial is the most reliable method for determining the effects of 
screening because participants are assigned to one of the two study arms on the basis 
of chance278. The effect of screening is evaluated by comparing the number of cancer-
specific deaths in the intervention and control group per unit time279. Disease-specific 
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mortality is considered to be the optimal surrogate endpoint, but actually all-cause mor-
tality is a superior endpoint because it also has the potential to measure the unexpected 
lethal side effects of screening. Whilst all-cause mortality might be the ideal endpoint, 
in practice, the relatively small contribution of disease-specific mortality to all-cause 
mortality means that no screening trial can feasibly be powered to show an effect on all-
cause mortality. Assuming a 30% relative reduction in disease-specific mortality would 
require that more than 3 million men be randomised to show a statistically significant 
0.7% relative reduction in all-cause mortality (assuming a median nine-year follow-up 
and a 15% overall mortality over the 9-year period). In other words, disease-specific 
mortality is defined as the endpoint of a screening trial because it is numerically impos-
sible to show a benefit in the all-cause mortality. Nevertheless, it would be preferable to 
have a measure that can capture the unexpected lethal side effects of the intervention. 
In chapters 7 through 10, we described an alternative surrogate endpoint, i.e., excess 
mortality. Excess mortality is defined as the difference between the actually observed 
and the expected number of deaths. As a result, an excess mortality analysis measures 
the difference between the mortality in a group of patients and the mortality in that 
group that would be expected in the absence of cancer.
In a randomised controlled cancer screening trial, the cause of death is based on the most 
likely primary cause of death. This is recorded on the death certificate or is determined 
by a cause-of-death committee that reviews patients’ medical records using predeter-
mined clinical algorithms. Participants that are diagnosed with cancer are considered 
to die from either the cancer of interest or an intercurrent cause of death. Participants 
that were not diagnosed with cancer during their lifetime are considered to have died 
from an intercurrent cause. Cause-of-death committees are required in randomised 
controlled trials to ensure a correct interpretation of the mortality results133, 280. Using 
these committees, the cause of death is based on the consensus of independent review-
ers who have gathered all of the available information from hospital charts, outpatient 
visit letters, laboratory results and reports from pathology and radiology153. Ideally, the 
review is carried out in a ‘blinded’ fashion, where the reviewers are unaware of the trial 
arm to which the subject belongs. In practise, however, it may be difficult to achieve this 
blinding because information about screening is likely to be included in the notes, e.g., 
the clinical stage at the time diagnosis and information provided during the patient’s 
consultation with a general practitioner or urologist is illustrative for determining the 
patient’s screening status. Cancer screening aims to provide an earlier diagnosis. As a 
result, the cancer incidence is typically significantly higher in the intervention group in 
randomised controlled trials. Consequently, the causes of death in men that are partici-
pating in the intervention group are more frequently based on the death certificate or 
on the consensus of the cause-of-death committee. Because more subjects are reviewed 
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in the intervention group, it is assumed that there is no cause of death ascertainment-
bias to ensure the principal of randomisation. All potential misclassifications that can 
occur during the process of ascertaining the cause of death are assumed to be equally 
distributed. If not, any such bias would be larger in the intervention group due to the 
imbalance in the cause-of-death evaluations. This may result in a net bias. For many 
types of cancer, it can be difficult to determine whether the patient died entirely due 
to the cancer in question or due to completely unrelated causes. Especially for patients 
who die at relatively older ages and have a considerable number of co-morbidities, the 
dichotomy seems to be difficult to assess. Studies that have questioned the validity of 
death-certificate-assigned causes of death in cancer and studies that have reviewed the 
agreement between death certificates and the consensus of the cause-of-death com-
mittee have revealed inaccurate coding, with increased levels of inaccuracy for individu-
als who die at an older age and have an advanced clinical stage of disease at the time of 
diagnosis133, 137, 281-283. Therefore, cause-specific mortality as an endpoint of randomised 
controlled trials for cancer screening might be biased due to the determination of the 
end point. Consequently, it would be desirable to have an additional surrogate endpoint 
to verify this potential bias. In chapters 7 through 10, we demonstrate that excess mor-
tality can be used to verify the validity of the disease-specific mortality outcomes in a 
randomised controlled trial.
We concluded that in any randomised controlled trial with disease-specific mortal-
ity as an endpoint, an additional excess mortality study is mandatory as it may reveal 
additional important information. However, we did not advise the replacement of 
disease-specific mortality with excess mortality as the optimal surrogate endpoint of 
a randomised controlled trial of cancer screening. Hence, excess mortality is a comple-
mentary approach to disease-specific mortality because it measures a different param-
eter. In a PC screening trial, disease-specific mortality refers to the mortality rate that is 
directly related to PC due to causes such as disease progression and treatment-related 
mortality. Excess mortality measures both the direct and indirect mortality due to PC, 
e.g., including cachexia, uraemia, suicidal depression and the loss of interest in life. In 
addition, an excess mortality analysis may not be superior because it is also subject to 
uncertainty and potential bias. Most of these sources of uncertainty and bias are pre-
sented and discussed in chapter 7.
A valid estimation of the expected mortality is the key assumption of an excess mor-
tality analysis, and this is the main limitation of such an analysis. To perform an accurate 
excess mortality analysis, the expected mortality in a group of men with PC is assumed 
to be equal to the expected mortality in the non-cancer group if the group with cancer 
had no cancer. In PC analyses, this assumption is often difficult to make. In general, 
men who are diagnosed with a screen-detected cancer are healthier and of higher so-
cioeconomic classes than men in the general population162, 181. Therefore, as shown in 
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chapters 7 and 8, the national population is not an appropriate reference group for the 
estimation of the expected mortality in a PC screening trial, and adjusted estimates are 
needed. A major limitation of an excess mortality analysis in general is that no test is 
available to test the key assumption of the analysis, i.e., the correctness of the estimate 
of the expected mortality. One method for validation is to estimate the interval-specific 
excess mortality ratios, suggested by Dickman et al252. This method might be useful for 
excess mortality estimations in cancers such as those of the stomach and pancreas, with 
no excess mortality 6-8 years after diagnosis284. For these cancers, the interval-specific 
excess mortality ratio is expected to be approximately 0 at 8 years after diagnosis. 
Consequently, an excess mortality ratio at the interval 8 years after diagnosis would be 
representative for a valid estimation of the expected mortality (Figure 4). However, this 
method is not useful for cancers such as those of the prostate or breast, where excess 
mortality remains at a relatively constant level for many years following diagnosis (Fig-
ure 4)284. Therefore, an alternative validation method is needed. Meanwhile, as long as 
a standardised method to validate the expected mortality is lacking, the interpretation 
and value of the excess mortality analyses remain questionable.
We applied a method to validate the data presented in chapter 8 and 9, which was not 
described in the method sections of the chapters. This verification method contains a test 
that measures the accuracy of the expected mortality. The method is possible in studies 
that have based the expected mortality on the non-cancer-diagnosed participants in 
a randomised controlled trial for cancer screening (the method performed in chapters 
8 and 9). The validation process begins with taking a random sample of approximately 
1000 participants without cancer from the study population. These participants are 
roughly similar (e.g., regarding screening attendance, age at diagnosis, date randomisa-
tion) to the cases that were diagnosed with cancer; the only exception is that the random 
sample cases were not diagnosed with cancer. In addition, the excess number of deaths 
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stomach (left graph) and female breast (right graph) in Finland, obtained with permission from 145. 
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is defined as the difference between the observed number of deaths in the random 
sample and the expected number of deaths determined using a bootstrap method. The 
outcome of this estimation is expected to be approximately 0. If this is the case, it means 
that the expected mortality is estimated with good confidence. Our validation test is 
feasible and does not require difficult routines in statistical packages. Most importantly, 
it allows for quantification of the main assumption and, if the assumption is proven, it 
supports the excess mortality results. Therefore, this validation test should become a 
standardised method in all future excess mortality estimations.
Both the two studies presented in chapters 8 and 9 are limited by the lack of a statisti-
cally significant difference between the excess mortality rates. In chapters 8 and 9, excess 
mortality rate ratios were compared with the disease-specific mortality rate ratios. The 
confidence intervals of the disease-specific mortality rate ratios were narrower than the 
confidence intervals of the excess mortality rate ratios. The 95% confidence interval of 
the excess-mortality rate ratio was assessed by means of the delta method (chapters 8 
and 9, appendix 1) with the observed number of deaths per study arm in cancer patients 
and the expected number of deaths per study arm in cancer patients not assumed to 
be constants because they depends on the number of PC cases per study arm and the 
chances of patient survival (a source of extra random variation). In contrast, the ratio of 
disease-specific mortality in the intervention group to the mortality in the control group 
was estimated by means of a Poisson regression analysis with the observed number of 
deaths per study arm in cancer patients regarded as constant. Consequently, it is evident 
that in some cases, it may be difficult to know the cause of death in cases of PC. For 
this reason, in the ERSPC study, efforts have been made to optimise the accuracy of 
the assessment of the cause of death in PC patients using a committee. Despite this, 
it remains impossible to confirm cases of PC-specific death without any uncertainty. 
For example, the cause of death often differed after the case was reviewed by three 
independent persons who did not exchange opinions about the case. Consequently, we 
might account for these uncertainties when estimating the 95% confidence interval of 
the disease-specific mortality rate ratio. For example, if the confidence interval for the 
disease-specific mortality rate ratio accounted for 5% of 10% uncertainty in cases of 
PC-related mortality, the RR with a 95%CI was not RR 0.79 (95%CI, 0.66-0.95), but rather 
RR 0.79 (95%CI, 0.62-0.99) and RR 0.79 (95%CI, 0.59-1.02), respectively, for 5% and 10% 
uncertainty in the number of PC-specific deaths in both the two study arms.
The results described in chapter 8 suggest that the effect of PC screening on mortal-
ity is larger than reported in the analyses that focussed on disease-specific mortality 
only, especially in men who were 70-74 years of age at the time of randomisation. This 
contains an additional segment of disease-related mortality that is measured with an 
excess mortality analysis, but not with a disease-specific mortality analysis. As discussed 
in chapters 7 through 10, disease-specific mortality may miss important benefits of 
206 Chapter 14
cancer screening because of misclassification of the causes of death. On the other 
hand, the difference might be explained by the observed deviance in non-PC mortality 
in screen- and clinically diagnosed PC (chapter 10). Men with clinically diagnosed PC 
were found to be at an increased risk of death due to causes unrelated to PC itself (a 
significantly increased risk of dying from neoplasms and diseases of the circulatory or 
respiratory system was detected). These findings should be subject of further research. 
To date, there is limited evidence available that men with PC have an increased risk of 
having a non-PC related causes of death. Based on our findings, components of meta-
bolic syndrome might be associated with an increased risk for PC progression. These 
components, including obesity, an abdominal fat distribution and hyperinsulinaemia, 
should be investigated further285-286. It is known that metabolic syndrome is a major risk 
factor for cardiovascular disease and adult-onset or type 2 diabetes mellitus287. The find-
ings described in chapters 8 and 10 suggest that lifestyle interventions that were related 
to a diagnosis with screen-detected cancer have had a major impact in decreasing the 
risk of non-PC-specific mortality. Apart from changes in lifestyle, other health problems 
unrelated to PC may be detected and treated earlier, which may lead to improvements 
in the life expectancy. For this reasons, studies are needed to assess the role of changes 
in lifestyle, the use of medications and medical interventions after PC screening. In 
addition, studies that assess the mechanisms of the preventive effects of medications, 
such as statins, on the natural history of PC are of interest with respect to the findings 
presented in chapters 8 and 10197-198.
A 24% relative effect of screening was measured by use of the excess mortality analy-
sis presented in chapter 9. However, more arguments than just a reduction in mortality 
are needed to support the introduction of population-based screening. Firm evidence 
of the positive effects is needed to outweigh the costs, both economic and in terms of 
quality of life, of adoption of screening in the general population (chapter 2). A clear 
consequence of the excess mortality analyses is that screening reduces rate of PC-
related mortality, while side effects of the screening procedure (e.g., anxiety, depression 
and related to a PC diagnosis) are unlikely to cause an increased risk of death.
14.3 PART IV
Part IV of this thesis aims to improve the currently used screening, early detection and 
treatment strategies. It includes an optimisation of the screening algorithm to poten-
tially increase the PC mortality reduction, and particularly, the prevention of unneces-
sary biopsies as well as the selective detection of clinically significant PCs to reduce 
overdiagnosis. Finally, it discusses the difficulties that men have who are diagnosed with 
localised PC and consider curative treatment.
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The screening programme currently used by the ERSPC might need improvement 
in the following areas. Today, the most significant negative effects of a PC screening 
programme are overdiagnosis and the healthy life years that are lost due to an earlier PC 
diagnosis as a result of screening. Consequently, to improve the health benefit trade-off, 
the overdiagnosis has to be reduced. Furthermore, the diagnosis of a screen-detected 
cancer might be postponed while having the same positive effect of reducing the PC 
mortality rate. Furthermore, the number of biopsies has to be reduced, even as a signifi-
cant side effect of invasive treatment of PC.
PC screening using a serum PSA-based threshold as a sole indicator for prostate 
biopsy lacks specificity. This results in large numbers of unnecessary biopsies and 
detection of indolent PCs, but it also misses significant cancer diagnoses in men with 
PSA levels below the chosen PSA cut-off value72, 74. Future screening strategies should 
aim to reduce the number of potentially unnecessary biopsies and potentially indolent 
PC diagnoses using risk-profile-based cut-off values as indicators for prostate biopsy. 
However, despite numerous attempts to assemble a set of risk factors for PC, no indi-
vidualised screening strategy utilising such stratifications has been introduced to date. 
Only hypothetical exercises have emerged. These show that an individualised screening 
algorithm using other available prebiopsy information (e.g., family history, DRE, TRUS 
findings, prostate volume) in addition to the PSA level can result in a considerable re-
duction of unnecessary biopsies and detection of insignificant PC227-228. In addition, new 
PC markers in serum and urine, in conjunction with these models, have been shown to 
improve their sensitivity and specificity288. The hypothetical models have clear implica-
tions for the improvement of screening strategies, making a first step toward the defini-
tion of a patient’s individual risk. The models could be the basis for future individual 
risk-based screening protocols, with factors such as screening interval, age of cessation 
of screening and the number of biopsies taken based on the patient’s individual risk. 
Multivariate risk stratifications seem to be the proper future approach because novel 
‘perfect markers’, with high sensitivity and specificity, are far from being introduced for 
clinical use and screening programmes289. Most recent discoveries, such as the gene-
fusion TMPRSS2:ERG or prostate cancer antigen 3 (PCA3), are not able to replace PSA 
while improving its performance290-291. Therefore, while basic research remains the 
main priority, improvement of PC screening seems to be restricted to screening based 
on patients individual age, comorbidity, family history, PSA, DRE and prostate volume, 
with incorporation of new makers such as TMPRSS2:ERG and PCA3. Finally, these risk 
strategies should be able to differentiate between ‘low-risk’ cancers that are not likely to 
become harmful during a patient’s life and ‘high-risk’ cancers that require interventions.
To date, the most commonly recommended screening interval is annual292-293. In the 
ERSPC, screening intervals of 2 and 4 years were used. In chapter 11, the proportional 
interval of cancer incidence was studied comparing a 2-year with a 4-year screening 
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interval. We concluded that the effectiveness of screening might be increased with a 
shorter screening interval. However, the data in chapter 11 show that a fixed biannual 
screening interval will still be too long for some cancers but is too short for most other 
cancers. Since overdiagnosis remains the major limitation of PC screening, it is unjustified 
to recommend a fixed screening interval in future screening algorithms. Nevertheless, 
the outcomes of the work described in chapter 11 have clear clinical implications. This 
study showed for the first time that some men can benefit from more frequent screen-
ings. Consequently, individual risk factors might be defined to select subgroups that are 
likely to benefit from shorter screening intervals. In chapter 6 and in [263, 285-286], it 
is shown that individualised screening intervals can be defined based on baseline PSA 
measurements. This supports the use of close surveillance with a more frequent screen-
ing interval for some and an extended screening interval for others. This approach will 
prevent unnecessary biopsies, tests and visits.
Using an individual risk-based strategy to define the optimal screening interval is an 
approach that is currently available to reduce overdiagnosis. Consequently, more as-
pects of the screening algorithm should be based on the patient’s individual risk. There 
is limited research addressing the mortality reduction due to screening among older 
men, with the optimal age of PC screening cessation remaining uncertain. It is known 
that overdiagnosis increases with age at the time of screening129. However, the optimal 
age of cessation of PC screening should be defined by more factors than age alone. 
There is great variation in the number and severity of comorbities, suggesting that a 
screening algorithm based solely on chronologic age will be incomplete. Life expectancy 
decreases not only with increasing age, but also with the number and severity of chronic 
diseases and the level of functional decline294. Health, functional status, and comorbidity 
are the most appropriate indicators of expected life span, compared with chronological 
age alone295-296. In addition, smoking, obesity and being overweight are associated with 
large decreases in life expectancy and increases in early mortality297. Predictions of life 
expectancy based on a multivariate set of co-morbidities are needed. These predictions 
must be incorporated in the decision of whether to continue or discontinue the screen-
ing procedure, e.g., whether to perform a biopsy or not.
To date, some PC guidelines recommend starting PSA testing at an age of 40 years292 
because PSA measurements before the age of 50 might help to risk-stratify men based 
on the frequency and/or type of later PC screening. Two studies have associated the 
serum PSA level with the long term risk of PC. Loeb et al. examined men in their 40s and 
showed that the subsequent PC diagnosis was 14.6-fold higher for men with a baseline 
PSA level between 0.7 and 2.5 ng/ml compared to men with PSA <0.7 ng/ml169. Lilja et al. 
assessed the PC risk among men younger than 50 years and showed that the PSA level 
at age 44–50 years was strongly associated with the likelihood of developing PC up to 25 
years later298. The odds ratio for a PC diagnosis at a PSA value of 0.51–1.0 ng/ml was 2.51 
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compared to PSA ≤0.50 ng/ml, which roughly corresponded to the population average. 
The odds ratio increased to 7.02 for a PSA of 1.0-1.5 ng/ml, and it increased further up 
to 19.01 for a PSA of 2.01-3.0 ng/ml compared to a PSA ≤0.50 ng/ml. Although these 
risk strategies are promising and in line with the results that are presented in chapter 6, 
it currently seems to be unjustified to lower the age of onset for PSA testing. Without a 
clear guideline for how to interpret the early PSA measurements and acceptable biopsy 
indications, lowering the age of screening onset will result in earlier diagnoses and in 
an undefined increase in overdiagnosis. Consequently, this will increase the number of 
years lived with cancer and increase the 62% negative effect estimated by Heijnsdijk et 
al. As a result, other changes to the screening algorithm seem to have a higher priority.
The number biopsies taken might also be based on a patient’s individual risk. In the 
ERSPC, sextant biopsies are used, although sextant biopsies are considered to be obso-
lete in current clinical practice. In clinical practice, for an initial biopsy, a minimum of 10 
but not >18 systematic cores are recommended, with 14-18 cores in glands ≥ 50 cm³. 
Further biopsy sets, either as extended repeats or as a saturation biopsies (≥20 cores), 
including the transition zone, are warranted in young and fit men with a persistent 
suspicion of PC299. Sextant biopsies are considered obsolete because extended biopsy 
schemes have been shown to increase the cancer detection rate170, 300. However, a gain 
in the cancer yield is only beneficial to the patients or participants when more clinically 
significant cancers are diagnosed without further increasing the detection of clinically 
insignificant PC. As the prostate volume is inversely related to cancer detection, this 
parameter is generally applied as an indicator for the number of cores per biopsy. Sub-
sequently, this hypothesis could also be obtained in a PC screening programme301-302. 
The hypothesis was tested in chapter 12. We found that, although a sextant biopsy 
was applied without considering prostate volume, men with smaller prostate gland 
volumes were at greater risk of aggressive cancer during the follow-up. In contrast, 
based on the hypothesis, an increased number of aggressive cancers was expected 
in the larger prostate gland volumes. We concluded that the volume-adjusted biopsy 
schemes should not be implemented automatically in a screening programme with 
repeated screening because this will further increase the rate of overdiagnosis. Lat-
eralised sextant biopsies miss approximately 19% of detectable cancers compared to 
a volume-adjusted biopsy protocol170, 299. However, the number of potentially missed 
cancers with a poor outcome in terms of progression-free survival and deaths from PC 
has been shown to be low170. The use of extended biopsy schemes is likely to detect 
more potentially indolent PCs and thus to increase the overdiagnosis and overtreat-
ment. Considering the dilemma of overdiagnosis and overtreatment, the usefulness of 
more extended biopsy schemes within this setting must be questioned. On the other 
hand, a percentage of potential clinically relevant cancers are clearly missed using 
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sextant biopsies. Therefore, extended biopsies might be introduced in future screen-
ing strategies. However, verification of the individual risk is needed first to decrease 
the number of biopsy indications and the detection of clinically insignificant cancers. 
Finally, the number of biopsies might not be solely based on the prostate volume, but 
also on the risk of ‘significant’ PC.
Another strategy to reduce overdiagnosis could be the primary prevention of PC. Mul-
tiple randomised trials of prevention strategies, including pharmaceutical, dietary, and 
supplementation, have been performed303. The most recent trials are the Selenium and 
Vitamine E Cancer Prevention Trial (SELECT), the Prostate Cancer Prevention Trial (PCPT) 
and REduction by DUtasteride of prostate Cancer Events (REDUCE trial). The SELECT 
showed no benefit of chemoprevention with vitamin E and selenium supplementation 
for reducing the incidence of PC304. The PCPT and REDUCE trial, which evaluated the use 
of 5α-reductase inhibitors (5ARI) with PC prevention as a primary endpoint, showed a 
successful result. In the PCPT, the period prevalence of PC was reduced by 24.8% in the 
5ARI (Finasteride) group compared with the placebo group (18.4% vs. 24.4%, P <.001)305. 
The REDUCE trial showed that the PC incidence decreased by 23% in men who received 
the 5ARI dutasteride in comparison to those who received a placebo after four years306. 
However, in the PCPT trial, the prevalence of high-grade tumours (Gleason score 7-10) 
detected through biopsy increased in the 5AR group (37.0% of all tumours) compared 
with the placebo group (22.2%; P <.001)305. These unfavourable outcomes in the PCPT 
seem to be based on study biases, i.e., (the detection was better in men with small 
prostate gland volumes). The REDUCE study has demonstrated that use of 5ARI is safe 
and effective for reducing the risk of cancer, regardless of the risk stratum307-309. If the 
incidence of PC with a Gleason score of 5-6 significantly can be reduced, and at the 
same time no increase in high-grade tumours with 5ARI use occurs, chemoprevention 
might have the potential to reduce the detection of favourable indolent disease, making 
screening more beneficial. However, more research is needed. Both trials were based 
on a study design in which men in both study arms (5ARI and placebo) were biopsied 
at a fixed interval without a clinical indication for biopsy. This study design makes the 
clinical implication difficult to determine. In patients with benign prostatic hyperplasia 
(BPH), 5-ARIs suppress serum PSA levels by about 50%, and when using 5-ARIs, the 
PSA kinetics are poor defined. To date, it is clear that a rise in PSA levels, but not their 
stabilisation, indicates a biopsy and the possible presence of Gleason 7–10 cancer310-311. 
However, additional information is needed to answer the question of what should be 
done if the PSA is not rising. Therefore, further research is needed to define which men 
might be treated with a 5ARI, and more importantly, what should be the indicator for a 
biopsy when using 5ARI. Until these results are available, primary prevention with 5ARI 
should not be recommended to decrease the risk of PC. This is in line with the recently 
published FDA policies.
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To date, population-based PC screening has not been introduced, and there is a wide 
variation in the detection strategies favoured among clinicians. In some countries, test-
ing for PC in asymptomatic men is permitted after men are informed of the potential 
benefits and costs293, 312-313. This seems to be ethically correct, however, the decision to 
screen for PC is not based solely on the facts about screening in clinical practice. The 
patient’s emotional state and the physician’s preference are of major influence. One of 
the arguments against screening is overdiagnosis; however, this is difficult to translate 
into men’s individual risk. When defining a patient’s individual risk, the potential ben-
efits of early detection are often considered more important than the potential harms. 
Nevertheless, it is the aim of physicians to provide the facts, allowing men to decide 
for or against screening. Therefore, physicians should use decision aids with PSA test-
ing. There is strong, consistent evidence that patient decision aids improve a patients’ 
understanding of PSA testing314. Most studies have indicated that decisional conflict is 
reduced among men who use a decision aid315. Secondly, physicians should be made 
aware of the risks of diagnosing PC based only on age and serum PSA. Nomograms 
and risk calculators have shown better accuracy than PSA in predicting the detection 
of PC through biopsy228. These tools, such as the SWOP/ERSPC risk calculator and the 
Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator, assess other 
factors, including digital rectal examination (DRE), family history for prostate cancer, a 
prior biopsy, race, and age. These tools have been shown to result in a considerable 
reduction in the number of unnecessary biopsies228, 316. A preliminary assessment of the 
risk of high-grade PC revealed by prostate biopsy can be made based on the PSA level, 
an abnormal digital rectal examination, and a family history of PC317-318. Both of these 
online risk calculators are user friendly319-320.
The risk calculators aim to allow men to understand the risks of PC in an individual 
setting. However, it remains questionable whether it will be possible for men to distin-
guish between the risks. Currently, the outcome of the risk calculators is the chance of 
a biopsy-detectable cancer, i.e., a score in the range of 0-100%321. Unfortunately, there 
is no threshold value defined for the overall cancer risk or for the high-grade cancer 
risk that should prompt a biopsy. Currently, the risk level at which a biopsy should be 
considered is based on factors related to a man’s life expectancy (age, comorbidities) as 
well as his level of concern regarding his risk. It is unclear whether patients are able to 
appreciate the difference between a 10% and 20% overall PC risk. Therefore, men’s life 
expectancy, based on age and comorbidity, might be added to the nomogram after 
which the nomogram should result in a positive or negative recommendation for biopsy 
without presenting the actual risk. Moreover, because high-grade tumours appear to 
pose the greatest risk and because there is a greater need to diagnose these high-grade 
cancers early, the risk of high-grade disease should be the primary determinant of the 
need for a prostate biopsy.
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The next challenging step in PC care occurs after screening and early diagnosis, i.e., 
the definition of the optimal treatment for men with localised PC. It can be a challenge 
to distinguish between patients who are at a higher risk of death from PC and those who 
are more likely to die from other causes. To date, there is no universally accepted defini-
tion of clinically significant or insignificant disease. Studies have shown that the cancer 
volume, clinical stage and tumour histology are important predictors of the long-term 
outcome21, 322-323. These characteristics are used to define which cancers should be treated 
and which can be managed expectantly. Based on these results, methods to reduce the 
overtreatment of indolent tumours have been implemented with active surveillance 
programmes for small, low-risk tumours. These programmes are urgently needed in 
conjunction with screening programmes to limit the increase in economic costs and to 
improve the overall quality of life outcomes. Sanda et al. reported on quality of life and 
satisfaction with the outcome following either surgery or radiation. Long-term incon-
tinence persists in 2-22% of patients, and erectile dysfunction affects 20-90% of men 
depending on factors such as the baseline sexual function, the age of the patient and 
surgical technique used109. In chapter 13, we have provided the disease outcomes for 990 
men with localised screen-detected PC who were treated with a radical prostatectomy. 
The results contribute to the understanding of treatment effectiveness among men with 
screen-detected localised PC stratified by the patients’ clinical characteristics. The pa-
tient age, tumour stage and Gleason score provided the most relevant data concerning 
the likelihood of dying from PC. According to the data presented in chapter 13, men who 
harbour tumours with a Gleason score larger than 7 are at a significant risk of death from 
PC. These men should consider aggressive treatment, such as radical surgery. By con-
trast, a large group of men with low-risk PC might have had similar outcomes with active 
surveillance. Several studies have shown outcomes from large, observational cohorts of 
men who have selected active surveillance as a treatment alternative41-42, 257, 324. These 
studies suggested that active surveillance is a viable treatment option for men with low-
grade, early-stage, and favourable-risk PC with limited life expectancy. The benefits of 
active surveillance are clear: This approach avoids the side effects associated with other 
treatment options, such as erectile dysfunction or incontinence. However, cancer spread 
during surveillance remains a great risk, and it requires lifetime of regular testing with 
PSA, DRE and biopsies. Therefore, it is questionable whether active surveillance is an 
adequate solution to the problem of overdiagnosis associated with screening. Recently, 
a retrospective analysis by Stattin et al. showed that among those with low-risk disease, 
the calculated cumulative 10-year PC-specific mortality was 2.4% in the surveillance 
group and 0.7% in the group that underwent surgery and radiation therapy258. These 
results seem to be in favour of curative treatment; however, a careful interpretation of 
the results reveals that 1427 men required curative treatment to save one man from PC 
death over a period of 10 years. The data highlight the present and future dilemma. An 
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upcoming RCT will possibly show a small benefit of surgery or radiation therapy over 
active surveillance; however, a large number of men would require curative treatment to 
prevent one PC-specific death. This leads to the question of how patients should be in-
formed and what information should be given. Consolation with a man diagnosed with 
localised, low-risk PC will be extremely difficult. Emotions will frequently stimulate the 
patient to choose the smaller benefit and thus opt for the curative treatment. Based on 
data on overdiagnosis and observational active surveillance, active surveillance can be 
considered as a treatment option. However, until better biomarkers for indolent disease 
are identified, we should bear in mind that the risk of disease progression persists no 
matter how small or well differentiated the disease seems to be. Therefore, more effort 
is needed to reduce the diagnosis of the low-risk cancers because the diagnosis of these 
cancers is too likely to result in curative treatment. Diagnostic tools that specify which 
cancers to detect and which cancers not to detect would be preferable.
14.5 CONCLUSIONS
To date, convincing evidence is lacking that PC screening is effective in PC mortality 
reduction or that it produces a beneficial net effect, i.e., the benefits exceed the adverse 
effects, such as overtreatment and overdiagnosis. Moreover, it is uncertain if the lack 
of a net effect will be solved by the expected increase in PC mortality reduction after a 
longer follow-up of the on-going randomised controlled trials of PC screening. A current 
problem is the inability to target men at risk of developing or harbouring not just histo-
logical PC, but also a significant disease that requires intervention. Strategies that aim 
to reduce overtreatment by not treating low-risk cases of PC and keeping them in the 
window of curability are still in the experimental phase. Establishing population-based 
screening for PC as a health policy will depend on lowering the rate of overdiagnosis 
while focusing on methods for more selective screening and achieving an acceptable 
risk-benefit ratio. This thesis contains significant information addressing this dilemma 
and recommends adjustments in the screening strategy. The following conclusions are 
drawn:
- The effect of PC screening on the PC mortality and metastases are underestimated 
by the on-going randomised controlled trials due to the effect of PSA testing (con-
tamination) on the control populations in the trials.
- Overdiagnosis, and thus the NNT, are underestimated by the on-going randomised 
controlled trials due to the effect of PSA testing (contamination) in the control popu-
lations of the trials.
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- The baseline serum PSA level before diagnosis is a strong predictor of PC mortality in 
screen-detected and clinically detected PC.
- For men with a low serum PSA, the benefits of aggressive testing and treatment 
seem to be limited because they are associated with a large increase in the cumula-
tive incidence and potential overtreatment.
- The estimation of excess mortality can be used in future studies to evaluate the ef-
fects of screening on PC mortality.
- The excess mortality analysis further strengthens previous reports on a beneficial 
effect of PSA screening.
- In any randomised study with disease-specific mortality reduction as an endpoint, an 
additional excess mortality study should be mandatory, as it may reveal additional 
important information regarding the effect of screening.
- Screening reduces the PC mortality while side effects of the screening procedure 
(e.g., anxiety and depression related to a PC diagnosis) do not increase the risks of 
all-cause death.
- Men with clinically diagnosed PC are at an increased risk of death unrelated to PC 
itself.
- A programme with a 2-year, as opposed to a 4-year, screening interval leads to a 
significant reduction in the incidence of advanced cancer but is associated with an 
increase in the incidence of “low-risk” screen-detected PC.
- A patient-specific screening interval seems to be the most efficient approach, as 
some men benefit from more frequent screenings, but most do not.
- Men with a smaller prostate gland volume are at an increased risk of harbouring 
tumour cells and developing an aggressive cancer.
- For men with high-grade PC, PC remained a major cause of death despite early 
detection through screening followed by radical prostatectomy and screening.
- The disease-specific survival of localised screen-detected cancers that are treated 
by radical surgery is lengthened due to diagnosis at an earlier point in time and the 
treatment of men who probably would never have presented clinical symptoms of 
PC in the absence of screening.
14.5 fUTURE PERSPECTIVE
If PC screening is implemented as a strategy to significantly decrease the mortality from 
PC, while considering and improving the overall quality of life aspects, the overall ben-
efits of screening will increase during the next decades. Due to the ageing of the general 
population, the total rate of PC-specific mortality is expected to increase by 131% in the 
Netherlands between 2010 and 2050, from 2524 PC-related deaths to 5855 PC-related 
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deaths269. Assuming a 20% relative reduction in PC mortality as an effect of screening 
in the general Dutch population, screening would prevent 505 PC deaths in the total 
Dutch population in 2010 and 1711 PC deaths in 2050. Meanwhile, ageing of the na-
tional population will have a large impact on the incidence PC. The total incidence of PC 
is expected to increase from 9905 new cases in 2010 to 14967 new cases in 2035, assum-
ing no increase in the frequency of PSA testing (Figure 1). Assuming an age-specific 50% 
overdiagnosis as a result of introducing population-based PC screening, the incidence 
would increase by 126% to 22450 new cases in 2035.
These future estimates indicate that we are faced with a significant dilemma related 
to PC. Therefore, we need to make decisions regarding how to continue our research on 
population-based PC screening. PC screening has proven to be effective for reducing the 
PC-specific mortality by providing level 1a evidence. However, it has been shown to be 
associated with a disproportionate increase in PC incidence. To improve the outcomes 
of population-based screening for PC, two future directions are possible.
1. Do more: Optimise PSA-based screening by lowering the PSA cut-off, shortening 
the screening interval and decreasing the age at which screening begins. This might 
increase the reduction in PC-specific mortality and the incidence of metastatic dis-
ease. Furthermore, it might positively affect the rate of all-cause mortality among 
men with screen-detected PC due to an early change in their medical regimens for 
co-morbidities. However, the more intensive screening strategy will certainly signifi-
cantly increase the harm associated with screening.
2. Do less: Introduce screening based on individualised risks. Make the screening 
intervals as long as possible, discontinue repeated screening in men as soon as pos-
sible, and define biopsy cut-offs based on a multivariate set of predictions that are 
based on the prediction of “significant PC”. This will require ways to predict which 
individuals are likely to develop high-risk cancers. Studies with this focus might 
result in fewer biopsies and diagnoses and thus in harm-benefit tradeoffs that justify 
introduction of population-based screening in the future.
Finally, we have to realise that population-based screening has the potential to reduce 
mortality from PC but not to completely eliminate PC mortality from the general popu-
lation. There will always be cancers that will escape detection despite screening. To save 
or cure the men with these exceptional cancers, other prevention strategies or treat-
ments are indicated. Wilson and Junger stated in 1968: “the condition sought should 
be an important health problem”. This means that population-based screening is not 
the optimal strategy to prevent death or progression in these few cancers that escape 
detection through the current programme.
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14.6 APPENdIx
Explanation of the statistical measures used in the general discussion.
The Number Needed to Screen (NNS) or Number Needed to Investigate (NNI) are pre-
sented as,
 NNS = NNI = (1/absolute reduction in PC mortality),
where the absolute mortality reduction is based on the absolute difference between 
the mortality rate in two populations. In the general discussion, the absolute difference 
in mortality is defined as the number of deaths per 10,000 person-years in the control 
population minus the number of deaths per 10,000 person-years in the screening popu-
lation.
The absolute difference in mortality = ((number deaths/10,000 person-years) control 
group) - ((number deaths/10,000 person-years) screening group).
The Number Needed to Treat (NNT) is presented as,
 NNT = ((1/absolute reduction in PC mortality) * excess incidence),
 NNT = ((NNS) * excess incidence),
Where the excess incidence is reduction is based on the absolute difference between 
the incidence rate in two populations. In the general discussion, the excess incidence 
is defined as the number of cancers diagnosed per 10,000 person-years in the screen-
ing population minus the number of cancers diagnosed per 10,000 person-years in the 
control population,
Excess incidence= ((the number of cancers diagnosed/10,000 person-years) screening 
group) − (the number of cancers diagnosed/10,000 person-years) control group).
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Summary
Prostate cancer is the most common cancer among men in the Netherlands. A total of 
9500 men were diagnosed with prostate cancer, and 2300 died from prostate cancer-
related causes in the Netherlands in 2006.
During the last three decades, many researchers have tried to assess the effectiveness 
of screening for prostate cancer. The objective of early detection (screening) is to detect 
a disease at a stage in its natural history where treatment can be applied to prevent 
death or suffering. By use of digital rectal examination (DRE) and prostate specific 
antigen (PSA), it is possible to diagnose prostate cancer at an earlier clinical stage. The 
European Randomised Study of Screening for Prostate Cancer (ERSPC) was begun in the 
early 1990s to study the effect of population-based screening for prostate cancer on the 
prostate cancer mortality rates and the quality of life. Today, it is known that screening 
has the potential to decrease the rate of prostate cancer-specific mortality significantly. 
However, prostate cancer screening is also associated with significant negative effects. 
Due to screening, many prostate cancers are diagnosed that would otherwise remain 
clinically unrecognised until the individual died from other causes. Currently, 50% of 
all diagnosed prostate cancers are slow-growing tumours that will not result in clinical 
signs or symptoms during the patient’s lifetime. The diagnosis of these cancers is re-
ferred to as overdiagnosis. Overdiagnosis appears to be especially problematic when 
it results in invasive treatment of tumours that are unlikely to be harmful. This thesis, 
entitled “prostate cancer screening, the effect on mortality and incidence”, includes 
studies on the effectiveness of prostate cancer screening and studies that contribute to 
the improvement of the screening programme.
Chapter 1 contains a general introduction on the different aspects of prostate cancer 
diagnosis and treatment. Chapter 2 is a review of the prostate cancer screening studies 
up to 2011. Based on the results presented in chapter 2, we concluded that screening 
for prostate cancer reduces the disease-specific mortality significantly. Nevertheless, 
there is no scientific basis for the introduction of a population-based prostate cancer 
screening programme because a number of essential criteria have not been met. For 
example, no robust evidence is available regarding the economical and quality-of-life 
implications of screening for prostate cancer. Chapter 3 comprises an overview of the 
value of measuring the trends in prostate cancer incidence, survival and mortality. The 
interpretations of these trends have shown to be confusing without proper knowledge 
of the natural history of prostate cancer and the statistical measures. We showed that 
trends in prostate cancer incidence are not reliable for measuring the increases in envi-
ronmental risk factors, as the practices in screening and early detection have changed 
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more than necessary during the last two decades. Trends in prostate cancer survival are 
suspected to be unreliable because they are based on the same series of patients as 
incidence rates, and any inflation of incidence due to the inclusion of less malignant or 
nonmalignant diseases creates a spurious increase in survival rates. As a result, prostate 
cancer survival rates should be interpreted with caution and with the knowledge of 
the effects of lead time, length time and overdiagnosis on survival outcomes. Trends in 
prostate cancer mortality are the principal measures through which the success of the 
different interventions on a population basis can be determined. Because the mortality 
rate measures of the number of deaths (in general, or due to a specific cause) in some 
populations are scaled to the size of those populations per unit time, the measure is not 
biased by the number of cancers diagnosed.
In chapters 5 and 6, we studied the effect of prostate cancer screening on the prostate 
cancer mortality rate and incidence. In chapter 5, we compared two populations, 11,970 
men in the Netherlands and 133,287 men Northern Ireland. Men in the Netherlands 
received systematic screening, and men in Northern Ireland receive usual care. During 
follow-up (median 9 year), 1,153 men (9.6%) were diagnosed with prostate cancer in 
the screening group (the Netherlands), and 3,962 men (3.0%) were diagnosed in the 
control group (Northern Ireland). In the screening group, 35 (0.29%) men, and in the 
control cohort 627 (0.47%) men, died due to prostate cancer. This equated to a reduc-
tion in prostate cancer mortality of 37% in the intervention population relative to the 
control population: RR 0.63 (95%CI, 0.45-0.88, p=0.008). Therefore, 555 men needed to 
be screened to prevent one prostate cancer death. In chapter 6, we tried to identify men, 
stratified by serum PSA, who would potentially gain the most benefit from prostate can-
cer screening. We showed that the potential harms of repeated screening exceeded the 
potential benefits in men aged 55-74 years with a serum PSA 0.1 to 1.9 ng/ml. The main 
conclusion was that in men with a low baseline serum PSA, the benefits of continued 
aggressive investigation and treatment may be limited, whilst they are associated with a 
large increase in cumulative incidence, overtreatment and costs.
In part 3 (chapters 7 through 10), of this thesis we aimed to assess the effect of prostate 
cancer screening on the excess mortality. Excess mortality is defined as the difference 
between the total (all-cause) mortality of the patients and the mortality that would be 
expected in the absence of cancer. In chapter 7, we described a method for performing a 
robust excess mortality analysis in a randomised control cancer screening trial. Chapters 
8 through 10 present the results of the excess mortality analysis. Chapter 8 is based on 
the analysis of 42,376 men that were randomised to systematic screening or usual care 
in the ERSPC the Netherlands. After a median follow-up, the disease-specific mortality 
rate was 0.42 men per 1000 person-years in the intervention and 0.48 men per 1000 
person-years in the control arm: RR 0.86 (95%CI, 0.64-1.17). The excess mortality rate 
was 0.40 per 1000 person-years in the intervention arm and 0.61 men per 1000 person-
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years in the control arm, and the RR for excess mortality was 0.66 (95%CI, 0.39-1.13). The 
difference was mainly among men aged 70-74 year at randomisation. In other words, 
we found a between-arm difference in the excess mortality rates that was more than 
twofold the between-arm difference in the disease-specific mortality rates. Two possible 
explanations for the observed discrepancy were found for this observation: 1) a system-
atic underestimation of the number of deaths from prostate cancer by the cause-of-
death committee of the study; 2) additional disease-related mortality that is measured 
by an excess mortality analysis but not with a disease-specific mortality. The main results 
found in chapter 8 were studied in more detail in chapter 10. This additional analysis 
confirmed that men with clinically diagnosed prostate cancer were at an increased risk 
of death unrelated to prostate cancer itself (increased excess mortality relative to the 
disease-specific mortality). The excess mortality was due to a significantly increased 
risk of dying from neoplasm and diseases of the circulatory or respiratory system. Many 
effects might have influenced these observations; however, the relatively increased use 
of hormone treatment in clinically diagnosed prostate cancer and the change of medical 
regimes and medication among men with screen-detected prostate cancer may have 
had the most influence. As a result, we concluded that if changes in the medical regimens 
do affect all-cause mortality in men with prostate cancer, uro-oncologists should look 
carefully at the management of abnormal parameters of the circulatory and respiratory 
system, and they should encourage prostate cancer patients to make lifestyle modifica-
tions. In chapter 9, we studied the excess mortality in prostate cancer screening based 
on data from the four largest centres of the European Randomised Study of Screening 
for Prostate Cancer (ERSPC). For this analysis, a total of 141578 men, aged 55-69 years, 
were randomised into groups that received either systematic screening or usual care in 
the ERSPC sections of Finland, Italy, the Netherlands and Sweden. After a mean follow-
up of nine years, the prostate cancer incidence rate was 9.24 per 1000 person-years in 
the intervention arm and 5.49 per 1000 person-years in the control arm, RR 1.68 (95%CI 
1.61-1.75). The excess mortality rate was 0.29 per 1000 person-years in the intervention 
arm and 0.36 men per 1000 person-years in the control arm; the RR for excess mortality 
was 0.76 (95%CI, 0.54-1.07). We concluded that PSA-based screening had a clear benefit 
on the excess mortality and that the estimated excess mortality reduction of 24% was 
in excellent agreement with the disease-specific mortality that was reported in a previ-
ous report by our group, implying that PSA-based screening is effective in reducing the 
mortality from prostate cancer.
Chapter 11 aimed to assess the optimal interval (time between two screening rounds) 
for prostate cancer screening. The rate of decrease in advanced cancers was estimated 
for a programme using a 2-year and one using a 4-year interval to determine the cancer 
screening programme effectiveness. Men aged 55-64 years from two centres of the ER-
SPC- Gothenburg (2-year screening interval, n=4202) and Rotterdam (4-year screening 
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interval, n=13,301) were included. The results showed that screening with a 2-year or 
a 4-year interval both significantly reduced the risk of being diagnosed with advanced 
cancer. A 2-year screening interval significantly reduced the incidence of advanced 
prostate cancer up to 43% relative to a programme that used a 4-year interval. The 
screening programmes that used more frequent screening were found to be associated 
with increased numbers of investigations and overall cancer incidence. Chapter 12 
contains an evaluation of the use of sextant biopsies in men with larger prostate glands 
who participated in a screening programme with a 4-year interval. Men with smaller 
prostate volumes and initially high serum PSA levels were at a greater risk of cancer 
detection and an aggressive cancer during the follow-up. We concluded that the use in 
clinical practice of volume-adjusted biopsy schemes should not be implemented auto-
matically in screening programmes with repeated screening. In chapter 13, a competing 
risk stratification (dying from prostate cancer or another cause of death) was made for 
men with localised prostate cancer who consider treatment with radical surgery. We 
found that men with a screen-detected clinically localised prostate cancer treated by 
radical surgery have a heterogeneous risk of dying either from prostate or other causes 
depending on their age and the histological characteristics of the biopsy specimen. Men 
aged 55-74 years at diagnosis with tumours that have Gleason scores of ≤6, 7 and ≥8, 
face a 2.1%, 4.2% or 16.1% probability, respectively, of dying from prostate cancer within 
12 years of diagnosis. The relative contribution of deaths unrelated to prostate itself 
increased with advancing age and decreasing Gleason scores. We concluded that for 
men with high-grade prostate cancer, prostate cancer remained a major cause of death 
despite early detection by screening followed by radical prostatectomy and screening.
The results of this thesis described in parts 1 through 4 are discussed in part 5. In 
this part, the results described in this thesis are discussed in relation to the most recent 
literature and suggestions for further research are mentioned.
Samenvatting (Dutch)
Prostaatkanker is de meest voorkomende maligniteit onder mannen in Nederland. In het 
jaar 2006 werden er 9500 mannen gediagnosticeerd met prostaatkanker en overleden 
in totaal 2300 mannen aan de gevolgen van prostaatkanker. Hiermee is prostaatkanker 
één van de belangrijkste gezondheidsproblemen voor mannen in Nederland. In 1993 
heeft dit geresulteerd in de start van een uitgebreid onderzoek naar de effectiviteit van 
de vroege opsporing van prostaatkanker in acht Europese landen.
Na de ontdekking van het prostaat specifiek antigeen (PSA), en het bewijs dat PSA 
als een serum marker voor de detectie van prostaatkanker kon worden gebruikt, kan 
prostaatkanker in een vroeg stadium worden gediagnosticeerd. Screening van pros-
taatkanker betreft het onderzoeken van een in principe gezonde populatie om de nog 
asymptomatische gevallen van prostaatkanker op het spoor te komen, in de veronder-
stelling dat de prostaatkanker in een vroeg stadium beter te behandelen is en hiermee 
de sterfte aan prostaatkanker kan worden verlaagd. De European Randomized Study of 
Screening for Prostate Cancer (ERSCP) is begin jaren negentig gestart om meer inzicht 
in te krijgen in de effectiviteit van screening naar prostaatkanker. Inmiddels is bekend 
dat door middel van screening de sterfte aan prostaatkanker kan worden verminderd. 
Screening op prostaatkanker brengt echter ook nadelen met zich mee. Bij een deel van 
de mannen ontwikkelt de prostaatkanker zich namelijk zo langzaam, dat mannen niet 
als gevolg van, maar wel met prostaatkanker overlijden. Bij sommige mannen blijft de 
tumor zo klein, dat ze er tijdens hun leven zelfs geen klachten van ondervinden. Wanneer 
bij deze mannen de tumor door middel van screening toch vroeg wordt opgespoord, 
worden ze wellicht onnodig behandeld middels een ingrijpende operatie of bestraling. 
Het probleem van screening is dat steeds meer van deze onschuldige prostaatkanker 
worden gediagnosticeerd. Dit proefschrift, getiteld “prostate cancer screening, the 
effect on prostate cancer mortality and incidence” geeft inzicht in het effect van pros-
taatkanker screening en geeft antwoord op enkele specifieke vragen betreffende de 
verbetering van het screeningsprogramma.
Hoofdstuk 1 is een algemene introductie waarin de diagnostiek en behandeling van 
prostaatkanker uiteen wordt gezet. Hoofdstuk 2 omvat een literatuuroverzicht van de 
gepubliceerde studies naar het effect van prostaatkanker screening tot medio 2011. 
Op basis van het overzicht in hoofdstuk 2 wordt geconcludeerd dat de door screening 
bereikte daling in prostaatkanker sterfte onvoldoende is om screening naar pros-
taatkanker te adviseren. Zodoende kan niet worden geadviseerd om prostaatkanker 
screening op bevolkingsniveau in te voeren. In hoofdstuk 3 worden de voor en nadelen 
van het meten van trends in prostaatkanker incidentie, overleving en sterfte besproken. 
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Geïllustreerd wordt dat de trend in prostaatkanker incidentie geen goede uitkomstmaat 
is om de mogelijke invloed van verschillende omgevingsfactoren op het krijgen van 
prostaatkanker te meten. Geïllustreerd wordt dat de verandering in de prostaatkanker 
incidentie volledig beïnvloed wordt door het toenemend gebruik van de PSA test. 
Dit maakt de mogelijke invloed van andere factoren op verandering in incidentie on-
meetbaar. Op basis van de resultaten in hoofdstuk 2 zijn de trends in prostaatkanker 
overleving een slechte maat om de verandering in de agressiviteit en de behandeling 
van prostaatkanker te meten. Zoals geïllustreerd in hoofdstuk 3 zijn de trends in pros-
taatkanker sterfte de enige uitkomstmaat waarmee het effect van de veranderingen in 
preventieve maatregelen en de behandelingen van prostaatkanker op de bevolking kan 
worden gemeten.
Hoofdstuk 5 en 6 geeft inzicht in het effect van prostaatkanker screening op de 
prostaatkanker incidentie en sterfte. In hoofdstuk 5 worden twee populaties vergele-
ken, 133287 mannen in Noord Ierland en 11970 mannen in Nederland. De mannen in 
Nederland kregen om de 4 jaar een PSA-bepaling aangeboden (screening), mannen 
in Noord Ierland niet. Tijdens de follow-up (gemiddeld 9 jaar) werd er bij 1153 (9.6%) 
mannen prostaatkanker gevonden in de screeningsgroep (Nederland), versus 3962 
(3.6%) in de controlegroep (Noord Ierland). Tijdens de onderzoeksperiode overleden 35 
(0.29%) mannen in de screeningsgroep aan prostaatkanker, 627 (0.47%) mannen over-
leden aan prostaatkanker in de controlegroep. Het relatieve risico om te overlijden aan 
prostaatkanker in de screeningsgroep ten opzichte van dat in de controlegroep was RR: 
0,63 (95%CI 0,45-0,88), een reductie van 37% in prostaatkanker specifieke sterfte als een 
gevolg van screening. Hoofdstuk 6 is een aanvulling op hoofdstuk 5. In tegenstelling tot 
de resultaten in hoofdstuk 5 is het hier gelukt om een groep mannen te identificeren 
die relatief het meeste voordeel hebben van prostaatkanker screening. Daarnaast is er 
een groep mannen geïdentificeerd bij wie de nadelen van screening zo groot zijn dat 
verdere screening moet worden afgeraden. Zo wordt in hoofdstuk 6 geillustreerd dat bij 
mannen van 55-74 jaar die een lage PSA-waarde hebben (tussen de 0.1 en 1.9 ng/ml) 
de nadelen van herhaald screening aanzienlijk groter zijn dan de voordelen. Op basis 
van deze resultaten van hoofdstuk 6 kan worden geconcludeerd dat als het initiele PSA 
(eerste meting) zou worden gehanteerd als criteria voor herhaald screenen, er een beter 
evenwicht kan ontstaan tussen de voor- en nadelen van prostaatkanker screening. Op 
die manier zouden we kunnen voorkomen dat mannen een behandeling ondergaan die 
ze eigenlijk niet nodig hebben.
In deel 3 (hoofdstuk 7-10) worden vier studies gepresenteerd die het effect van 
prostaatkanker screening op de “excess mortality” onderzoeken. Excess mortality is 
gedefinieerd als het verschil tussen de waargenomen totale sterfte in patiënten met 
prostaatkanker en de verwachte sterfte op basis van een gelijke groep in de bevolking 
naar leeftijd en geslacht. In hoofdstuk 7 wordt aangetoond dat het mogelijk is om een 
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betrouwbare “excess mortality” analyse te maken binnen een gerandomiseerde studie 
naar het effect van prostaatkanker screening. De resultaten betreffende de effectiviteit 
van prostaatkanker screening op de excess mortality volgen in hoofdstuk 8-10. Hoofd-
stuk 8 betreft de analyse van totaal 42376 mannen, leeftijd 55-74 jaar, gerandomiseerd 
(1:1) in de ERSPC-Nederland. De resultaten tonen een ziekte specifieke sterfte van 0.42 
man per 1000 persoonsjaren in de screening groep en 0.48 man per 1000 persoonsjaren 
in de controle groep na gemiddelde follow-up van 9 jaar, RR: 0.86 (95%CI, 0.64-1.17), een 
reductie van 14%. De excess mortality was 0.40 per 1000 persoonsjaren in de screening 
groep en 0.61 man per 1000 persoonsjaren in de controle groep: RR 0.66 (95%CI, 0.39-
1.13), een reductie van 34%. Hiermee was het effect van screening meer dan twee keer 
zo groot op de excess mortality ten opzichte van de ziekte specifieke sterfte. De conclu-
sies en mogelijke verklaringen gegeven in hoofdstuk 8 waren: ten eerste, er is sprake 
van een systematische onderschatting van de prostaatkanker specifieke sterfte door de 
“cause of death committee” van de studie; ten tweede, er is sprake van een prostaat-
kanker gerelateerde sterfte die gemeten kan worden met een excess mortality analyse 
maar niet met de ziekte specifieke mortaliteit analyse. Deze observaties en suggesties 
zijn aanvullend bestudeerd in hoofdstuk 10. In deze case-control studie is de mogelijke 
aanvullende prostaatkanker gerelateerde sterfte onderzocht. Op grond van de resulta-
ten in hoofdstuk 10 blijkt dat mannen met klinisch gediagnosticeerd prostaatkanker, 
naast een verhoogde kans om te overlijden aan prostaatkanker, een verhoogde kans 
hebben om te overlijden aan andere doodsoorzaken ten opzichte van met mannen die 
zijn gediagnosticeerd met prostaatkanker als een gevolg van screening. In hoofdstuk 
10 hadden mannen met klinisch gediagnosticeerd prostaatkanker een verhoogd risico 
om te overlijden aan een aan andere vorm van kanker, aan hart-en-vaat ziektes en long-
ziektes. Een verklaring voor deze bevinding is het gebruik van de hormonale therapie 
bij mannen met klinisch gediagnosticeerd prostaatkanker. Daarnaast wordt er mogelijk 
een overlevingsvoordeel gezien bij mannen met een screen-detected prostaatkanker 
doordat zij op relatief jonge leeftijd (na vroege diagnose prostaatkanker) een veran-
dering maken in hun gezondheid (bijkomend positief effect diagnose prostaatkanker). 
In hoofdstuk 9 omvat de excess mortality analyse in de vier grootste centra (Finland, 
Italië, Zweden en Nederland) van de ERSPC. Hierbij zijn in totaal 141578 mannen, leeftijd 
55-69 jaar, gerandomiseerd tussen screening en de reguliere gezondheidszorg. Na een 
gemiddelde follow-up van negen jaar was de prostaatkanker incidentie 9.25 per 1000 
persoonsjaren in de screening groep en 5.49 per 1000 persoonsjaren in de controle 
groep, RR 1.69 (95%CI 1.62-1.76). De excess mortality rate was 0.29 per 1000 persoons-
jaren in de screening groep en 0.37 man per 1000 persoonsjaren in de controle groep; 
de RR voor excess mortality was 0.77 (95%CI, 0.54-1.08), reductie 23%. Op grond van 
deze resultaten is geconcludeerd dat het verschil in excess mortality tussen de twee 
studiearmen goed overeenkomt met de eerder aangetoonde 20% reductie in de ziekte 
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specifieke sterfte. De bevindingen bevestigen dat PSA screening de sterfte aan prostaat-
kanker kan reduceren. Verder toont het aan dat een excess mortality analyse, mits op de 
door in hoofdstuk 7-9 beschreven methode, uitgevoerd kan worden gebruikt om het 
effect van screening op kanker te onderzoeken.
In deel 4 van het proefschrift worden er drie belangrijke deelvragen binnen de effectivi-
teit van prostaatkanker screening beantwoord. Allereerst is er in hoofdstuk 11 gekeken 
naar de waarde van het screeningsinterval (de tijd tussen twee screenings onderzoeken). 
Vergeleken is het aantal gediagnosticeerde agressieve prostaatkanker (kankers relatief 
te laat gediagnosticeerd met een slechte prognose) wanneer een screeningsinterval 
van 2 of 4 jaar wordt gebruikt. Resultaten in hoofdstuk 11 laten zien dat met beide 
screeningsintervallen een significante reductie in het aantal agressieve prostaatkanker 
kan worden bereikt. Echter, met een programma dat een 2-jaars screenings interval 
hanteert, daalt de incidentie van het aantal agressieve kankers met nog eens met 43% 
ten opzichte van een programma met een 4-jaars interval. Het nadeel is wel dat het 
programma met het kortere interval in totaal meer kankers diagnosticeert en daarmee 
de overdiagnose verder laat stijgen.
In hoofdstuk 12 is de waarde van het aantal prostaatbiopten bestudeerd in mannen 
met een groter prostaatvolume. De hypothese was dat in mannen met een groter pros-
taatvolume meer biopten zouden moeten worden genomen omdat anders kankers in 
metname grotere prostaten gemist zouden worden. Resultaten laten zien dat mannen 
met een initieel verhoogde PSA en mannen met een relatief kleiner prostaatvolume een 
verhoogd risico hebben op de diagnose van een agressief prostaatkanker gedurende 
de follow-up. Deze bevindingen tonen aan dat in een screeningsprogramma het aantal 
prostaatbiopten niet moet worden aangepast naar het totale prostaatvolume.
In hoofdstuk 13 is een risico stratificatie gemaakt bedoeld voor mannen met prostaat-
kanker die geïnformeerd willen worden over hun prognose indien gekozen wordt voor 
behandeling middels chirurgie (radicale prostatectomie). In totaal werden 1043 man-
nen, in de leeftijd van 55 tot 75 jaar, gescreend op prostaatkanker en gediagnosticeerd 
met een gelokaliseerde vorm van prostaatkanker. De resultaten laten zien dat mannen 
die behandeld zijn met een radicale prostatectomie voor een bij screening gediagnos-
ticeerd gelokaliseerd prostaatkanker met een Gleason score ≤6, 7 en ≥8, respectievelijk 
een 1.3%, 2.7% of 10.3% kans hebben om te overlijden aan prostaatkanker in een pe-
riode van 12 jaar na diagnose. Het relatieve risico om te overlijden aan prostaatkanker, 
ten opzichte van het risico om te overlijden aan een andere doodsoorzaak, is het hoogst 
voor de relatief jonge man (55-60 jaar) met een relatef hoge Gleason score (Gleason 
score ≥8). Geconcludeerd is dat mannen met een bij screening gediagnosticeerd 
gelokaliseerd prostaatkanker Gleason score ≤6 die behandeld zijn met een radicale 
prostatectomie een minimale kans hebben om te overlijden aan prostaatkanker in een 
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periode van 12 jaar na diagnose. Echter, van de mannen met gelokaliseerd prostaatkan-
ker Gleason score ≥8 die overlijden in de periode van 12 jaar na diagnose, overlijden 1 
op de 2.2 mannen alsnog aan de gevolgen van prostaatkanker ondanks de screening en 
behandeling met radicale chirurgie.
De resultaten uit deel 1-4 zijn besproken in deel 5. Hierbij zijn meerdere vergelijkingen 
gemaakt met de recente literatuur. Dit heeft geresulteerd in verscheidende conclusies 
evenals suggesties voor toekomstig onderzoek.
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